Novel freshener and preparation containing same
By designing the cooling agents of the new compounds of formula (I) to (VIII), the shortcomings of existing cooling agents in terms of efficacy and durability are solved, and efficient and long-lasting cooling effects are achieved, and are suitable for a variety of products, especially In the food and nursing field.
Patent Information
- Application Number
- CN202380030400.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-28
- Filing Date
- 2023-01-27
- Publication Date
- 2024-11-19
AI Technical Summary
Existing coolants have defects in efficacy, duration of action, skin/mucosal irritation, odor, taste, solubility and volatile, which are difficult to provide lasting cooling effects, and are sensitive to hydrolysis or have bitter taste, and cannot be applied to foods and faces. Care products.
A novel compound, cooling agent of general formulas (I) to (VIII), has a weak inherent taste and low irritation, and forms a co-forming structure through specific structural designs such as triazine, pyrazine, oxazole and imidazole ring structures. Valid bonds are used to enhance cooling properties and are present in their salt form to improve solubility.
It achieves efficient and long-lasting cooling effect at low concentrations, can conceal bad taste, is suitable for food, care products and oral care fields, and produces a strong sense of cooling at low doses.
Smart Images

Figure BDA0005059652740000031 
Figure BDA0005059652740000041 
Figure BDA0005059652740000042
Abstract
Description
Technical Field
[0001] The invention belongs to the field of physiological cooling agents and relates to novel representatives of this group, the use of these cooling agents and articles and preparations containing these cooling agents. Background Art
[0002] Physiological cooling agents are generally used to produce a cool sensory impression on the skin or mucous membranes, such as on the mucous membranes of the mouth, nose and / or throat, although no body cooling actually occurs, such as with the evaporation of the solvent. Both individual components and mixtures can be used as physiological cooling agents. It should be noted that not all compounds that affect receptors in vitro (the receptors (also) participate in mediating the physiological cooling effect) actually produce this effect on the skin or mucous membranes in vivo. In particular, this effect is not always the same. This means that, for example, the intensity of the mediated physiological cooling effect and the intensity of the cooling effect over time cannot be inferred only from the fact that a specific compound is an agonist of a receptor that participates in mediating the cooling effect.
[0003] TRP channels play an important role in sensing temperature (cold-hot). TRP channels (transient receptor potential channels) are a large family of cellular ion channels, which can be divided into seven subfamilies.
[0004] The cold menthol receptor TRPM8 (also known as cold membrane receptor (CMR1)) belongs to the family of "transient receptor potential ion channels" that are specifically expressed in a particular group of neurons and form pores in the cell membrane (four units cluster together to form a tetramer) that selectively allow Ca 2+ Ions pass through. The protein has six transmembrane domains and cytoplasmic C- and N-termini. The receptor is stimulated by low temperatures (preferably 10 to 25°C), resulting in signal transduction that the nervous system interprets as a sensation of cold.
[0005] There is evidence that several TRP channels are important for growth control. Changes in the expression of some of these channels may contribute to the development of cancer. For example, the expression of the TRPM8 gene is upregulated in prostate cancer. Therefore, TRPM8 is also an attractive target for the treatment of prostate or bladder cancer.
[0006] Prior art
[0007] Cooling compounds, such as menthol, have long played an important role in the flavor and fragrance industry for creating associations with freshness and cleanliness.
[0008] The best-known physiologically effective cooling agent is L-menthol. The compound menthol has been shown to act as a natural modulator of the TRPM8 receptor. Administration of menthol activates TRPM8, leading to Ca 2+The electrical signals generated are then perceived as a sensation of cold.
[0009] However, menthol has many disadvantages, such as strong odor, high volatility, and, at higher concentrations, its own bitter and / or spicy taste and skin irritation. Excessive concentrations of menthol may also cause irritation and anesthetic effects on the skin or mucous membranes.
[0010] There has been a search for strong cooling agents which do not have the adverse properties of L-menthol.
[0011] For example, lactic acid esters of menthol according to DE 2608226 A1 and mixed carbonates with menthol and polyols according to DE 4226043 A1, and also menthone ketals according to EP 0507190 B1 have been described.
[0012] Furthermore, menthol derivatives having similar effects have been described in various publications.
[0013] Although the menthyl diacid monoesters according to US Pat. No. 5,725,865 and US Pat. No. 5,843,466 are interesting naturally occurring alternatives, they are unable to achieve the intensity of the previously described coolants in sensory tests.
[0014] It was found that the compounds L-menthanecarboxylic acid N-ethylamide ("WS-3"), and especially Nα-(L-menthanecarbonyl)glycine ethyl ester ("WS-5"), are strong cooling agents. However, the latter have the disadvantage of being sensitive to hydrolysis and forming the corresponding free acid Nα-(L-menthanecarbonyl)glycine, which itself has only a very weak cooling effect. Despite the above detailed studies, a systematic prediction of the properties of potential cooling agents, in particular their bitter taste and / or their other trigeminal effects, is not possible and has not yet been described. For example, many molecules belonging to the class of menthanecarboxylic acid amides have a strong cooling effect, but often at the same time exhibit a pronounced bitter taste, such as the menthanecarboxylic acid N-(alkoxyalkyl)amides described in JP 2004059474A2, or are also highly irritating, such as N-[[5-methyl-2-(1-methylethyl)cyclohexyl]carbonyl]glycine ethyl ester described in US20050222256 A1, and are therefore not suitable for use in food preparations, etc.
[0015] Nα-(menthanecarbonyl)alkoxyalkylamides are described in JP 2004059474 A2. However, these amides have the disadvantage of being very bitter despite their strong cooling effect and high hydrolytic stability and therefore cannot be used in foods or in cosmetics for facial care.
[0016] Furthermore, menthyl glyoxylate and its hydrate are described as cooling substances in JP 2005343795 A2.
[0017] An overview of the cooling agents produced and used to date is known to the person skilled in the art.
[0018] There are also some isolated compounds that are structurally unrelated to menthol, which lead to a significant TRPM8 modulation, such as the cooling agent WS-23 or the compounds listed in patent application WO2007019719A1.
[0019] However, many of the TRPM8 modulators discovered to date suffer from deficiencies in potency, duration of action, skin / mucosal irritation, odor, taste, solubility, and volatility.
[0020] WO2010026094A1 discloses single compounds for modulating the TRPM8 receptor.
[0021] WO2011061330A2 also proposes further compounds for modulating the TRPM8 receptor.
[0022] Also known from WO2012061698A1 is a special cooling agent having a carboxamide structure (I)
[0023]
[0024] On the oral mucosa, some to all of the conventional cooling substances mentioned above and known from the prior art exhibit more or less the same cooling behavior. The fresh cooling sensation they bring begins after about 0.5 minutes, but levels off again relatively quickly after a peak of 3 to 5 minutes, with the cooling being clearly perceptible for up to 30 minutes, and experience has shown that intensity and duration are only slightly affected by varying the dosage. On the consumer side, however, a particularly long-lasting cooling effect is desired, which is associated with a related sensation of freshness and well-being for the user. Summary of the invention
[0025] Invention Task
[0026] Therefore, the main task of the present invention is to determine new substances with specific physiological cooling effects, preferably those substances that lead to TRPM8 receptor modulation (so-called modulators), which can be used as a substitute for previously known modulators, preferably as a more suitable agent. Such compounds should also be particularly suitable for cosmetics, nutritional products, textiles, OTC products (such as burn creams), pharmaceuticals (such as tumor treatment, bladder weakness) or packaging fields. The compound or compound mixture to be disclosed should preferably have an inherent taste as weak as possible, in particular almost no or no bitterness, and as non-irritating as possible.
[0027] In order to solve the problem according to the invention, active ingredients which can impart a particularly long-lasting cooling sensation are mainly investigated. Preferably, these active ingredients should also be able to impart a particularly strong and / or rapid cooling sensation. The cooling agents should be effective, i.e., they should have a high cooling effect or sensation even at low concentrations.
[0028] Another task is to compensate for the off-flavors that many flavoring agents, especially sweeteners such as representatives of the stevioside group, have. This applies in particular to their bitter, astringent and metallic aftertaste.
[0029] Said problem is solved by the subject matter of the independent patent claims. Further aspects of the invention are apparent from the wording of the dependent patent claims, the following description and the examples. DETAILED DESCRIPTION OF THE INVENTION
[0031] The main object of the present invention is achieved according to the present invention by a physiological cooling agent, which is selected from the compounds represented by the general formulae (I) to (IV)
[0032]
[0033] Or general formula (II)
[0034]
[0035] Or general formula (III)
[0036]
[0037] Or general formula (IV)
[0038]
[0039] wherein in each of formulae (I) to (IV),
[0040]
[0041]
[0042]
[0043]
[0044]
[0045]
[0046] and salts thereof, preferably acid addition salts formed with inorganic or organic acids.
[0047] The cooling agent according to the present invention, which is represented by the general formula (I) to (IV), may exist in a stereoisomerically pure form or as a mixture of different stereoisomers.
[0048] In a preferred variant of the first aspect according to the invention, it is a physiological cooling agent according to one of the general formulae (I) and (II), wherein X is selected from S, SO, NH and O. Even more preferred are cooling agents according to the invention, wherein in the general formulae (I) and (II), X is S.
[0049] In an alternative preferred variant according to the first aspect of the invention, it is a physiological cooling agent according to one of the general formulae (III) and (IV), wherein X is selected from: S, SO2, an optionally substituted linear or branched alkyl group, an optionally substituted cycloalkyl group and a piperidinyl group.
[0050] In an even more preferred variant according to the first aspect of the invention, it is a physiological cooling agent chosen from compounds represented by the following general formula:
[0051] Formula (V)
[0052]
[0053] Or general formula (VI)
[0054]
[0055] wherein in each case, in formulae (V) and (VI),
[0056]
[0057]
[0058]
[0059]
[0060] and their salts, preferably acid addition salts formed with inorganic or organic acids; or
[0061] Physiological cooling agents of compounds given by the general formula:
[0062] General formula (VII)
[0063]
[0064] Or general formula (VIII)
[0065]
[0066] wherein in each of formula (VII) and (VIII),
[0067]
[0068]
[0069]
[0070]
[0071] and salts thereof, preferably acid addition salts formed with inorganic or organic acids.
[0072] The cooling agents of the general formulae (V) to (VIII) according to the invention may be present both in stereoisomerically pure form and as a mixture of different stereoisomers.
[0073] In an even more preferred variant according to the first aspect of the invention, it is a physiological cooling agent chosen from compounds represented by the following general formula:
[0074] General formula (Va)
[0075]
[0076] Or general formula (VIa)
[0077]
[0078] wherein in each case, in formulae (Va) and (VIa),
[0079]
[0080]
[0081]
[0082]
[0083]
[0084] and their salts, in particular acid addition salts with inorganic or organic acids, wherein the cooling agent may be present in stereoisomerically pure form or as a mixture of different stereoisomers;
[0085] Or a physiological cooling agent of a compound represented by the following general formula:
[0086] General formula (VIIa)
[0087]
[0088] Or general formula (VIIIa)
[0089]
[0090] wherein in each of formulae (VIIa) and (VIIIa),
[0091]
[0092]
[0093]
[0094]
[0095]
[0096] and their salts, in particular acid addition salts with inorganic or organic acids, wherein the cooling agent may be present in stereoisomerically pure form or as a mixture of different stereoisomers.
[0097] The cooling agents of the general formulae (Va) to (VIIIa) according to the invention may be present both in stereoisomerically pure form and as a mixture of different stereoisomers.
[0098] The present invention also includes physiological cooling agents in which the oxygen atom in the oxazole ring of the basic structure of the general formula (III), (VII) or (VIIa) is replaced by a sulfur atom, i.e., physiological cooling agents in which the oxazole ring of the basic structure of the general formula (III), (VII) or (VIIa) is a thiazole ring.
[0099] Among the compounds of the general formulae (I) to (VIII) and (Va) to (VIIIa), compounds in which the heterocyclic ring of the basic structure of the general formulae (I) to (VIII) and (Va) to (VIIIa) has at least two nitrogen atoms, i.e. compounds having a triazine ring in the basic structure of the general formulae (I), (V) and (Va) or compounds having a pyrazine ring in the basic structure of the general formulae (II), (VI) and (VIa), are particularly preferred due to their free electron pairs suitable for forming covalent bonds (so-called Lewis bases), i.e. compounds having a triazine ring in the basic structure of the general formulae (I), (V) and (Va), or compounds having a pyrazine ring (diazine) in the basic structure of the general formulae (II), (VI) and (VIa), or compounds having an imidazole ring in the basic structure of the general formulae (IV), (VIII) and (VIIIa). Such compounds exhibit particularly significant cooling properties as described below.
[0100] The most preferred are compounds having a triazine ring in the basic structure of the general formulae (I), (V) and (Va) and compounds having an oxazole ring in the basic structure of the general formulae (III), (VII) and (VIIa) due to their Lewis base properties. Such compounds are characterized by a particularly strong cooling effect.
[0101] In the context of the present invention, in particular for the definitions of the general formulae (I) to (VIII) and (Va) to (VIIIa), the following general meanings apply:
[0102] The term "or" or "and / or" is used as a function word indicating that two words or expressions should be taken together or separately.
[0103] The terms "comprising," "having," "including," and "containing" should be construed as open terms, ie, "includes," "including," or "containing," but not "limited to."
[0104] All endpoints pointing to regions of the same component or property can be combined inclusively and independently of each other.
[0105] The term "compound" or "compound of the present invention" refers to all compounds covered by the structural formula (I) and / or formula (II) disclosed herein, and includes any subgenus and any specific compound whose structure is within the formula disclosed herein. The compounds can be identified by their chemical structure and / or their chemical name. When the chemical structure and chemical name conflict, the chemical structure determines the identity of the compound. The compounds described herein may include one or more chiral centers and / or double bonds, and may therefore exist as stereoisomers, such as double bond isomers, i.e., geometric isomers, enantiomers or diastereomers. Therefore, the chemical structures of general formula (I) and / or formula (II) shown herein include all possible enantiomers and diastereomers or stereoisomers.
[0106] In the context of the present invention, the term "at least one cooling agent" means, for example, that the composition contains at least one cooling agent, but may also contain two, three, four or even several different cooling agents.
[0107] According to the present invention, the term "alkyl" alone or as part of another substituent refers to a saturated or mono- or poly-unsaturated straight-chain or branched monovalent hydrocarbon residue obtained by removing a hydrogen atom from a single carbon atom of the corresponding starting alkane.
[0108] In a preferred variant, the term "alkyl" also includes all alkyl moieties in the residues derived therefrom, such as alkoxy, alkylthio, alkylsulfonyl, saturated straight-chain or branched hydrocarbon residues having 1 to 10, 1 to 8, 1 to 6 or 1 to 4 carbon atoms.
[0109] If the alkyl residue is further bonded to another atom, it becomes an alkylene residue or an alkyl group. In other words, the term "alkylene" also refers to a divalent alkyl group. For example, -CH2CH3 is an ethyl group, while -CH2CH2- is an ethylene group.
[0110] The term "alkylene" by itself or as part of another substituent refers to a saturated straight or branched chain divalent hydrocarbon residue derived by the removal of two hydrogen atoms from a single carbon atom or from two different carbon atoms of a starting alkane.
[0111] In a preferred variant according to the invention, the alkyl group or alkylene group contains 1 to 10 carbon atoms. In other more preferred variants, the alkyl group or alkylene group contains 1 to 6 carbon atoms.
[0112] Most preferred are alkyl groups or alkylene groups having 1 to 4 carbon atoms.
[0113] Preferred alkyl residues or alkyl groups include, but are not limited to:
[0114] C1- to C6-alkyl including methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl and 1-ethyl-2-methylpropyl;
[0115] C1- to C6-alkoxy, including C1- to C4-alkoxy, such as methoxy, ethoxy, n-propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy or 1,1-dimethylethoxy; and pentoxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, 2,2-dimethylpropoxy, 1-ethylpropoxy, hexyloxy, 1-methylpentoxy 1-ethyl-1-methyl-propoxy or 1-ethyl-2-methyl-propoxy.
[0116] Most preferred according to the invention are saturated straight-chain or branched C1- to C6-alkyl groups or saturated straight-chain or branched C1- to C6-alkylene groups.
[0117] The term "alkyl" or "alkylene" also includes residues or groups with any degree of saturation, i.e., groups having only single carbon-carbon bonds ("alkyl" or "alkylene"), groups having one or more double carbon-carbon bonds ("alkenyl"), residues having one or more triple carbon-carbon bonds ("alkynyl"), and groups having mixtures of single, double and / or triple carbon-carbon bonds.
[0118] According to the present invention, the term "alkenyl" alone or as part of another substituent refers to an unsaturated straight or branched monovalent hydrocarbon residue having at least one carbon-carbon double bond (C=C double bond). The remainder may be in a cis or trans conformation around the double bond. Therefore, the term "alkenyl" also includes the corresponding cis / trans isomers.
[0119] Typical alkenyl residues or alkenyl groups include, but are not limited to, vinyl; propenyl, such as prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl), prop-2-en-2-yl, cycloprop-1-en-1-yl, cycloprop-2-en-1-yl; butenyl, such as but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, but-1,3-dien-1-yl, but-1,3-dien-2-yl, etc.
[0120] In a preferred variant according to the invention, the alkenyl group comprises 2 to 10 carbon atoms. In other preferred variants, the alkenyl group comprises 2 to 6 carbon atoms. In a more preferred variant, the alkenyl group comprises 2 to 4 carbon atoms.
[0121] Most preferred according to the invention are mono- or di-unsaturated straight-chain or branched C1- to C6-alkenyl groups.
[0122] According to the present invention, the term "alkynyl" alone or as part of another substituent refers to an unsaturated straight or branched monovalent hydrocarbon residue having at least one carbon-carbon triple bond (C≡C triple bond).
[0123] Typical alkynyl residues or alkynyl groups include, but are not limited to, ethynyl; propynyl, such as prop-1-yn-1-yl, prop-2-yn-1-yl, etc.; butynyl, such as but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl, etc.
[0124] In preferred variants according to the invention, the alkynyl group contains 2 to 10 carbon atoms. In other preferred variants, the alkynyl group contains 2 to 6 carbon atoms. In more preferred variants, the alkynyl group contains 2 to 4 carbon atoms.
[0125] According to the present invention, the term "alkoxy" alone or as part of another substituent refers to a residue of the formula -OR, wherein R is alkyl or substituted alkyl as defined herein.
[0126] According to the present invention, the term "alkylthio" or "thioalkoxy" alone or as part of another substituent refers to a residue of the formula -SR, wherein R is alkyl or substituted alkyl as defined herein.
[0127] According to the present invention, the term "alkyl" or "alkylene" also includes heteroalkyl residues or heteroalkyl groups. The term "heteroalkyl" itself or as a part of other substituents refers to the following alkyl group, in which one or more carbon atoms are independently replaced by the same or different heteroatoms or the same or different heteroatom groups. The typical heteroatoms or heteroatom groups that can replace the carbon atom include but are not limited to-O-,-S-,-N-,-Si-,-NH-,-S(O)-,-S(O)2-,-S(O)NH-,-S(O)2NH-, etc., and combinations thereof. The heteroatoms or heteroatom groups can be located at any internal position of the alkyl group. Typical heteroatom groups that can be included in these groups include, but are not limited to, -O-, -S-, -OO-, -SS-, -OS-, -NRR-, =NN=, -N=N-, -N=N-NRR, -PR-, -P(O)2-, -POR-, -OP(O)2-, -SO-, -SO2-, -SR2OR-, and the like, where R is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, substituted aryl, substituted aryl, etc., aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, or substituted heteroarylalkyl, as defined herein.
[0128] An alkyl group or an alkylene group as defined above may also be substituted.
[0129] According to the present invention, the term "acyl" alone or as part of another substituent refers to the residue -R(C=O)-, wherein R is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroarylalkyl or substituted to give heteroarylalkyl, as defined herein.
[0130] Representative examples include, but are not limited to, formyl, acetyl, propionyl, butyryl, valeryl, benzoyl, cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzylcarbonyl, and the like.
[0131] According to the present invention, the term "cycloalkyl" alone or as part of another substituent refers to a saturated or mono- or polyunsaturated non-aromatic cyclic monovalent hydrocarbon residue, wherein the carbon atoms are linked together in a ring and have no heteroatoms.
[0132] The carbocycle may occur as a monocyclic compound (having only a single ring) or as a polycyclic compound (having two or more rings).
[0133] In a preferred variant, the term "cycloalkyl" comprises a three-membered to ten-membered monocyclic cycloalkyl residue or cycloalkyl group or a nine-membered to twelve-membered polycyclic cycloalkyl residue or cycloalkyl group. In other more preferred variants, the cycloalkyl moiety comprises a three-membered, four-membered, five-membered, six-membered or seven-membered monocyclic cycloalkyl moiety or a nine-membered to twelve-membered bicyclic cycloalkyl moiety.
[0134] In a preferred variant according to the invention, the cycloalkyl residue or cycloalkyl group comprises 3 to 20 carbon atoms. In an even more preferred variant, the cycloalkyl residue comprises 3 to 15 carbon atoms. In a most preferred variant, the cycloalkyl residue comprises 3 to 10 carbon atoms. Most preferred is a monocyclic C3- to C7-cycloalkyl group.
[0135] Typical cycloalkyl groups include, but are not limited to, saturated carbocyclic residues having 3 to 20 carbon atoms, such as C3- to C4- 12 -Carbocyclic radicals, including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl and cyclododecyl; preferably cyclopentyl, cyclohexyl, cycloheptyl and cyclopropyl-methyl, cyclopropyl-ethyl, cyclobutyl-methyl, cyclobutyl-ethyl, cyclopentyl-methyl, cyclopentyl-ethyl, cyclohexyl-methyl or C3- to C7-carbocyclic radicals, including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cycloheptyl and cyclopropyl-methyl, cyclopropyl-ethyl, cyclobutyl-methyl, cyclobutyl-ethyl, cyclopentyl-methyl, cyclopentyl-ethyl, cyclohexyl-methyl or C3- to C7-carbocyclic radicals, including cyclopropyl, cyclo Butyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopropyl-methyl, cyclopropyl-ethyl, cyclobutyl-methyl, cyclopentyl-ethyl, cyclohexyl-methyl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, buta-1,3-dien-1-yl, buta-1,3-dien-1-yl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobut-1,3-dien-1-yl, etc.
[0136] Preferred saturated polycycloalkyl residues or cycloalkyl groups according to the present invention include, but are not limited to, adamantyl groups and the like.
[0137] According to the invention, the term "cycloalkyl" also includes cycloalkenyl, i.e. an unsaturated cyclic hydrocarbon residue containing a C=C double bond between two carbon atoms of the ring molecule. In a broader sense, cycloalkenyl is a compound with one, two or more double bonds, wherein the number of double bonds with the most possible conjugation in the molecule depends on the size of the ring.
[0138] Typical cycloalkenyl groups include, but are not limited to, cyclopropenyl, cyclopentenyl, cyclohexenyl, cyclopentadienyl, and the like.
[0139] According to the invention, the term "cycloalkyl" also includes cycloalkynyl groups, ie unsaturated cyclic hydrocarbon residues containing a -C≡C triple bond between two carbon atoms of the ring molecule, said triple bond depending on the size of the ring due to ring strain.
[0140] Typical cycloalkynes include cyclooctyne.
[0141] The cycloalkyl residue or the cycloalkyl group may be linked to the remainder of the molecule of formula (I) and / or formula (II) via any suitable C atom.
[0142] As defined above, the cycloalkyl residue or the cycloalkyl group may also be substituted.
[0143] According to the present invention, the term "aryl" alone or as part of another substituent refers to a monovalent aromatic hydrocarbon residue derived by removing a hydrogen atom from a single carbon atom of an aromatic ring system.
[0144] In a preferred variant, the term "aryl" comprises a three- to ten-membered monocyclic aryl residue or aryl group or a nine- to twelve-membered polycyclic aryl residue or aryl group. In other more preferred variants, the carboaryl moiety comprises a three-, four-, five-, six- or seven-membered monocyclic carboaryl moiety or a nine- to twelve-membered bicyclic carboaryl moiety.
[0145] In a preferred variant according to the invention, the aryl residue contains 3 to 20 carbon atoms. In an even more preferred variant, the aryl residue contains 3 to 15 carbon atoms. In a most preferred variant, the aryl residue contains 3 to 10 carbon atoms. Most preferred according to the invention are monocyclic C3- to C 12 -Aryl groups. Most preferred are monocyclic C3- to C7-aryl groups.
[0146] Typical aryl residues include, but are not limited to, benzene, phenyl, biphenyl, naphthyl, such as 1- or 2-naphthyl, tetrahydronaphthyl, fluorenyl, indenyl and phenanthrenyl. Typical carboaryl residues also include, but are not limited to, groups derived from: aceanthrylen, acenaphthyl, benzo[e]acenaphthyl, anthracene, azulene, benzene, Coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalen, asymmetric indacene, symmetric indacene, indane, indene, naphthalene, octacene, octalene, octalene, ovale, pentacene, pentalene, pentalene, perylene, phenalene, phenanthrene, pyrene, pyranthene, pyridine, triphenylene, trinaphthalene, etc.
[0147] Preferred aromatic polycyclic aryl residues or aryl groups according to the present invention include, but are not limited to, naphthalene, biphenyl and the like.
[0148] The aryl residue or the aryl group may be bonded to the remainder of the molecule of formulae (I) to (VIII) and (Va) to (VIIIa) via any suitable C atom.
[0149] As defined above, the aryl residue or the aryl group may also be substituted. For example, the aryl residue forms an anisole group.
[0150] According to the present invention, the term "arylalkyl" refers to the following non-cyclic alkyl group individually or as a part of another substituent, in which one of the hydrogen atoms connected to a carbon atom (usually a terminal or sp carbon atom) is replaced by an aryl group as defined herein. In other words, arylalkyl can also be considered as an alkyl substituted with an aryl group. Typical arylalkyl groups include but are not limited to benzyl, 2-phenylethane-1-yl, 2-phenylethylene-1-yl, naphthylmethyl, 2-naphthylethane-1-yl, 2-naphthylethylene-1-yl, naphthobenzyl, 2-naphthophenylethane-1-yl, etc.
[0151] The term "heteroarylalkyl" by itself or as part of another substituent refers to a cyclic alkyl group in which one or more of the hydrogen atoms attached to a carbon atom are replaced with a heteroaryl group.
[0152] In a preferred embodiment according to the present invention, the heteroarylalkyl group is a 6-20-membered heteroarylalkyl group, for example, the alkyl, alkenyl or alkynyl group of the heteroarylalkyl group is a C1- to C6-alkyl group, and the heteroaryl group is a 5- to 15-membered heteroaryl group. In other embodiments, the heteroarylalkyl group is a 6- to 13-membered heteroarylalkyl group, for example, the alkyl, alkenyl or alkynyl group is a C1 to C3 alkyl group, and the heteroaryl group is a 5- to 10-membered heteroaryl group.
[0153] According to the present invention, the term "heterocycloalkyl" alone or as part of another substituent refers to the following saturated non-aromatic, cyclic monovalent hydrocarbon residues, in which one or more carbon atoms are independently replaced by the same or different heteroatoms. Typical heteroatoms used to replace the carbon atoms include, but are not limited to, N, P, O, S, Si, etc. Typical heterocycloalkyl groups include, but are not limited to, groups derived from the following substances: epoxides, aziridines, thiirane, imidazolidine, morpholine, piperazine, piperidine, pyrazolidine, pyrrolidone, quinuclidine, etc.
[0154] The heterocycloalkyl residue may occur as a monocyclic compound (which has only a single ring) or as a polycyclic compound (which has two or more rings).
[0155] Preferably, the term "heterocycloalkyl" includes a three-membered to seven-membered saturated or mono- or poly-unsaturated heterocycloalkyl residue containing one, two, three or four heteroatoms selected from O, N and S. The one or more heteroatoms may occupy any position in the heterocycloalkyl ring. The one or more heteroatoms may occupy any position in the heterocycloalkyl ring.
[0156] In a preferred variant, the term "heterocycloalkyl" comprises a three-membered to ten-membered monocyclic heterocycloalkyl residue or a nine-membered to twelve-membered polycyclic heterocycloalkyl residue. In other more preferred variants, the heterocycloalkyl moiety comprises a three-membered, four-membered, five-membered, six-membered or seven-membered monocyclic heterocycloalkyl moiety or a nine-membered to twelve-membered bicyclic heterocycloalkyl moiety.
[0157] In a preferred variant according to the invention, the "heterocycloalkyl" residue or heterocycloalkyl group contains 3 to 20 ring atoms. In a preferred variant, the heterocycloalkyl moiety contains 3 to 15 ring atoms. In an even more preferred variant, the heterocycloalkyl moiety contains 3 to 10 carbon atoms. Most preferred according to the invention are monocyclic heterocycloalkyl residues containing 3 to 12 carbon atoms. Most preferred are monocyclic heterocycloalkyl residues with 5 to 7 ring atoms.
[0158] Typical heterocycloalkyl residues include, but are not limited to, three- to six-membered saturated heterocycloalkyl radicals containing one or two nitrogen atoms and / or one oxygen or sulfur atom or one or two oxygen and / or sulfur atoms as ring members, including aziridinyl, oxiranyl, thiirane, azetidinyl, oxetanyl, thietanyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothienyl, 3-tetrahydrothienyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 3-isoxazolidinyl, 4-isoxazolidinyl, 5-isoxazolidinyl, 3-isothiazolidinyl, 4-isothiazolidinyl, 5-isothiazolidinyl, 3-pyrazolidinyl, 4-isothiazoli ... -pyrazolidinyl, 5-pyrazolidinyl, 2-oxazolidinyl, 4-oxazolidinyl, 5-oxazolidinyl, 2-thiazolidinyl, 4-thiazolidinyl, 5-thiazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 2-pyrrolin-2-yl, 2-pyrrolin-3-yl, 3-pyrrolin-2-yl, 3-pyrrolin-3-yl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1,3-dioxane-5-yl, 2-tetrahydropyranyl, 4-tetrahydropyranyl, 2-tetrahydrothienyl, 3-hexahydropyridazinyl, 4-hexahydropyridazinyl, 2-hexahydropyrimidinyl, 4-hexahydropyrimidinyl, 5-hexahydropyrimidinyl, 2-piperazinyl, etc.
[0159] As defined above, the heterocycloalkyl residue or the heterocycloalkyl group may also be substituted.
[0160] The heterocycloalkyl residue or the heterocycloalkyl group may be bonded to the remainder of the molecule of the formulae (I) to (VIII) and (Va) and (VIII) via a ring carbon atom or a ring heteroatom.
[0161] According to the present invention, the term "heteroaryl" by itself or as part of another substituent refers to a monovalent heteroaromatic residue obtained by removing a hydrogen atom from a single atom of a heteroaromatic ring system. Typical heteroaryl residues or heteroaryl groups include, but are not limited to, those derived from acridine, β-carboline, chroman, chromium (Chrom), cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromium (Isochrom), isoindole, isoindolin, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, phenanthridine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazole, xanthene and the like.
[0162] The heteroaryl residue may occur as a monocyclic compound (which has only a single ring) or as a polycyclic compound (which has two or more rings).
[0163] In a preferred variant, the term "heteroaryl" comprises a three- to ten-membered monocyclic heteroaryl residue or a nine- to twelve-membered polycyclic heteroaryl residue. In other more preferred variants, the heteroaryl moiety comprises a three-, four-, five-, six- or seven-membered monocyclic heteroaryl moiety or a nine- to twelve-membered bicyclic heteroaryl moiety.
[0164] Preferably, the term "heteroaryl" comprises three- to seven-membered monocyclic heteroaryl residues containing one, two, three or four heteroatoms selected from O, N and S. The one or more heteroatoms may occupy any position in the heteroaryl ring. The one or more heteroatoms may occupy any position in the heteroaryl ring.
[0165] In a preferred variant according to the invention, the heteroaryl moiety or group comprises 3 to 20 ring atoms. In an even more preferred variant, the heteroaryl moiety comprises 6 to 15 ring atoms. In a most preferred variant, the heteroaryl group comprises 6 to 10 ring atoms. Most preferred according to the invention is a monocyclic C3- to C7-heteroaryl group.
[0166] Particularly preferred heteroaryl residues or groups include, but are not limited to, those derived from furan, thiophene, pyrrole, benzothiophene, benzofuran, benzimidazole, indole, pyridine, pyrazole, quinoline, imidazole, oxazole, isoxazole and pyrazine.
[0167] Three-membered aromatic heteroaryl radicals which contain nitrogen or sulfur or oxygen atoms as ring atoms in addition to carbon atoms include aziridinyl, oxirenyl or thiiridine.
[0168] Four-membered aromatic heteroaryl radicals which contain nitrogen or sulfur or oxygen atoms as ring atoms in addition to carbon atoms include azetyl, oxetiumion or thietiumion.
[0169] Five-membered aromatic heteroaryl residues which contain, in addition to carbon atoms, one, two or three nitrogen atoms or one or two nitrogen atoms and one sulfur or oxygen atom as ring atoms include 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-imidazolyl, 4-imidazolyl and 1,3,4-triazol-2-yl.
[0170] Five-membered aromatic heteroaryl residues containing one, two, three or four nitrogen atoms as ring atoms include 1-pyrrolyl, 2-pyrrolyl or 3-pyrrolyl, 1-pyrazolyl, 3-pyrazolyl or 4-pyrazolyl, 1-imidazolyl, 2-imidazolyl or 4-imidazolyl, 1,2,3-[1H]-triazol-1-yl, 1,2,3-[2H]-triazol-2-yl, 1,2,3-[1H]-triazol-4-yl, 1,2,3-[1H]-triazol-5-yl, , 1,2,3-[2H]-triazol-4-yl, 1,2,4-[1H]-triazol-1-yl, 1,2,4-[1H]-triazol-3-yl, 1,2,4-[1H]-triazol-5-yl, 1,2,4-[4H]-triazol-4-yl, 1,2,4-[4H]-triazol-3-yl, [1H]-tetrazole-1-yl, [1H]-tetrazole-5-yl, [2H]-tetrazole-2-yl, [2H]-tetrazole-5-yl, and the like.
[0171] Five-membered aromatic heteroaryl residues containing as ring atoms a heteroatom selected from oxygen or sulfur and optionally one, two or three nitrogen atoms include 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 3-isoxazolyl or 4-isoxazolyl, 3-isothiazolyl or 4-isothiazolyl, 2-oxazolyl, 4-oxazolyl or 5-oxazolyl, 2-thiazolyl, 4-thiazolyl or 5-thiazolyl, 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl, 1,3,4-thiadiazol-2-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl and 1,3,4-oxadiazol-2-yl.
[0172] In addition to carbon atoms, the six-membered heteroaryl radicals contain one or two or one, two or three nitrogen atoms as ring atoms and include, for example, 2-pyridyl, 3-pyridyl, 4-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 1,2,4-triazin-3-yl; 1,2,4-triazin-5-yl, 1,2,4-triazin-6-yl and 1,3,5-triazin-2-yl.
[0173] As defined above, the heteroaryl residue or the heteroaryl group may also be substituted.
[0174] The heteroaryl residue or the heteroaryl group may be bonded to the remainder of the molecule of formulae (I) to (VIII) and (Va) and (VIII) via a ring carbon atom or a ring heteroatom.
[0175] Among the monocyclic heteroaryl radicals mentioned above, those derived from five-membered or six-membered saturated compounds including pyrrolidone, tetrahydrofuran, tetrahydrothiophene, piperidine, tetrahydropyran, tetrahydrothiopyran, or five-membered or six-membered aromatic compounds including pyrrole, furan, thiophene, pyridine, pyrylium and thiopyrylium, pyrazole, imidazole, imidazoline, pyrimidine, oxazole, thiazole and 1,4-thiazine are particularly preferred in the context of the present invention.
[0176] According to the present invention, the term "arylalkyl" refers to the following non-cyclic alkyl group individually or as a part of another substituent, in which one of the hydrogen atoms connected to a carbon atom (usually a terminal or sp carbon atom) is replaced by an aryl group as defined herein. In other words, arylalkyl can also be considered as an alkyl substituted with an aryl group. Typical arylalkyl groups include but are not limited to benzyl, 2-phenylethane-1-yl, 2-phenylethene-1-yl, naphthylmethyl, 2-naphthylethane-1-yl, 2-naphthylethene-1-yl, naphthobenzyl, 2-naphthophenylethane-1-yl, etc.
[0177] The term "heteroarylalkyl" by itself or as part of another substituent refers to a cyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom is replaced by a heteroaryl radical.
[0178] In a preferred embodiment according to the present invention, the heteroarylalkyl group is a 6- to 20-membered heteroarylalkyl group, for example, the alkyl, alkenyl or alkynyl group of the heteroarylalkyl group is a C1- to C6-alkyl group, and the heteroaryl group is a 5- to 15-membered heteroaryl group. In other embodiments, the heteroarylalkyl group is a 6- to 13-membered heteroarylalkyl group, for example, the alkyl, alkenyl or alkynyl group is a C1 to C3 alkyl group, and the heteroaryl group is a 5- to 10-membered heteroaryl group.
[0179] In the context of the present invention, the term "substituted" means that the specified residue or one or more hydrogen atoms of the specified residue are independently replaced by the same or another substituent.
[0180] Substituents or substituent groups that may be used to replace saturated carbon atoms in the specified radicals or moieties include, but are not limited to, -X, halo, =O, -OY, -SiR3, -SY, =S, -NZZ, =NY, =N-OY, trihalomethyl, -CF3, -CN, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(O)2Y, -S(O)2OY, -OS(O)2Y, -OS(O)2OY, -P(O)(OY)2, -P(O)(OY)(OY), -C(O -NYC(O)Y, -NYC(S)Y, -NYC(O)OY, -NYC(S)OY, -NYC(O)NZZ, -NYC(NY)Y or -NYC(NY)NZZ; wherein X is selected from: an optionally substituted alkyl residue, in particular an optionally substituted C1- to C2- 10 - an alkyl group, in particular an optionally substituted C1- to C6-alkyl residue, in particular an optionally substituted C1-, C2-, C3- or C4-alkyl residue, an optionally substituted alkoxy residue, in particular an optionally substituted C1- to C6-alkoxy residue, in particular an optionally substituted C1-, C2-, C3- or C4-alkoxy residue, an optionally substituted alkylthio residue, in particular an optionally substituted C1- to C6-alkylthio residue, in particular an optionally substituted C1-, C2-, C3- or C4-alkylthio residue, an optionally substituted cycloalkyl residue, an optionally substituted aryl residue, an optionally substituted carboaryl residue, an optionally substituted carboarylalkyl residue, an optionally substituted heteroalkyl residue, an optionally substituted heterocycloalkyl residue, an optionally substituted heteroaryl residue and an optionally substituted heteroarylalkyl residue, as well as as defined above; and / or
[0181] Y represents hydrogen or X; and / or
[0182] Z is Y, or alternatively, two Zs together with the nitrogen atom to which they are attached form a four-, five-, six- or seven-membered heterocycloalkyl or heteroaryl ring, wherein the heterocycloalkyl or heteroaryl ring may contain one, two, three or four identical or different heteroatoms selected from nitrogen, oxygen and sulfur;
[0183] Specific preferred examples of substitution are: OH, methyl, ethyl, methoxy, ethoxy, phenyl, which in turn may be substituted by OH, methyl, ethyl, methoxy, ethoxy or CH3-C(O)- or thiophene.
[0184] In another variation, the one or more substituent groups (preferably phenyl groups) together with the atoms to which they are attached may form a cyclic ring including a cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl group.
[0185] Similarly, substituent groups for replacing unsaturated carbon atoms in the specified groups or residues include, but are not limited to, -X, halo, =O, -OY, -SiR3, -SY, =S, -NZZ, =NY, =N-OY, trihalomethyl, -CF3, -CN, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(O)2Y, -S(O)2OY, -OS(O)2Y, -OS(O)2OY, -P(O)(OY)2, -P(O)(OY)(OY), - -C(O)Y, -C(S)Y, -C(NY)Y, -C(O)OY, -C(S)OY, -C(O)NZZ, -C(NY)NZZ, -OC(O)Y, -OC(S)Y, -OC(O)OY, -OC(S)OY, -NYC(O)Y, -NYC(S)Y, -NYC(O)OY, -NYC(S)OY, -NYC(O)NZZ, -NYC(NY)Y and -NYC(NY)NZZ, wherein X, Y and Z have the same meanings as defined above.
[0186] Substituents or substituent groups for substituting nitrogen atoms in heteroalkyl groups and in heterocycloalkyl residues, but not limited thereto, -X, -OY, -SiR3, -SY, -NZZ, trihalomethyl, -CF3, -CN, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(O)2Y, -S(O)2OY, -OS(O)2Y, -OS(O)2OY, -P(O)(OY)2, -P(O)(OY)(OY), -C(O)Y, -C( -NYC(O)Y, -NYC(S)Y, -NYC(O)OY, -NYC(S)OY, -NYC(O)NZZ, -NYC(NY)Y and -NYC(NY)NZZ, wherein X, Y and Z also have the same meanings as defined above.
[0187] The term "substituted" specifically provides one or more, i.e., two, three, four, five, six or more substitutions commonly found in the art. However, those skilled in the art generally recognize that substituents should be selected so as not to adversely affect the useful properties of the compound or its function.
[0188] Suitable substituents within the scope of the present invention preferably include halogen groups, perfluoroalkyl groups, perfluoroalkoxy groups, alkyl groups, alkenyl groups, alkynyl groups, hydroxyl groups, oxo groups, thiol groups, alkylthio groups, alkoxy groups, aryl or heteroaryl groups, aryloxy groups or heteroaryloxy groups, arylalkyl or heteroarylalkyl groups, arylalkoxy groups or heteroarylalkoxy groups, amino groups, alkyl and dialkylamino groups, carbamoyl groups, alkylcarbonyl groups, carboxyl groups, alkoxycarbonyl groups, alkylaminocarbonyl groups, dialkylaminocarbonyl groups, arylcarbonyl groups, aryloxycarbonyl groups, alkylsulfonyl groups, arylsulfonyl groups, cycloalkyl groups, cyano groups, C1- to C6-alkylthio groups, arylthio groups, nitro groups, keto groups, acyl groups, borate or boroyl groups, phosphate or phosphonyl groups, sulfamide groups, sulfonyl groups, sulfinyl groups and combinations thereof. In the case of substituted combinations, such as substituted arylalkyl, either the aryl or the alkyl group may be substituted with one or more substituents, or both the aryl and alkyl groups may be substituted with one or more substituents.
[0189] Preferred substituents for the aforementioned groups or residues are in particular selected from COOH, COO-alkyl, NH2, NO2, OH, SH, CN, Si, halogen, straight-chain or branched C1- to C6-alkyl groups, straight-chain or branched C1- to C6-alkoxy groups or straight-chain or branched C1- to C6-alkylthio groups, where one or more H atoms in the alkyl group can be replaced by halogen.
[0190] Furthermore, in some cases, suitable substituents may be combined to form one or more rings known to those skilled in the art.
[0191] The term "optionally substituted" in the context of the present invention indicates the presence or absence of the substituent group, i.e., means "substituted" or "unsubstituted". For example, the term "optionally substituted alkyl" includes both unsubstituted alkyl and substituted alkyl.
[0192] According to the invention, the substituents used to replace a particular residue or residues may be further substituted, typically with one or more identical or different residues selected from the various groups shown above and as defined in detail above.
[0193] In a particularly preferred variant according to the first aspect of the invention, the residues R1 and R2 in the general formulae (I) to (VIII) and (Va) and (VIII) are identical or different.
[0194] Preferably, R1 in the general formulae (I) to (VIII) and (Va) to (VIIIa) represents H or an optionally substituted alkyl group or an optionally substituted phenyl group or an optionally substituted thiophene group.
[0195] Further preferably, R2 in the general formulae (I) to (VIII) and (Va) to (VIIIa) represents H or an optionally substituted alkyl group or an optionally substituted phenyl group or an optionally substituted thiophene group.
[0196] Cooling agents having particularly advantageous properties, namely a particularly strong and effective and preferably simultaneously long-lasting cooling effect, are generally present in structures in which, in the general formula (I), (V) or (Va) (having a triazine ring in its basic structure), at least one of the residues R1 and R2 represents an optionally substituted phenyl group or an optionally substituted thiophene group.
[0197] Even more preferably, at least one of the residues R1 and R2 is an optionally substituted phenyl group.
[0198] Most preferred are compounds of formula (I), (V) or (Va) wherein R1 and R2 both represent an optionally substituted phenyl group.
[0199] Specific preferred examples of substitution of the phenyl group are: OH, methyl, ethyl, methoxy or ethoxy.
[0200] Most preferably, R1 and R2 represent phenyl groups.
[0201] In an even more preferred variation, the two phenyl groups together with the atoms to which they are attached form a cyclic ring, including a cycloalkyl or heterocycloalkyl group.
[0202] The most preferred compounds are those of formula (I), (V) or (Va) wherein R1 and R2 are both unsubstituted phenyl groups.
[0203] In a further preferred variant, in the compounds of the general formula (I), (V) or (Va), R1 and R2 are each a substituted or unsubstituted phenyl group which, together with the C atom of the core structure to which they are bound, forms a conjugated or non-conjugated ring system.
[0204] It has been demonstrated that compounds of the general formula (I), (V) or (Va) described above, in particular, wherein R1 and R2 are both substituted or unsubstituted phenyl groups, exhibit excellent TRPM8 activity and are able to produce an exceptionally strong sensory cooling effect even when used in small amounts.
[0205] Cooling agents having particularly advantageous properties, namely a particularly strong and effective and preferably simultaneously long-lasting cooling effect, are also present in structures in which, in the general formula (II), (VI) or (VIa) (having a pyrazine ring in its basic structure), at least one of the residues R1 and R2 represents an optionally substituted phenyl group or an optionally substituted thiophene group.
[0206] Even more preferably, at least one of the residues R1 and R2 is an optionally substituted phenyl group.
[0207] Most preferred are compounds of formula (II), (VI) or (VIa) wherein R1 and R2 both represent an optionally substituted phenyl group.
[0208] Specific preferred examples of substitution are: OH, methyl, ethyl, methoxy or ethoxy.
[0209] Most preferably, R1 and R2 represent phenyl groups.
[0210] In an even more preferred variation, the two phenyl groups together with the atoms to which they are attached form a cyclic ring, including a cycloalkyl or heterocycloalkyl group.
[0211] The most preferred compounds are those of formula (II), (VI) or (VIa) wherein R1 and R2 are both unsubstituted phenyl groups.
[0212] In a further preferred variant, in the compounds of the general formula (II), (VI) or (VIa), R1 and R2 are each a substituted or unsubstituted phenyl group which, together with the C atom of the core structure to which they are bound, form a conjugated or non-conjugated ring system.
[0213] It has been shown that in particular compounds of the general formula (I), (V) or (Va), in which R1 and R2 are both substituted or unsubstituted phenyl groups, exhibit excellent TRPM8 activity and are able to produce an exceptionally strong sensory cooling effect even when used in small amounts.
[0214] Cooling agents having particularly advantageous properties, namely a particularly strong and effective and preferably at the same time long-lasting cooling effect and / or optionally particularly effectively masking an unpleasant taste impression, are also present in structures in which, in the general formula (III), (VII) or (VIIa) (having an oxazole ring in its basic structure), at least one of the residues R1 and R2 represents an optionally substituted phenyl group or an optionally substituted thiophene group.
[0215] Even more preferably, at least one of the residues R1 and R2 is an optionally substituted phenyl group.
[0216] Most preferred are compounds of the general formula (III), (VII) or (VIIa) wherein R1 and R2 both represent an optionally substituted phenyl group.
[0217] Specific preferred examples of substitution are: OH, methyl, ethyl, methoxy or ethoxy.
[0218] Most preferably, R1 and R2 represent phenyl groups.
[0219] In an even more preferred variation, the two phenyl groups together with the atoms to which they are attached form a cyclic ring, including a cycloalkyl or heterocycloalkyl group.
[0220] The most preferred compounds are those of formula (III), (VII) or (VIIa) wherein R1 and R2 are both unsubstituted phenyl groups.
[0221] In a further preferred variant, in the compounds of the general formula (III), (VII) or (VIIa), R1 and R2 are each a substituted or unsubstituted phenyl group which, together with the C atom of the core structure to which they are bound, form a conjugated or non-conjugated ring system.
[0222] It has been shown that in particular those compounds of the general formula (III), (VII) or (VIIa), in which R1 and R2 are both substituted or unsubstituted phenyl groups, exhibit excellent TRPM8 activity and are able to produce an exceptionally strong sensory cooling effect even in small amounts.
[0223] Cooling agents having particularly advantageous properties, namely a particularly strong and effective and preferably simultaneously long-lasting cooling effect, are also present in structures in which, in the general formula (IV), (VIII) or (VIIIa) (having an imidazole ring in its basic structure), at least one of the residues R1 and R2 represents an optionally substituted phenyl group or an optionally substituted thiophene group.
[0224] Even more preferably, at least one of the residues R1 and R2 is an optionally substituted phenyl group.
[0225] Most preferred are compounds of the general formula (IV), (VIII) and (VIIIa) wherein R1 and R2 both represent an optionally substituted phenyl group.
[0226] Specific preferred examples of substitution are: OH, methyl, ethyl, methoxy or ethoxy.
[0227] Most preferably, R1 and R2 represent phenyl groups.
[0228] In an even more preferred variation, the two phenyl groups together with the atoms to which they are attached form a cyclic ring, including a cycloalkyl or heterocycloalkyl group.
[0229] The most preferred compounds are those of formula (IV), (VIII) or (VIIIa) wherein R1 and R2 are both unsubstituted phenyl groups.
[0230] In a further preferred variant, in the compounds of the general formula (IV), (VIII) or (VIIIa), R1 and R2 are each a substituted or unsubstituted phenyl group which, together with the C atom of the core structure to which they are bound, form a conjugated or non-conjugated ring system.
[0231] It has been shown that in particular those compounds of the general formula (IV), (VIII) or (VIIIa), in which R1 and R2 are both substituted or unsubstituted phenyl groups, exhibit excellent TRPM8 activity and are able to produce an exceptionally strong sensory cooling effect even in small amounts.
[0232] Also preferred according to the present invention are cooling agents of general formula (I) to (VIII), wherein Y also represents a straight chain alkylene group, an optional branched chain alkylene group, an alkylaryl group or an alkyl heteroaryl group. Preferably, the alkylene group is a methylene group -CH2-, an ethylene group -CH2-CH2- or a propylene group -CH2-CH2-CH2-. Alternatively, Y in general formula (I) to (VIII) also represents a branched chain alkylene group, preferably a methylene group, which is substituted by a methyl group, an ethyl group, a straight chain or branched chain propyl group or a straight chain or branched chain butyl group.
[0233] Even more preferred according to the invention are compounds of the general formulae (I) to (VIII) in which Y represents a methylene group or a methylene group substituted by a methyl group, an ethyl group, a linear or branched propyl group or a linear or branched butyl group. Such compounds have particularly pronounced cooling properties, as described below.
[0234] Even more preferred are cooling agents of general formula (I) or (V) having one of the following structural combinations:
[0235] R1 and / or R2 = optionally substituted phenyl group, and Y = methylene;
[0236] R1 and / or R2 = optionally substituted phenyl group, and Y = straight chain ethylene; or
[0237] R1 and / or R2 = optionally substituted phenyl group, and Y = straight-chain or branched propylene; or
[0238] R1 and / or R2 = optionally substituted phenyl group, and Y = methylene group substituted by a methyl group, an ethyl group, a straight-chain or branched propyl group or a straight-chain or branched butyl group.
[0239] Also preferred are cooling agents of general formula (II) or (VI) having one of the following structural combinations:
[0240] R1 and / or R2 = optionally substituted phenyl group, and Y = methylene;
[0241] R1 and / or R2 = optionally substituted phenyl group, and Y = straight chain ethylene; or
[0242] R1 and / or R2 = optionally substituted phenyl group, and Y = straight-chain or branched propylene; or
[0243] R1 and / or R2 = optionally substituted phenyl group, and Y = methylene group substituted by a methyl group, an ethyl group, a straight-chain or branched propyl group or a straight-chain or branched butyl group.
[0244] Further preferred are those cooling agents of the general formula (III) or (VII) having one of the following structural combinations:
[0245] R1 and / or R2 = optionally substituted phenyl group, and Y = methylene;
[0246] R1 and / or R2 = optionally substituted phenyl group, and Y = straight chain ethylene; or
[0247] R1 and / or R2 = optionally substituted phenyl group, and Y = straight-chain or branched propylene; or
[0248] R1 and / or R2 = optionally substituted phenyl group, and Y = methylene group substituted by a methyl group, an ethyl group, a straight-chain or branched propyl group or a straight-chain or branched butyl group.
[0249] Further preferred are those cooling agents of the general formula (IV) or (VIII) having one of the following structural combinations:
[0250] R1 and / or R2 = optionally substituted phenyl group, and Y = methylene;
[0251] R1 and / or R2 = optionally substituted phenyl group, and Y = straight chain ethylene; or
[0252] R1 and / or R2 = optionally substituted phenyl group, and Y = straight-chain or branched propylene; or
[0253] R1 and / or R2 = optionally substituted phenyl group, and Y = methylene group substituted by a methyl group, an ethyl group, a straight-chain or branched propyl group or a straight-chain or branched butyl group.
[0254] Even more preferred are those cooling agents of general formula (I) or (V) having one of the following structural combinations:
[0255] R1 and / or R2 = phenyl group, and Y = methylene;
[0256] R1 and / or R2 = phenyl group, and Y = straight-chain ethylene; or
[0257] R1 and / or R2 = phenyl group, and Y = straight-chain or branched propylene; or
[0258] R1 and / or R2 = phenyl group, and Y = methylene substituted by a methyl group, an ethyl group, a straight-chain or branched propyl group or a straight-chain or branched butyl group.
[0259] Also preferred are cooling agents of general formula (II) or (VI) having one of the following structural combinations:
[0260] R1 and / or R2 = phenyl group, and Y = methylene;
[0261] R1 and / or R2 = phenyl group, and Y = straight-chain ethylene; or
[0262] R1 and / or R2 = phenyl group, and Y = straight-chain or branched propylene; or
[0263] R1 and / or R2 = phenyl group, and Y = methylene substituted by a methyl group, an ethyl group, a straight-chain or branched propyl group or a straight-chain or branched butyl group.
[0264] Further preferred are cooling agents of general formula (III) or (VII) having one of the following structures:
[0265] R1 and / or R2 = phenyl group, and Y = methylene;
[0266] R1 and / or R2 = phenyl group, and Y = straight-chain ethylene; or
[0267] R1 and / or R2 = phenyl group, and Y = straight-chain or branched propylene; or
[0268] R1 and / or R2 = phenyl group, and Y = methylene substituted by a methyl group, an ethyl group, a straight-chain or branched propyl group or a straight-chain or branched butyl group.
[0269] Further preferred are cooling agents of general formula (IV) or (VIII) having one of the following structures:
[0270] R1 and / or R2 = phenyl group, and Y = methylene;
[0271] R1 and / or R2 = phenyl group, and Y = straight-chain ethylene; or
[0272] R1 and / or R2 = phenyl group, and Y = straight-chain or branched propylene; or
[0273] R1 and / or R2 = phenyl group, and Y = methylene substituted by a methyl group, an ethyl group, a straight-chain or branched propyl group or a straight-chain or branched butyl group.
[0274] Among the last-mentioned cooling agents according to the general formulae (I) to (VIII), most preference is given to those compounds in which Y represents a methylene group substituted by a methyl group or an ethyl group.
[0275] These compounds are characterized by a particularly strong cooling effect.
[0276] In the general formulae (I) to (VIII), Z is selected from: NH2, NHRa group, NRaRb group, optionally substituted straight chain or branched alkyl group, optionally substituted straight chain or branched alkenyl group, optionally substituted straight chain or branched alkylthio group, optionally substituted straight chain or branched alkoxy group, OH, optionally substituted cycloalkyl group, optionally substituted heterocycloalkyl group, optionally substituted aryl group or optionally substituted heteroaryl group, wherein Ra and / or Rb are
[0277] is an optionally substituted straight or branched chain alkyl group, or
[0278] is an optionally substituted straight-chain or branched alkenyl group, or
[0279] is an optionally substituted straight-chain or branched alkenyl group, or
[0280] is an optionally substituted straight-chain or branched alkynyl group, or
[0281] is an optionally substituted straight-chain or branched alkoxy group, or
[0282] is an optionally substituted straight-chain or branched alkylthio group, or
[0283] is an optionally substituted acyl group R-(C=O)-, or
[0284] is an optionally substituted cycloalkyl group, or
[0285] is an optionally substituted aryl group, or
[0286] is an optionally substituted heterocycloalkyl group, or
[0287] is an optionally substituted heteroaryl group.
[0288] In another alternative variation, the Ra and Rb residues of the NRaRb group as defined above are linked together and form a saturated or unsaturated ring, preferably a saturated or unsaturated three- to eight-membered ring.
[0289] Particularly preferred according to the invention are cooling agents of the general formulae (I) to (VIII) in which Ra and / or Rb in the NHRa group or the NRaRb group represents a C1 to C3 alkyl group, preferably a methyl group.
[0290] Even more preferred according to the invention are those cooling agents of the general formulae (I) to (VIII) in which Z is selected from:
[0291]
[0292]
[0293] Therefore, in a preferred variant according to the first aspect of the present invention, the cooling agent is of the general formula (I) to (VIII) having the following structure:
[0294]
[0295]
[0296]
[0297]
[0298]
[0299]
[0300]
[0301] Even more preferred according to the invention are cooling agents of the general formula (I), (II), (V) or (VI) having the following structure:
[0302]
[0303]
[0304] Even more preferred according to the invention are cooling agents of the general formula (III), (IV), (VII) or (VIII) having the following structure:
[0305]
[0306]
[0307] With regard to the TRPM8 activity determined, preference is also given to compounds of the general formulae (I) to (VIII) in which n and m are each 1.
[0308] Among the physiological cooling agents defined and described above, those of the general formulae (I) to (IV) in which X represents a sulfur atom are particularly preferred. Such compounds have particularly pronounced cooling properties, as described below.
[0309] Particularly advantageous cooling properties are surprisingly exhibited by the following compounds according to the present invention, in which, in the general formulae (I) to (VIII), R1 and R2 each represent an unsubstituted phenyl group, X represents a sulfur atom, Y represents a methylene group or a methylene group substituted by a methyl group, an ethyl group, a linear or branched propyl group or a linear or branched butyl group, and Z has the meaning as defined above.
[0310] Such compounds are particularly effective cooling substances, as shown below.
[0311] Most preferred according to the invention are compounds of the general formula (Va) to (VIIIa) in which the residues R1 and / or R2 represent an unsubstituted phenyl group or a substituted phenyl group, Y represents a branched alkylene group, preferably a methylene group, which is substituted by a methyl group, an ethyl group, a straight-chain or branched propyl group or a straight-chain or branched butyl group, and Z has the meaning as defined above for the compounds of the general formula (I) to (VIII).
[0312] This class of compounds exhibits significant TRPM8 activity and are very potent sensory cooling agents even in small amounts.
[0313] The cooling agents of the general formula (Va) or (VIa) having one of the following structural combinations are particularly preferred:
[0314] R1 and / or R2 = optionally substituted phenyl group and Y = methylene substituted by a methyl group; or
[0315] R1 and / or R2 = optionally substituted phenyl group and Y = methylene substituted by an ethyl group; or
[0316] R1 and / or R2 = optionally substituted phenyl group and Y = methylene substituted by a linear or branched propyl group; or
[0317] R1 and / or R2 = optionally substituted phenyl group and Y = methylene substituted by a linear or branched butyl group.
[0318] Particularly preferred are those cooling agents of the general formula (VIIa) or (VIIIa) which have one of the following structural combinations:
[0319] R1 and / or R2 = optionally substituted phenyl group and Y = methylene substituted by a methyl group; or
[0320] R1 and / or R2 = optionally substituted phenyl group and Y = methylene substituted by an ethyl group; or
[0321] R1 and / or R2 = optionally substituted phenyl group and Y = methylene substituted by a linear or branched propyl group; or
[0322] R1 and / or R2 = optionally substituted phenyl group and Y = methylene substituted by a linear or branched butyl group.
[0323] Also preferred are cooling agents of general formula (Va) or (VIa) having one of the following structural combinations:
[0324] R1 and / or R2 = phenyl group and Y = methylene substituted by a methyl group; or
[0325] R1 and / or R2 = phenyl group and Y = methylene substituted by an ethyl group; or
[0326] R1 and / or R2 = phenyl group and Y = methylene substituted by a linear or branched propyl group; or
[0327] R1 and / or R2 = phenyl group and Y = methylene substituted by a linear or branched butyl group.
[0328] Also preferred are cooling agents of general formula (VIIa) or (VIIIa) having one of the following structural combinations:
[0329] R1 and / or R2 = phenyl group and Y = methylene substituted by a methyl group; or
[0330] R1 and / or R2 = phenyl group and Y = methylene substituted by an ethyl group; or
[0331] R1 and / or R2 = phenyl group and Y = methylene substituted by a linear or branched propyl group; or
[0332] R1 and / or R2 = phenyl group and Y = methylene substituted by a linear or branched butyl group.
[0333] Surprisingly, excellent cooling properties are exhibited by the following compounds according to the invention, in which, in the general formulae (Va) to (VIIIa), R1 and R2 each represent an unsubstituted phenyl group, Y represents a branched alkylene group, preferably a methylene group, which is substituted by a methyl group, an ethyl group, a linear or branched propyl group or a linear or branched butyl group, and Z has the meaning defined above for the compounds of the general formulae (I) to (VIII).
[0334] Therefore, the most preferred is the cooling agent of general formula (Va) or (VIa), which has one of the following structural combinations:
[0335] R1 and R2 = phenyl groups and Y = methylene substituted by a methyl group; or
[0336] R1 and R2 = phenyl groups and Y = methylene substituted by an ethyl group; or
[0337] R1 and R2 = phenyl groups and Y = methylene substituted by a straight-chain or branched propyl group; or
[0338] R1 and R2 = phenyl groups and Y = methylene substituted by a linear or branched butyl group; and
[0339] The cooling agent of general formula (VIIa) or (VIIIa) has one of the following structural combinations:
[0340] R1 and R2 = phenyl groups and Y = methylene substituted by a methyl group; or
[0341] R1 and R2 = phenyl groups and Y = methylene substituted by an ethyl group; or
[0342] R1 and R2 = phenyl groups and Y = methylene substituted by a straight-chain or branched propyl group; or
[0343] R1 and R2 = phenyl groups and Y = methylene substituted by a linear or branched butyl group.
[0344] Among the last-mentioned coolants according to the general formulae (Va) to (VIIIa), those compounds in which Y represents a methylene group substituted by a methyl group or an ethyl group are most preferred.
[0345] These compounds have particularly high TRPM8 activity and produce an exceptionally strong sensory cooling effect even when used in small amounts.
[0346] In the general formulae (Va), (VIa), (VIIa) and (VIIIa), Z is selected from the group consisting of NH2, NHRa group, NRaRb group, optionally substituted straight or branched alkyl group, optionally substituted straight or branched alkenyl group, optionally substituted straight or branched alkylthio group, optionally substituted straight or branched alkoxy group, OH, optionally substituted cycloalkyl group, optionally substituted heterocycloalkyl group, optionally substituted aryl group or optionally substituted heterocycloalkyl group, optionally substituted straight or branched alkoxy group, OH, optionally substituted cycloalkyl group, optionally substituted heterocycloalkyl group, optionally substituted aryl group or optionally substituted heteroaryl group, wherein Ra and / or Rb are
[0347] is an optionally substituted straight or branched chain alkyl group, or
[0348] is an optionally substituted straight-chain or branched alkenyl group, or
[0349] is an optionally substituted straight-chain or branched alkenyl group, or
[0350] is an optionally substituted straight-chain or branched alkynyl group, or
[0351] is an optionally substituted straight-chain or branched alkoxy group, or
[0352] is an optionally substituted straight-chain or branched alkylthio group,
[0353] is an optionally substituted acyl group R-(C=O)-, or
[0354] is an optionally substituted cycloalkyl group, or
[0355] is an optionally substituted aryl group, or
[0356] is an optionally substituted heterocycloalkyl group, or
[0357] is an optionally substituted heteroaryl group.
[0358] In another alternative variation, the Ra and Rb residues of the NRaRb group as defined above are linked together and form a saturated or unsaturated ring, preferably a saturated or unsaturated three- to eight-membered ring.
[0359] Particularly preferred according to the invention are cooling agents of the general formulae (Va) to (VIIIa), in which Ra and / or Rb in the NHRa group or in the NRaRb group represent a C1 to C3 alkyl group, preferably a methyl group.
[0360] Even more preferred according to the invention are those cooling agents of the general formulae (Va), (VIIa) and (VIIIa), in which Z is selected from:
[0361]
[0362]
[0363] Even more preferred according to the invention are those cooling agents of the general formula (VIa) in which Z is selected from: -NH2, -NH-CH3, -NH-CH2-CH3, -NH-CH2-CH2-CH3, -NH-CH2-CH2-CH2-CH3, -NH-CH(CH3)-CH(CH3)2, -NH-CH(CH3)-CH2-CH2-CH3, -NH-CH2-CH(CH3)2, -NH-CH2-CH2-O-CH3, -NH-CH(CH3)-CH2-O-CH3, -NH-C(=O)-CH3, -NH-C(=O)-O-CH3, -NH-CH(CH3)-CH2-OH, -NH-CH(CH3)-CH2-OH, -NH-CH(CH3)-CH2-CH3 ...O-CH3, -NH-CH(CH3)-CH2-O-CH3, -NH-C(=O)-CH3, -NH-C(=O)-O-CH3, -NH-CH(CH3)-CH2-OH, -NH-CH(CH3)-CH2-OH, -NH-CH(CH3)-CH2-OH, -NH-CH(CH3)-CH2-OH, -NH-CH(CH3)-CH2-OH NH-CH2-furanyl, -NH-CH2-tetrahydrofuranyl, -NH-CH2-phenylthio, -NH-tolyl, -NH-CH-(CH3)2, -NH-C(CH3)3, -NH-cyclopropyl, -NH-cyclobutyl, -NH-cyclopentyl, -N(CH3)2, -N(CH3)-cyclohexyl, -N(CH2-CH3)2, azetidinyl, pyrrolidinyl, piperidinyl, azetidinyl, pyrrolyl, pyridinyl, -O, -O-CH3, -OC(=O)-CH3, oxetanyl, -CH3, -CH2-CH3, -CH(CH3)2, -C(OH)-CH2-OH, cyclopropyl, phenyl, and -CH2-S-CH3.
[0364] In the general formula (VIa), Z does not represent -NH-phenyl, -N(CH3)-phenyl, -OH, -OC2H5 or -OC(CH3)3.
[0365] Therefore, in a preferred variant according to the first aspect of the present invention, the cooling agent is of the general formula (Va) to (VIIIa) having the following structure:
[0366]
[0367]
[0368]
[0369]
[0370]
[0371]
[0372] According to the present invention, the cooling agents of the general formula (Va) or (VIa) having the following structure are even more preferred:
[0373]
[0374]
[0375] Even more preferred according to the invention are also those cooling agents of the general formula (VIIa) or (VIIIa) which have the following structure:
[0376]
[0377] Furthermore, compounds of the general formulae (Va) to (VIIIa) in which m is in each case 1 appear to be preferred with regard to the TRPM8 activity determined.
[0378] In particular, the cooling agent according to the general formula (VIa) does not include those compounds where, in the general formula (VIa), R1 and R2 represent phenyl, Y represents a branched alkyl group, in particular Y represents a methylene group substituted by -CH3 or -CH2CO2C2H5, and Z in the general formula (VIa) represents -NH-phenyl, -N(CH3)-phenyl, -OH, -OC2H5 or -OC(CH3)3.
[0379] The physiological cooling agents according to the general formulae (I) to (VIII) and (Va) to (VIII) are present in neutral, ie uncharged, form or in the form of their salts, for example as acid addition salts with inorganic or organic acids.
[0380] The term "salt" in the context of the present invention refers to a salt of a compound that has the desired effect or pharmacological activity of the parent compound. Such salts include:
[0381] (1) an acid addition salt formed with an inorganic acid or an organic acid, wherein the organic acid is preferably a monovalent or polyvalent carboxylic acid; or
[0382] (2) Salts formed when the acidic protons present in the starting compound are replaced by metal ions (such as alkali metal ions, alkaline earth ions or aluminum ions); or when coordinated with organic bases.
[0383] Of these salts, the acid addition salts are again particularly preferred, since the physiological cooling agents according to the general formulae (I) to (VIII) contain protonatable N atoms.
[0384] The inorganic acid that forms an acid addition salt with the physiological cooling agent of the present invention is preferably selected from: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. Among these salts, hydrochloride or sulfate is most preferred. Hydrochloride or sulfate is particularly preferred.
[0385] Even more preferred are acid addition salts with organic mono- or polycarboxylic acids. Further preferred are acid addition salts with organic mono- or polycarboxylic acids, wherein the carboxylic acid is selected from saturated or monounsaturated or polyunsaturated C1 to C30 monocarboxylic acids, saturated or monounsaturated or polyunsaturated C3 to 10 dicarboxylic acids or tricarboxylic acids. The carboxylic acids may be mono- or polysubstituted with hydroxyl groups, preferably α-hydroxycarboxylic acids in which the hydroxyl groups are located on carbon atoms adjacent to the carboxyl groups. Many representative substances occur naturally as so-called fruit acids. Preferred α-hydroxycarboxylic acids are malic acid, citric acid, 2-hydroxy-4-methylmercaptobutyric acid, glycolic acid, isocitric acid, mandelic acid, lactic acid, tartronic acid or tartaric acid.
[0386] The organic acid which forms an acid addition salt with the physiological cooling agent according to the invention is preferably selected from the group consisting of amino acids, acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, oxalic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, dodecylsulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, hexadienedioic acid, 4-hydroxybutyric acid, and the like.
[0387] Among the organic acids which form acid addition salts with the physiological cooling agents of the invention, the most preferred are acetic acid, lactic acid, malonic acid, succinic acid, malic acid, citric acid or tartaric acid.
[0388] The metal ions used for salt formation (which replace the acidic protons present in the starting compound) are selected from: alkali metal ions (preferably Na + or K + ), alkaline earth metal ions (preferably Ca ++ Mg ++ and aluminum +++ ).
[0389] The coordinating organic base used for salt formation is selected from: ethanolamine, diethanolamine, triethanolamine, N-methylglucamine and the like.
[0390] In the following description and in the patent claims, the term "physiological cooling agent" or "compound" comprises the neutral, uncharged form of said cooling agent / compound as well as the salt form of likewise said cooling agent / compound.
[0391] Due to their better solubility, the salts of the physiological cooling agents according to the invention are particularly preferred. Better water solubility also leads to better availability of the cooling agent or compound during its use.
[0392] Surprisingly, it is found that the compounds or cooling agents or salts thereof according to the present invention have a common characteristic: even at low doses within the low ppm range of about 5ppm, a particularly long-lasting and strong cooling effect can be produced on the skin or mucous membrane in vivo. This means that in the final preparation, a relatively low dose of the cooling agent or salt thereof according to the present invention is required to achieve a strong cooling effect. Therefore, the compounds described herein are particularly effective cooling substances. This is unforeseeable for the TRPM8 modulators mentioned in this application.
[0393] The cooling agents according to the invention are further characterized in that their cooling effect starts very quickly; on the other hand, other cooling agents according to the invention have a cumulative cooling effect, ie the cooling effect increases over time and produces a longer and more intense cooling effect.
[0394] The cooling agent according to the present invention is still colorless and does not change color, which is particularly advantageous for their storage and / or use in the final product. Therefore, the compound feature as described herein is a particularly suitable additive in various preparations. In addition, the compound according to the present invention as described herein is substantially tasteless and odorless, so they are also very suitable for being incorporated into neutral and / or seasoning preparations, and will not produce a taste impression that is considered to be negative, such as bitter taste, or adversely affecting the taste or smell impression of expectation.
[0395] The salts of the cooling agents according to the invention exhibit better solubility in vitro than their neutral, uncharged equivalents, which is particularly advantageous when they are used in the oral care field.
[0396] To date, there has been no evidence at all in the prior art that the compounds to be used according to the invention or their salts can produce a cooling effect in particular and certainly not a particularly long-lasting cooling effect.
[0397] It is also surprising that the cooling agent or its salt according to the present invention can mask the taste disadvantages of known flavoring agents (especially sweeteners such as stevioside). In particular, even if added in small amounts, it can effectively mask spicy, bitter and metallic aftertaste.
[0398] The compounds described herein are therefore suitable as particularly effective cooling substances which can be incorporated particularly well into various formulations. Due to their improved solubility, the salts of the compounds according to the invention, and even more preferably the acid addition salts, are particularly advantageous for use in the oral care sector.
[0399] Particularly preferred are physiological cooling agents of the general formula (I), (II), (V) or (VI) selected from the compounds shown in Table 1:
[0400] Table 1: Structures according to the present invention and relative TRPM8 activation (%)
[0401]
[0402]
[0403]
[0404]
[0405]
[0406]
[0407]
[0408]
[0409]
[0410]
[0411]
[0412]
[0413] The cooling agents according to the invention listed in Table 1 according to the general formula (I), (II), (V) or (VI) are present either in neutral, uncharged form or in the form of their salts, for example as acid addition salts with inorganic or organic monovalent or polyvalent carboxylic acids, as described in detail above. In this respect, the above also applies here.
[0414] The coolants according to Table 1 can be present in stereoisomerically pure form or as a mixture of different stereoisomers and can therefore also be used in this way in the formulations.
[0415] Surprisingly, it has been shown that the compounds according to Table 1 have a particularly high TRPM8 activation and are therefore very suitable for use as cooling agents.
[0416] The most preferred cooling agents, i.e. cooling agents with particularly effective and strong TRPM8 activation, i.e. cooling agents which achieve an effective and strong cooling effect at low application rates, are compounds B-01, B-02, B-03, B-04, B-05, B-06, B-07, B-11, B-14, B-15, B-17, B-18, B-19 and B-21 (TRPM8 activation ≥90%), and in particular compounds B-01, B-02, B-03, B-04, B-05, B-06, B-07, B-11, B-14, B-15, B-17, B-18 and B-19 (TRPM8 activation ≥100%). Particularly preferred are compounds B-01, B-02, B-03, B-04, B-05, B-06, and B-07, which exhibit extremely high TRPM8 activity (TRPM8 activation ≥ 150%).
[0417] Due to their outstanding relative TRPM8 activation, compounds B-01 (TRPM8 activation of 262%), B-02 (TRPM8 activation of 227%), B-03 (TRPM8 activation of 221%), B-04 (TRPM8 activation of 210%), B-05 (TRPM8 activation of 205%), B-06 (TRPM8 activation of 205%) and B-07 (TRPM8 activation of 203%) are most preferred.
[0418] Compound B-01 (triazine derivative) is characterized in that, in the general formula (V), R1 and R2 represent phenyl groups, Y represents a branched methylene group substituted with an ethyl group, and Z represents an -NH-cyclopropyl group.
[0419] Compound B-02 (pyrazine derivative) is characterized in that, in the general formula (VI), R1 and R2 represent phenyl groups, Y represents a branched methylene group substituted with an ethyl group, and Z represents a -NH-CH3- group.
[0420] Compound B-03 (triazine derivative) is characterized in that, in the general formula (V), R1 and R2 represent phenyl groups, Y represents a branched methylene group substituted with an ethyl group, and Z represents a -NH-CH3- group.
[0421] Compound B-04 (pyrazine derivative) is characterized in that, in the general formula (VI), R1 and R2 represent phenyl groups, Y represents a methylene group, and Z represents a -NH-CH3- group.
[0422] Compound B-05 (triazine derivative) is characterized in that, in the general formula (V), R1 and R2 represent phenyl groups, Y represents a branched methylene group substituted with an ethyl group, and Z represents a -N(CH3)2- group.
[0423] Compound B-06 (triazine derivative) is characterized in that, in the general formula (V), R1 and R2 represent a phenyl group, Y represents a methylene group, and Z represents an azetidinium group.
[0424] Compound B-07 (triazine derivative) is characterized in that, in the general formula (V), R1 and R2 represent phenyl groups, which together with the C atoms of the triazine ring to which they are connected form a condensed ring system, namely 1,2,4-triazaphenylene, Y represents a branched methylene group substituted by a methyl group, and Z represents a -NH-CH3- group.
[0425] Even more preferred are physiological cooling agents of general formula (Va) or (VIa) selected from the compounds shown in Table A:
[0426] Table A: Structures according to the invention and relative TRPM8 activation (%)
[0427]
[0428]
[0429]
[0430]
[0431]
[0432]
[0433]
[0434] The cooling agents according to the invention listed in Table A according to the general formula (Va) or (VIa) are present either in neutral, uncharged form or in the form of their salts, for example as acid addition salts with inorganic or organic monovalent or polyvalent carboxylic acids, as described in detail above. In this respect, the above also applies here.
[0435] The cooling agents according to table A may be present in stereoisomerically pure form or as a mixture of different stereoisomers and can therefore also be used in this way in the formulations.
[0436] Surprisingly, it has been shown that the compounds according to Table A have a particularly high TRPM8 activation activity and are therefore very suitable for use as cooling agents.
[0437] The most preferred cooling agents, i.e. cooling agents with particularly effective and strong TRPM8 activation, i.e. cooling agents that achieve a highly effective and strong cooling effect at low application rates, are compounds B-01, B-02, B-03, B-05, B-07, B-11, B-14, B-15 and B-18 (TRPM8 activation ≥ 100%). Compounds B-01, B-02, B-03, B-05 and B-07 are particularly preferred because they exhibit extremely high TRPM8 activity (TRPM8 activation ≥ 150%).
[0438] Due to their outstanding relative TRPM8 activation, compounds B-01 (TRPM8 activation of 262%), B-02 (TRPM8 activation of 227%), B-03 (TRPM8 activation of 221%), B-05 (TRPM8 activation of 205%) and B-07 (TRPM8 activation of 203%) are most preferred.
[0439] Likewise particularly preferred are physiological cooling agents of the general formula (III), (IV), (VII) or (VIII) which are selected from the compounds shown in Table 2:
[0440] Table 2: Structures according to the present invention and relative TRPM8 activation (%)
[0441]
[0442]
[0443]
[0444]
[0445]
[0446]
[0447]
[0448]
[0449]
[0450]
[0451]
[0452]
[0453]
[0454] The cooling agents according to the invention listed in Table 2 according to the general formula (III), (IV), (VII) or (VIII) are present either in neutral, uncharged form or in the form of their salts, for example as acid addition salts with inorganic or organic monovalent or polyvalent carboxylic acids, as described in detail above. In this respect, the above also applies here.
[0455] The coolants according to Table 2 can be present in stereoisomerically pure form or as a mixture of different stereoisomers and can therefore also be used in this way in the formulations.
[0456] Surprisingly, it has been shown that the compounds according to the invention have a particularly high TRPM8 activation activity and are therefore very suitable for use as cooling agents.
[0457] The most preferred cooling agents, i.e. cooling agents with particularly effective and strong TRPM8 activation, i.e. cooling agents which achieve an effective and strong cooling effect at low application rates, are compounds A-01, A-02, A-03, A-04, A-05, A-06, A-07, A-08, A-09, A-10, A-11, A-12, A-15, A-16 and A-17 (TRPM8 activation ≥90%), and in particular compounds A-01, A-02, A-03, A-04, A-05, A-06, A-07, A-08, A-09, A-10, A-11, A-12, A-15 and A-16 (TRPM8 activation ≥100%). Particularly preferred are compounds A-01, A-02, A-03, A-04, A-05, A-06, A-07 and A-08, which exhibit extremely high TRPM8 activity (TRPM8 activation ≥ 150%).
[0458] Due to their outstanding relative TRPM8 activation, compounds A-01 (TRPM8 activation of 278%), A-02 (TRPM8 activation of 265%), A-03 (TRPM8 activation of 260%), A-04 (TRPM8 activation of 215%), A-05 (TRPM8 activation of 190%), A-06 (TRPM8 activation of 186%) and A-07 (TRPM8 activation of 183%) as well as A-08 (TRPM8 activation of 177%) are most preferred.
[0459] Compound A-01 (oxazole derivative) is characterized in that, in the general formula (VII), R1 and R2 represent phenyl groups, X represents an S atom, Y represents a branched methylene group substituted by a methyl group, and Z represents a -NH-CH3- group.
[0460] Compound A-02 (oxazole derivative) is characterized in that, in the general formula (VII), R1 and R2 represent phenyl groups, X represents an S atom, Y represents a branched methylene group substituted with a methyl group, and Z represents a -NH-CH3- group.
[0461] Compound A-03 (oxazole derivative) is characterized in that, in the general formula (VII), R1 and R2 represent phenyl groups, X represents an S atom, Y represents a branched methylene group substituted with a methyl group, and Z represents a -NH-CH3- group.
[0462] Compound A-04 (oxazole derivative) is characterized in that, in the general formula (VII), R1 and R2 represent phenyl groups, X represents a cis-cyclopropyl group, and Z represents a -NH-CH3- group.
[0463] Compound A-05 (oxazole derivative) is characterized in that, in the general formula (VII), R1 represents a CH3 group and R2 represents a phenyl group, X represents an S atom, Y represents a branched methylene group substituted by a methyl group, and Z represents a -NH-CH3- group.
[0464] Compound A-06 (oxazole derivative) is characterized in that, in the general formula (VII), R1 and R2 represent phenyl groups, X represents an S atom, Y represents a methylene group, and Z represents an -NH-cyclopropyl group.
[0465] Compound A-07 (oxazole derivative) is characterized in that, in the general formula (VII), R1 and R2 represent phenyl groups, X and Y represent methylene groups, and Z represents a -NH-CH2-CH3- group.
[0466] Even more preferred are physiological cooling agents of the general formula (VIIa) or (VIIIa) selected from the compounds shown in Table B:
[0467] Table B: Structures according to the invention and relative TRPM8 activation (%)
[0468]
[0469]
[0470]
[0471]
[0472] The cooling agents according to the invention listed in Table B according to the general formula (VIIa) or (VIIIa) are present either in neutral, uncharged form or in the form of their salts, for example as acid addition salts with inorganic or organic monovalent or polyvalent carboxylic acids, as described in detail above. In this respect, the above also applies here.
[0473] The cooling agents according to table B may be present in stereoisomerically pure form or as a mixture of different stereoisomers and can therefore also be used in this way in the formulations.
[0474] Surprisingly, it has been shown that the compounds according to Table B have a particularly high TRPM8 activation and are therefore very suitable for use as cooling agents.
[0475] The most preferred cooling agents, i.e. cooling agents with particularly effective and strong TRPM8 activation, i.e. cooling agents that achieve an effective and strong cooling effect at low application rates, are compounds A-01, A-02, A-03, A-05, A-09, A-10 and A-12 (TRPM8 activation ≥ 100%). Compounds A-01, A-02, A-03 and A-05 are particularly preferred because they exhibit extremely high TRPM8 activity (TRPM8 activation ≥ 150%).
[0476] Due to their outstanding relative TRPM8 activation, compounds A-01 (TRPM8 activation of 278%), A-02 (TRPM8 activation of 265%), A-03 (TRPM8 activation of 260%) and A-05 (TRPM8 activation of 190%) are most preferred.
[0477] It has been shown that the above-mentioned preferred compounds B-01, B-02, B-03, B-04, B-05, B-06, B-07, B-11, B-14, B-15, B-17, B-18, B-19 and B-21 and A-01, A-02, A-03, A-04, A-05, A-06, A-07, A-08, A-09, A-10, A-11, A-12, A-15, A-16 and A-17 have a particularly high TRPM8 activity and therefore exhibit a strong and simultaneously effective cooling effect; i.e., only small amounts (low ppm range of about 5 ppm) of the substances according to the invention are required to produce a strong cooling effect (low EC50, see experimental data below). That is, only small amounts of the substances according to the invention in the low ppm range of about 5 ppm are required to produce a strong cooling effect (low EC50 values, see experimental data below). A strong cooling effect was also demonstrated during the sensory evaluation (i.e., tasting the corresponding samples). For example, the panelists rated the cooling effect of compound B-11 as 5.3 points at an application level of 5 ppm. Therefore, considering the amount of compound used, the sensory evaluation of cooling intensity is comparable to the results of the reference cooling substance WS-3, which has a six-fold higher concentration (dosage: 30 ppm; sensory evaluation of cooling intensity: score 5.4).
[0478] Compounds A-2 and A-10 also exhibited very high TRPM8 activity and a strongly perceived cooling effect (sensory cooling intensity: score 5.4 and score 5.38, respectively), and are therefore suitable as particularly effective cooling agents.
[0479] Among the compounds of the general formula (I) to (IV) defined above, the compounds of the general formula (V), (VI), (VII) and (VIII) are the most preferred. The compounds of the general formula (Va), (VIa), (VIIa) and (VIIIa) are the most preferred. These cooling agents are characterized by high TRPM8 activation and at the same time exhibit very high sensory cooling intensity. They can cause a strong cooling effect even at low concentrations, and are generally well below the EC50 reference value of 1.72 μM of substance WS-3, as shown in the following experimental section.
[0480] Although the physiological amine coolants according to the invention are not known in the prior art, they can be produced according to standard methods of generally known preparative organic chemistry, which are shown in general form as an example in the following figure.
[0481] Scenario 1:
[0482]
[0483] Scenario 2:
[0484]
[0485] Solution 3:
[0486]
[0487] Solution 4:
[0488]
[0489] Solution 5:
[0490]
[0491] Solution 6:
[0492]
[0493] Solution 7:
[0494]
[0495] Solution 8:
[0496]
[0497] Solution 9:
[0498]
[0499] Solution 10:
[0500]
[0501] Solution 11:
[0502]
[0503] In principle, the present invention comprises all mixtures of the individual compounds of the general formula (I) to (IV), and therefore also all mixtures of the individual compounds of the general formula (V) to (VIII) or (Va) to (VIII), and their use as cooling agents or cooling agent mixtures. However, the present compounds are also suitable for mixing with other known cooling agents.
[0504] Therefore, another object of the present invention relates to a physiological cooling agent mixture, which comprises or consists of:
[0505] (a) one, two, three or more cooling agents of formula (I) to (VIII), (Va), (VIa), (VIIa) or (VIIIa) or as listed in Table 1, Table 2, Table A or Table B and as defined above; and optionally
[0506] (b) at least one other physiological cooling agent; and / or optionally
[0507] (c) at least one solvent.
[0508] In a preferred embodiment, the present invention relates to a cooling agent mixture comprising or consisting of at least one of the compounds according to the invention of the general formula (I) to (VIII), (Va), (VIa), (VIIa) or as listed in Table 1, Table 2, Table A or Table B and as defined above. Optionally, the cooling agent mixture also comprises a further physiological cooling agent and optionally at least one suitable solvent.
[0509] A particular advantage of such cooling agent mixtures is that a synergistic increase in the cooling effect may be observed.
[0510] Suitable cooling agent forming component (b) different from cooling agent forming component (a) is selected from: menthol, menthol methyl ether (FEMA GRAS 4054), monomenthyl glutamate (FEMA GRAS 4006), menthyl-1,2-propanediol (FEMA GRAS 3784), dimenthyl glutarate (FEMA GRAS 4604), hydroxymethyl cyclohexyl ethyl ketone (FEMA GRAS 4742), 2-(4-ethylphenoxy)-N-(1H-pyrazol-3-yl)-N-(thiophen-2-ylmethyl)acetamide (FEMA GRAS 4880), WS-23 (2-isopropyl-N,2,3-trimethylbutanamide, FEMA GRAS 3804), N-(4-(cyanomethyl)phenyl)-2-isopropyl-5,5-dimethylcyclohexanecarboxamide (FEMA GRAS 4882), N-(3-hydroxy-4-methoxyphenyl)-2-isopropyl-5,5-dimethylcyclohexanecarboxamide (FEMA GRAS 4881), N-(2-hydroxy-2-phenylethyl)-2-isopropyl-5,5-dimethylcyclohexane-1-carboxamide (FEMA GRAS 4896), 3,4-methylenedioxycinnamic acid, (E)-3-benzo[1,3]dioxol-5-yl-N,N-diphenyl-2-acrylamide (FEMA GRAS 4788), menthol propylene glycol carbonate (FEMA GRAS 3806), N-ethyl oxalate, monomethyl succinate (FEMA GRAS 3810), WS-3 (N-ethyl-p-menthane-3-carboxamide, FEMA GRAS 3455), menthol glycol carbonate (FEMA GRAS 3805), WS-5 (3-(p-menthane-3-carboxamido) ethyl acetate, FEMA GRAS 4309), WS-12 (1R, 2S, 5R)-N-(4-methoxyphenyl)-p-menthane carboxamide (FEMA GRAS 4681), WS-27 (N-ethyl-2,2-diisopropylbutanamide, FEMA GRAS4557), N-cyclopropyl-5-methyl-2-isopropylcyclohexanecarboxamide (FEMA GRAS 4693), WS-116 (N-(1,1-dimethyl-2-hydroxyethyl)-2,2-diethylbutanamide, FEMA GRAS 4603), menthoxyethanol (FEMA GRAS 4154), N-(4-cyanomethylphenyl)-p-menthane carboxamide (FEMA GRAS 4496), N-(2-(pyridin-2-yl)ethyl)-3-p-menthanecarboxamide (FEMA GRAS 4549), N-(2-hydroxyethyl)-2-isopropyl-1-2,3-dimethylbutanamide (FEMA GRAS 4602), (2S,5R)-N-[4-(2-amino-2-oxoethyl)phenyl]-p-menthanecarboxamide (FEMA GRAS4684), N-cyclopropyl-5-methyl-2-isopropylcyclohexanecarboxamide (FEMA GRAS 4693), 2-[(2-p-menthoxy)ethoxy]-ethanol (FEMA GRAS 4718), (2,6-diethyl-5-isopropyl-2-methyltetrahydropyran (FEMA GRAS4680), trans-4-tert-butylcyclohexanol (FEMA GRAS 4724), 2-(p-tolyloxy)-N-(1H-pyrazol-5-yl)-N-((thiophen-2-yl)methyl)acetamide (FEMA GRAS 4809), menthone glycerol ketal (FEMA GRAS 3807 and 3808), (-)-menthoxypropane-1,2-diol, 3-(1-menthoxy)-2-methylpropane-1,2-diol (FEMA GRAS 3849), isopulegol, (+)-cis- and (-)-trans-p-menthane-3,8-diol (62:38, FEMA GRAS 4053), 2,3-dihydroxy-p-menthane, 3,3,5-trimethylcyclohexanone glycerol ketal, pyrrolidone carboxylic acid menthyl ester, 3,6-dioxaheptanoic acid (1R,3R,4S)-3-menthyl ester, methoxyacetic acid (1R,2S,5R)-3-menthyl ester, 3,6,9-trioxadecanoic acid (1R,2S,5R)-3-menthyl ester, 3,6,9-trioxadecanoic acid (1R,2S,5R)-3-menthyl ester, (2-hydroxyethoxy)acetic acid (1R,2S,5R)-3-menthyl ester, 11-hydroxy-3,6,9-trioxaundecanoic acid (1R,2S,5R)-menthyl ester, cubebol (FEMA GRAS 4497), 4-(dimethylamino)-4-oxobutyric acid 2-isopropyl-5-methylcyclohexyl ester (FEMA GRAS 4230), menthyl lactate (FEMA GRAS 3748), 6-isopropyl-3,9-dimethyl-1,4-dioxaspiro[4.5]decan-2-one (FEMA GRAS 4285), N-benzo[1,3]-dioxol-5-yl-3-p-menthanecarboxamide, N-(1-isopropyl-1,2-dimethylpropyl)-1,3-benzodioxol-5-carboxamide, N-(R)-2-oxotetrahydrofuran-3-yl-(1R,2S,5R)-p-menthane-3-carboxamide, a mixture of 2,2,5,6,6-pentamethyl-2,3,6,6a-tetrahydropentalene-3a(1H)-ol and 5-(2-hydroxy-2-methylpropyl)-3,4,4-trimethylcyclopent-2-en-1-one; (2S,5R)-2-isopropyl-5-methyl-N-(2-(pyridin-4-yl)ethyl)cyclohexanecarboxamide; (1S,2S,5R)-N-(4-(cyanomethyl)phenyl)-2-isopropyl-5-methylcyclohexanecarboxamide, 1,7-isopropyl-4,5-methyl-bicyclo[2.2.2]oct-5-ene derivatives, 4-methoxy-N-phenyl-N-[2-(pyridin-2-yl)ethyl]benzamide, 4-methoxy-N-phenyl-N-[2-(pyridin-2-yl)ethyl]benzenesulfonamide, 4-chloro-N-phenyl-N-[2-(pyridin-2-yl)ethyl]benzenesulfonamide, 4-cyano-N-phenyl-N-[2-(pyridin-2-yl)ethyl]-benzenesulfonamide, 4-((diphenylmethylamino)methyl )-2-methoxyphenol, 4-((bis(4-methoxyphenyl)methylamino)methyl)-2-methoxyphenol, 4-((1,2-diphenylethylamino)methyl)-2-methoxyphenol, 4-((diphenylmethyloxy)methyl)-2-methoxyphenol, 4-((9H-fluoren-9-ylamino)methyl)-2-methoxyphenol, 4-((diphenylmethylamino)methyl)-2-ethoxyphenol, 1-(4-methoxyphenyl)-2-(1-methyl-1H-benzo[d]imidazol-2-yl)vinyl-4-methoxybenzoate, 2-(1-isopropyl-6-methyl-1H- benzo[d]imidazol-2-yl)-1-(4-methoxyphenyl)vinyl-4-methoxybenzoate, (Z)-2-(1-isopropyl-5-methyl-1H-benzo[d]imidazol-2-yl)-1-(4-methoxyphenyl)vinyl-4-methoxybenzoate, 3-alkyl-p-methan-3-ol derivatives, derivatives of the following groups: fenchyl, D-bornyl, L-bornyl, exonorbornyl, 2-methylisobornyl, 2-ethylfenchyl, 2-methylbornyl, cis-pinan-2-yl, verbanyl and isobornyl, menthyl oxalate derivatives, menthyl Fluorenyl 3-oxocarboxylate, N-α-(menthanecarbonyl)amino acid amide, p-menthanecarboxamide and WS-23 analogs, (-)-(1R,2R,4S)-dihydroumbellulol, p-menthaneoxyamide, cyclohexane derivatives, butanone derivatives, mixtures formed by 3-menthoxy-1-propanol and 1-menthoxy-2-propanol, 1-[2-hydroxyphenyl]-4-[2-nitrophenyl]-1,2,3,6-tetrahydropyrimidin-2-one, 4-methyl-3-(1-pyrrolidinyl)-2-[5H]-furanone and mixtures thereof. FEMA stands for "Food Flavor and Extract Manufacturers Association" and GRAS means "Generally Recognized as Safe". The FEMAGRAS designation means that the substance so marked has been tested according to standard methods and is considered to be toxicologically safe. ,
[0511] In principle, all substances known to have a cooling effect are suitable as component (b). However, for reasons of food safety, preference is given to those compounds which have the FEMAGRAS designation, or if the cooling mixture in question requires this.
[0512] The first important representative of the substances forming component (b) is monomenthyl succinate (FEMA GRAS 3810). The succinate and the analogous monomenthyl glutarate (FEMA GRAS 4006) are important representatives of monomenthyl esters based on dicarboxylic acids and polycarboxylic acids.
[0513] The next important group of menthol compounds preferred in the present invention comprises carbonates of menthol and polyols (e.g. glycols, glycerol or carbohydrates), such as menthol glycol carbonate (FEMA GRAS 3805 = MGC), menthol propylene glycol carbonate (FEMAGRAS3784= MPC), menthol 2-methyl-1,2-propanediol carbonate (FEMAGRAS3849) or corresponding sugar derivatives. Also preferred as component (b) are N-(4-cyanomethylphenyl)-p-menthanecarboxamide (FEMAGRAS4496), N-(2-(pyridin-2-yl)ethyl)-3-p-menthanecarboxamide (FEMAGRAS4549) and (E)-3-benzo[1,3]dioxol-5-yl-N,N-diphenyl-2-acrylamide (FEMAGRAS4788).
[0514] Menthol compound Menthyl lactate (FEMAGRAS3748= ML), and especially menthone glycerol acetal (FEMA GRAS 3807) or menthone glycerol ketal (FEMA GRAS 3808) (known under the names MGA), is preferred for the purposes of the present invention.
[0515] This group of compounds also includes 3-(1-menthoxy)-1,2-propanediol, also known as Coolant 10 (FEMAGRAS 3784), and 3-(1-menthoxy)-2-methyl-1,2-propanediol (FEMAGRAS 3849), which have an additional methyl group.
[0516] Menthone glycerol acetal / ketal, menthyl lactate, menthol ethylene glycol carbonate and menthol propylene glycol carbonate (applicant's MGA, ML, MGC and MPC) has proven to be particularly advantageous among the above-mentioned substances.
[0517] Other preferred components (b) are shown in Table 3 below:
[0518] Table 3: Other substances suitable as component (b)
[0519]
[0520]
[0521]
[0522]
[0523]
[0524]
[0525]
[0526] In the 1970s, menthol compounds were first developed which have a C-C bond in the 3-position, of which several representative compounds can also be used in the sense of the present invention. These substances are generally referred to as WS types. The base is a menthol derivative in which the hydroxyl group is replaced by a carboxyl group (WS-1). All other WS types are derived from this structure, for example the substances WS-3, WS-4, WS-5, WS-12, WS-14, WS-23, WS-27 and WS-30, which are also preferred in the sense of the present invention, or esters or N-substituted amides of the above compounds.
[0527] In addition, the cooling agent 2-(p-tolyloxy)-N-(1H-pyrazol-5-yl)-N-((thiophen-2-yl)methyl)acetamide (FEMAGRAS4809) is particularly preferred. Also preferred are 2-(4-ethylphenoxy)-N-(1H-pyrazol-3-yl)-N-(thiophen-2-ylmethyl)acetamide (FEMAGRAS4880) and / or N-(3-hydroxy-4-methoxyphenyl)-2-isopropyl-5,5-dimethylcyclohexanecarboxamide (FEMAGRAS4881) and / or N-(4-(cyanomethyl)phenyl)-2-isopropyl-5,5-dimethylcyclohexanecarboxamide (FEMAGRAS4882).
[0528] Further preferred components (b) are shown in Table 4 below, in combination with at least one cooling agent according to the invention of the general formula (I) to (VIII) or as listed in Table 1 or Table 2 and as defined above:
[0529] Table 4: Other substances suitable as component (b)
[0530]
[0531]
[0532]
[0533]
[0534]
[0535]
[0536]
[0537]
[0538]
[0539]
[0540]
[0541]
[0542]
[0543]
[0544]
[0545]
[0546] and salts thereof, preferably acid addition salts formed with inorganic or organic acids.
[0547] The coolant mixture according to the present invention may contain, relative to the total coolant mixture, components (a) and (b) in a weight ratio of about 0.1:99.9 to about 99.0:0.1, preferably about 1:99 to about 99:1, even more preferably about 10:90 to about 90:10, still more preferably about 25:75 to about 75:25, and in particular about 40:60 to about 60:40.
[0548] In order to be able to utilize and optimize the cooling effect of the cooling agents and to ensure easier processing in flavorings and semi-finished products or other end products, the cooling agents must be converted into a solution before processing. However, in some cases, the cooling agents according to the invention are not sufficiently soluble, which can cause problems during storage, handling or further processing.
[0549] In one aspect, the above-mentioned cooling agents forming component (b) of the cooling agent mixture may be used as a solvent for one or more cooling agents forming component (a) of the cooling agent mixture.
[0550] Advantageously, the coolant mixture according to the invention also comprises at least one solvent as a further component (c).
[0551] A single solvent or a solvent system has proven to be advantageous, wherein the solvent is selected from the group consisting of benzyl alcohol, 2-phenylethanol, benzyl benzoate, diethyl succinate, triethyl citrate, triacetin, ethanol, peppermint oil, anethole, Optamint, propylene glycol, phenoxyethanol and mixtures thereof.
[0552] For example, Optamint is a mixture of more than 50 different natural essential oils and natural or nature-identical flavorings. Optamint has a variable composition of different (partially fractionated) oils, which are preferably a mixture of, for example, different peppermint and spearmint oils, as well as eucalyptus oil, star anise oil, menthol, menthone, isomenthone, menthyl acetate, anethole, eucalyptol, etc. Therefore, it is impossible to replicate the composition of Optamint exactly. The SYNTHET(R) product line is commercially available from Symrise AG.
[0553] For example, benzyl alcohol or 2-phenylethanol or benzyl benzoate can be used as solvent in the coolant mixture according to the invention.
[0554] For example, benzyl alcohol or 2-phenylethanol or benzyl benzoate may be used to dissolve the coolant according to the invention and obtain a stable solution, ie a coolant mixture, for suitable storage.
[0555] Solvent systems, ie solvent combinations of two or more solvents, can also be used to dissolve the cooling agents according to the invention. In particular for subsequent fields of application, the use of solvents which can also have a cooling effect can save another step in the (final) production step.
[0556] Thus, in an exemplary embodiment, the solvent in the coolant mixture is a binary system of two solvent species selected from the group consisting of benzyl alcohol, 2-phenylethanol, benzyl benzoate, diethyl succinate, triethyl citrate, triacetin, ethanol, peppermint oil, anethole, Optamint, propylene glycol, phenoxyethanol, and as component (b) an additional coolant as described above.
[0557] For example, according to the invention, a binary solvent system formed from benzyl alcohol and a further substance selected from the group consisting of: 2-phenylethanol, benzyl benzoate, diethyl succinate, triethyl citrate, triacetin, ethanol, peppermint oil, anethole, Optamint, propylene glycol, phenoxyethanol and as component (b) a further cooling agent as described above is suitable.
[0558] Binary solvent combinations or mixtures (which contain, for example, benzyl alcohol and another solvent or consist of them) are also suitable. Binary solvent combinations or mixtures selected from the group consisting of benzyl alcohol and 2-phenylethanol, benzyl alcohol and benzyl benzoate, benzyl alcohol and diethyl succinate, benzyl alcohol and triethyl citrate, benzyl alcohol and triacetin, benzyl alcohol and ethanol, benzyl alcohol and peppermint oil, benzyl alcohol and anethole, benzyl alcohol and Optamint, benzyl alcohol and propylene glycol, benzyl alcohol and menthol, benzyl alcohol and menthyl lactate ( ML), benzyl alcohol and menthol propylene glycol carbonate ( MPC), benzyl alcohol and menthol glycol carbonate ( MGC), benzyl alcohol and menthone glycerol acetal ( MGA), benzyl alcohol and menthane carboxylic acid esters and amides.
[0559] The following binary solvent combinations or mixtures are also suitable - mixtures are also suitable: 2-phenylethanol and menthol propylene glycol carbonate ( MPC), diethyl succinate and 2-phenylethanol, triacetin and benzyl benzoate, triethyl citrate and triacetin, 2-phenylethanol and peppermint oil, 2-phenylethanol and Optamint, anethole and triacetin, peppermint oil and menthyl lactate ( ML), triacetin and menthone glyceryl acetal ( MAG), Optamint, and Menthyl Lactate ( ML), triethyl citrate and menthol glycol carbonate ( MGC).
[0560] Suitable coolant mixtures in the sense of the present invention therefore contain, for example as solvent (c), a binary solvent combination or mixture as described above.
[0561] The binary solvent mixture according to the invention has, for example, the following ratios: solvent (1): solvent (2) ratio: 10:1 to 1:10, preferably a ratio of 8:2 to 2:8, even more preferably 6:4 to 4:6, and most preferably a ratio of 5:5.
[0562] The above-mentioned suitable binary solvent mixture can dissolve the cooling agent according to the invention and keep the cooling agent stable in solution in a wide range, depending on the solvent or the combination of solvents, in an amount of 2% to 50% by weight, preferably 5% to 40% by weight, further preferably 5% to 20% by weight.
[0563] In a further exemplary embodiment, the solvent or solvent system for the cooling agent according to the present invention is a ternary system of three solvents selected from the group consisting of benzyl alcohol, 2-phenylethanol, benzyl benzoate, diethyl succinate, triethyl citrate, triacetin, ethanol, peppermint oil, anethole, Optamint, propylene glycol, phenoxyethanol and as component (b) an additional cooling agent as described above.
[0564] For example, a ternary solvent combination or mixture of benzyl alcohol and two further substances selected from the group consisting of: 2-phenylethanol, benzyl benzoate, diethyl succinate, triethyl citrate, triacetin, ethanol, peppermint oil, anethole, Optamint, propylene glycol, phenoxyethanol and as component (b) a further cooling agent as described above is suitable for this purpose.
[0565] Ternary solvent combinations or mixtures are suitable in this regard. - Suitable are ternary solvent combinations or mixtures which contain or consist of, for example, benzyl alcohol and two further solvents selected from the group consisting of: 2-phenylethanol and benzyl benzoate, 2-phenylethanol and diethyl succinate, triethyl citrate and triacetin, triacetin and ethanol, triacetin and peppermint oil, menthol glycol carbonate ( MGC) and anethole, 2-phenylethanol and Optamint, Optamint and propylene glycol, diethyl succinate and menthol, triacetin and menthyl lactate ( ML), anethole and menthol propylene glycol carbonate ( MPC), triacetin and menthol glycol carbonate ( MGC), 2-phenylethanol and menthone glycerol acetal ( MGA), 2-phenylethanol and menthone carboxylic acid esters and amides, 2-phenylethanol and menthol propylene glycol carbonate ( MPC), triacetin and benzyl benzoate, 2-phenylethanol and peppermint oil, anethole and triacetin, peppermint oil and menthyl lactate ( ML), triacetin and menthone glyceryl acetal ( MGA), Optamint, and Menthyl Lactate ( ML), triethyl citrate and menthol glycol carbonate ( MGC). Benzyl benzoate and menthol glycol carbonate ( MGC), 2-phenylethanol and triethyl citrate, triethyl citrate and diethyl succinate, peppermint oil and menthyl lactate ( ML) and ethanol and menthyl lactate ( ML).
[0566] The following ternary solvent combinations or mixtures are also suitable, for example:
[0567] Triethyl citrate, triacetin, menthyl lactate ( ML),
[0568] Triacetin, 2-phenylethanol and peppermint oil,
[0569] 2-phenylethanol, Optamint and peppermint oil,
[0570] 2-phenylethanol, triacetin and Optamint,
[0571] Anethole, Benzyl Alcohol and Triacetin,
[0572] 2-phenylethanol, benzyl benzoate and Optamint,
[0573] 2-phenylethanol, diethyl succinate and Optamint,
[0574] Triethyl citrate, triacetin and peppermint oil,
[0575] Optamint, triacetin and ethanol,
[0576] Triacetin, Menthyl Glycol Carbonate ( MGC) and anethole, 2-phenylethanol, Optamint and propylene glycol,
[0577] Diethyl succinate, triacetin and menthol,
[0578] Glyceryl triacetate, benzyl benzoate and menthyl lactate ( ML),
[0579] Anethole, Menthol, Propylene Glycol Carbonate ( MPC) and menthol glycol carbonate ( MGC),
[0580] Triacetin, 2-phenylethanol and menthone glycerol ketal ( MGA),
[0581] Peppermint oil, 2-phenylethanol and menthane carboxylic acid esters and amides,
[0582] Triacetin, 2-phenylethyl alcohol and menthol propylene glycol carbonate ( MPC), Menthyl Lactate ( ML), 2-phenylethanol and peppermint oil,
[0583] Anethole, triacetin and menthone glycerol acetal ( MGA),
[0584] Optamint, benzyl benzoate, and menthyl lactate ( ML) and
[0585] Benzyl benzoate, triethyl citrate and menthol glycol carbonate ( MGC).
[0586] The ternary solvent mixture according to the present invention has, for example, the following ratios: solvent (1): solvent (2): solvent (3) in the range of 10:1:15 to 5:1:3, or in the range of 4:1:7 to 7:1:4, or in the range of 2:2:4 to 4:4:2.
[0587] The above-mentioned suitable ternary solvent mixtures show a particularly good ability to dissolve the cooling agent according to the invention and, depending on the solvent or the combination of solvents, are able to keep the cooling agent stable in solution in a wide range in an amount of 2% to 50% by weight, preferably 5% to 40% by weight, further preferably 5% to 20% by weight.
[0588] This has the advantage that the coolants according to the invention can thus be present in variable amounts suitable for the final formulation, so that a wide range of coolant mixtures is possible in which the coolants are present in solution.
[0589] In a further suitable embodiment, the solvent or solvent system for the coolant according to the invention is a quaternary system of four solvents selected from the group consisting of benzyl alcohol, 2-phenylethanol, benzyl benzoate, diethyl succinate, triethyl citrate, triacetin, ethanol, peppermint oil, anethole, Optamint, propylene glycol, phenoxyethanol and other coolants as further described above as component (b).
[0590] A suitable solvent combination is, for example, a quaternary solvent combination of benzyl alcohol and three other substances selected from the group consisting of: 2-phenylethanol, benzyl benzoate, diethyl succinate, triethyl citrate, triacetin, ethanol, peppermint oil, anethole, Optamint, propylene glycol, phenoxyethanol and other cooling agents as described above as component (b).
[0591] Suitable quaternary solvent combinations or mixtures are those comprising or consisting of, for example, benzyl alcohol and three additional solvents selected from:
[0592] 2-phenylethanol, triethyl citrate and triacetin,
[0593] Peppermint oil, 2-phenylethanol and triethyl citrate,
[0594] Triethyl citrate, menthyl lactate ( ML) and diethyl succinate
[0595] Triethyl citrate, triacetin and anethole,
[0596] 2-phenylethanol, triacetin and Optamint,
[0597] Peppermint oil, benzyl alcohol and menthyl lactate ( ML),
[0598] Optamint, ethanol and menthyl lactate ( ML),
[0599] 2-phenylethanol, benzyl benzoate and diethyl succinate,
[0600] Triethyl citrate, triacetin and ethanol,
[0601] Peppermint Oil, Anethole and Optamint,
[0602] 2-phenylethanol, benzyl benzoate and propylene glycol,
[0603] 2-phenylethanol, benzyl benzoate and menthol propylene glycol carbonate ( MPC), triethyl citrate, Optamint and ethanol,
[0604] Triacetin, benzyl benzoate and menthoxy-2-methyl-1,2-propanediol, menthone glyceryl acetal ( MGA), triacetin, and anethole.
[0605] The following quaternary solvent combinations and solvent mixtures are also suitable:
[0606] Anethole, triacetin, peppermint oil and menthol glycol carbonate ( MGC),
[0607] Triacetin, ethanol, 2-phenylethanol and peppermint oil,
[0608] 2-Phenylethanol, Optamint, Diethyl Succinate and Peppermint Oil, Anethole, 2-Phenylethanol, Benzyl Alcohol and Triacetin.
[0609] The above-mentioned suitable quaternary solvent mixtures show a particularly good ability to dissolve the cooling agent according to the invention and, depending on the solvent or the combination of solvents, are able to keep the cooling agent stable in solution in a wide range in an amount of 2% to 50% by weight, preferably 5% to 40% by weight, further preferably 5% to 20% by weight.
[0610] This has the advantage that the coolants according to the invention can thus be present in variable amounts suitable for the final formulation, so that a wide range of coolant mixtures is possible in which the coolants are present in solution.
[0611] The coolant mixture according to the invention preferably contains or consists of component (a) and / or component (b) and / or component (c), wherein the amount of component (a) and / or component (b) is 2 to 20% by weight, preferably 2 to 10% by weight, even more preferably 5 to 10% by weight, most preferably 5 to 8% by weight, based on the total coolant mixture, and the amount of component (c) is 80 to 98% by weight, preferably 90 to 98% by weight, even more preferably 90 to 95% by weight, most preferably 92 to 95% by weight, with the proviso that components (a) and / or (b) and / or (c) total 100% by weight).
[0612] This composition of the cooling agent mixture according to the invention is particularly advantageous since it allows the amount of cooling agent in the final formulation to be controlled.
[0613] Preferably, the final product contains the cooling agent in an amount of about 0.00001 wt % to 50 wt %, preferably 0.0001 wt % to 10 wt %, more preferably 0.001 wt % to 5 wt %, and even more preferably 0.005 wt % to 1 wt % or 0.1 wt % to 20 wt %, more preferably 0.5 wt % to 15 wt % or 1 wt % to 5 wt %, based on the weight of the final product, especially in the case of an oral care composition.
[0614] Suitable cooling agent mixtures according to the invention have, for example, the following composition or consist thereof:
[0615] 5% to 10% by weight of a cooling agent in 95% to 90% benzyl alcohol, or 8% to 10% by weight of a cooling agent in 92% to 90% benzyl alcohol, or
[0616] 1% to 4% by weight of a cooling agent in 99% to 96% triethyl citrate, or
[0617] 1% to 3% by weight of a cooling agent in 99% to 97% triacetin, or
[0618] · 3% to 6% by weight of a cooling agent in 97% to 94% of diethyl succinate, or
[0619] 5% to 15% by weight of a cooling agent in 95% to 85% 2-phenylethanol, or
[0620] 5%-10% by weight of a cooling agent in 95%-90% benzyl benzoate, or
[0621] 1%-3% by weight of cooling agent in 99%-97% Optamint, or
[0622] 1% to 4% by weight of a cooling agent in 99% to 96% of other cooling agents as described above as component (b), or
[0623] 2%-4% cooling agent in 98%-96% propylene glycol, by weight, or
[0624] 0.5% to 2% by weight of a cooling agent in 95.5% to 98% ethanol, or
[0625] 0.5% to 2% by weight of a cooling agent in 95.5% to 98% menthyl acetate, or
[0626] 1% to 4% by weight of a cooling agent in 99% to 96% peppermint oil, or
[0627] · 2%-5% cooling agent in 98%-95% anethole by weight,
[0628] Therein, the two components (coolant and solvent) in the coolant mixture always add up to 100 wt. %. For example, a suitable coolant mixture according to the invention comprises 5-10 wt. % coolant in 95-90 wt. % benzyl alcohol, particularly preferably 8-10 wt. % coolant in 92-90 wt. % benzyl alcohol.
[0629] Another object of the present invention relates to a flavoring preparation comprising or consisting of:
[0630] (d) one, two, three or more cooling agents of formula (I) to (VIII) or as listed in Table 1 or Table 2 and as defined above; and
[0631] (e) at least one flavoring agent.
[0632] A particular advantage of these mixtures or flavoring preparations is that, even at low concentrations, these cooling agents are able to mask unpleasant taste impressions (such as bitterness or astringency) of flavoring agents, especially sweeteners, while providing an intense and effective cooling effect.
[0633] The above applies in the same way as for component (a) of the physiological cooling agent mixture according to the invention to component (d), which comprises or consists of: (a) one, two, three or more cooling agents of the general formula (I) to (VIII), (Va), (VIa), (VIIa) or (VIIIa) or cooling agents as listed in Table 1, Table 2, Table A or Table B and as defined above
[0634] The flavoring preparation according to the present invention comprises one or more flavoring agents as component (e) selected from the group consisting of acetophenone, allyl hexanoate, α-ionone, β-ionone, anisaldehyde, anisyl acetate, anisyl formate, anethole, benzaldehyde, benzothiazole, benzyl acetate, benzyl alcohol, benzyl benzoate, β-ionone, butyl butyrate, butyl hexanoate, butenylphthalide, carvone, camphene, caryophyllene, eucalyptol, cinnamyl acetate, citral, citronellol, citronellal, citronellyl acetate, cyclohexyl acetate, cymene, damascenone, decalactone, dihydrocoumarin , methyl o-aminobenzoate, methyl o-aminobenzoate, lauryl lactone, ethyl ethoxylate, ethyl butyrate, ethyl butyrate, ethyl decanoate, ethyl caproate, ethyl crotonate, ethyl furanone (Ethylfuraneol), ethyl guaiacol, ethyl isobutyrate, ethyl isovalerate, ethyl lactate, ethyl methyl butyrate, ethyl propionate, eucalyptol, eugenol, ethyl heptanoate, 4-(p-hydroxyphenyl)-2-butanone, γ-decanoyl lactone, geraniol, geranyl acetate, geranyl acetate, grapefruit aldehyde, methyl dihydrojasmonate (e.g., ), piperonal, 2-heptanone, 3-heptanone, 4-heptanone, trans-2-heptenal, cis-4-heptenal, trans-2-hexenal, cis-3-hexenol, trans-2-hexenoic acid, trans-3-hexenoic acid, cis-2-hexenyl acetate, cis-3-hexenyl acetate, cis-3-hexenyl hexanoate, trans-2-hexenyl hexanoate, cis-3-hexenyl formate, cis-2-hexyl acetate, cis-3-hexyl acetate, trans-2-hexyl acetate, cis-3-hexyl formate, p-hydroxybenzyl acetone, isopentanol, isopentanyl isovalerate, isobutyl butyrate, isobutylaldehyde, isoeugenol methyl ether, isopropyl methylthiazole, lauric acid, levulinic acid (Leavulinic acid), linalool, aromatic oxide Linalool, linalyl acetate, menthol, menthofuran, methyl anthranilate, methyl butanol, methyl butyric acid, 2-methylbutyl acetate, methyl caproate, methyl cinnamate, 5-methylfurfural, 3,2,2-methylcyclopentenolone, 6,5,2-methylheptenone, methyl dihydrojasmonate, methyl jasmonate, methyl 2-methylbutyrate, 2-methyl-2-pentenoic acid, methyl thiobutyrate, 3,1-methylthiohexanol, 3-methylthiohexyl acetate, nerol, neryl acetate, trans, trans-2,4-nonadienal, 2,4-nonadienol, 2,6-nonadienol, 2,4-nonadienol, nootkatone, δ-octalactone, γ-octalactone, 2-octanol, 3-octanol, 1,3-octenol, 1-octyl acetate , 3-octyl acetate, palmitic acid, paraldehyde, phellandrene, pentanedione, phenylethyl acetate, phenylethyl alcohol, phenylethyl isovalerate, piperonal, propionaldehyde, propyl butyrate, longleaf menthol, longleaf menthol, sweet orange aldehyde, thiothiazole, terpinene, terpineol, terpinolene, 8,3-thiomenthanone, 4,4,2-thiomethylpentyl ketone, thymol, δ-undecanoic acid lactone, γ-undecanoic acid lactone, valencia orange alkene, valeric acid, vanillic acid, vanillin, acetoin, ethyl vanillin, ethyl vanillyl isobutyrate (= 3-ethoxy-4-isobutyryloxybenzaldehyde), 2,5-dimethyl-4-hydroxy-3(2H)-furanone and its derivatives (preferably cyclohomofuranone (= 2-ethyl-4-hydroxy-5-methyl-3(2 H)-furanone), soy sauce ketone (= 2-ethyl-5-methyl-4-hydroxy-3 (2H)-furanone and 5-ethyl-2-methyl-4-hydroxy-3 (2H)-furanone), maltol and maltol derivatives (preferably ethyl maltol), coumarin and coumarin derivatives, γ-lactone (preferably γ-undecanoic acid lactone, γ-nonalactone, γ-decanoic acid lactone), δ-lactone (preferably 4-methyl δ-decanoic acid lactone, Massoilacton, δ-decanoic acid lactone, Tuberolacton), methyl sorbate, divanillin, 4-hydroxy-2 (or 5)-ethyl-5 (or 2)-methyl-3 (2H)-furanone, 2-hydroxy-3-methyl-2-cyclopentenone, 3-hydroxy-4,5-dimethyl-2(5H)-furanone, isopentyl acetate, ethyl butyrate, n-butyl butyrate, isopentyl butyrate, ethyl 3-methylbutyrate, ethyl hexanoate, allyl hexanoate, n-butyl hexanoate, ethyl octanoate, ethyl 3-methyl-3-phenylglycidate, ethyl 2-trans-4-cis-decadienoate, 4-(p-hydroxyphenyl)-2-butanone, 1,1-dimethoxy-2,2,5-trimethyl-4-hexane, 2,6-dimethyl-5-heptyl En-1-aldehyde and phenylacetaldehyde, 2-methyl-3-(methylthio)furan, 2-methyl-3-furanthiol, bis(2-methyl-3-furanyl) disulfide, furfurylthiol, methylthiopropionaldehyde, 2-acetyl-2-thiazoline, 3-mercapto-2-pentanone, 2,5-dimethyl-3-furanthiol, 2,4,5-trimethylthiazole, 2-acetylthiazole, 2,4-dimethyl-5-ethylthiazole, 2-acetyl-1-pyrroline, 2-methyl-3-ethyl Pyrazine, 2-ethyl-3,5-dimethylpyrazine, 2-ethyl-3,6-dimethylpyrazine, 2,3-diethyl-5-methylpyrazine, 3-isopropyl-2-methoxypyrazine, 3-isobutyl-2-methoxypyrazine, 2-acetylpyrazine, 2-pentylpyridine, (E,E)-2,4-decadienal, (E,E)-2,4-nonadienal, (E)-2-octenal, (E)-2-nonenal, 2-undecenal, 12-methyltridecanal, 1 -penten-3-one, 4-hydroxy-2,5-dimethyl-3(2H)-furanone, guaiacol, 3-hydroxy-4,5-dimethyl-2(5H)-furanone, 3-hydroxy-4-methyl-5-ethyl-2(5H)-furanone, cinnamaldehyde, cinnamyl alcohol, methyl salicylate, isopulegol and stereoisomers, enantiomers, positional isomers, diastereomers, cis / trans isomers or epimers of these substances (not explicitly mentioned herein). Epimers of these substances. ,
[0635] For the purposes of the present invention, artificial as well as natural sweeteners and sweetener enhancers may also be considered as flavorings of component (e). These may be selected from:
[0636] Sugar alcohols (e.g., erythritol, threitol, arabitol, ribitol, xylitol, sorbitol, mannitol, dulcitol, lactitol);
[0637] Proteins (e.g., miraculin, monellin, thaumatin, curculin, brazzein);
[0638] Synthetic sweeteners (e.g. Magap, Sodium Cyclamate, Acesulfame, Neohesperidin Dihydrochalcone, Saccharin Sodium, Aspartame, Super Aspartame, Neotame, Alitame, Sucralose, Stevioside, Rebaudioside, Lugduname, Carrelame, Sucrononate, Sucrooctate, Monatine, Phenylodulcin);
[0639] Sweet amino acids (e.g. glycine, D-leucine, D-threonine, D-asparagine, D-phenylalanine, D-tryptophan, L-proline);
[0640] Sweet low molecular weight substances, such as Hernandulcin, dihydrochalcone glycosides, glycyrrhizin, glycyrrhizic acid derivatives and salts thereof, extracts of Glycyrrhizza glabra ssp., extracts of Lippia dulcis, extracts of Momordica ssp. and / or
[0641] - Plant extracts, such as Momordica grosvenori and mogrosides obtained therefrom, Hydrangea dulcis or Stevia (eg Stevia rebaudiana) extracts or steviosides obtained therefrom.
[0642] Component (e) comprises at least one of the above-mentioned flavoring agents.
[0643] The fragrance formulation according to the present invention may contain components (d) and (e) in a weight ratio of about 1:99 to about 99:1, preferably about 10:90 to about 90:10, more preferably about 25:75 to about 75:25, and particularly about 40:60 to 60:40.
[0644] In a further preferred variant, the one or more cooling agents or cooling agent mixtures or fragrances are present in encapsulated form. This is particularly interesting, for example, if capsules loaded with one or more cooling agents are applied to textile surfaces, for example as a component of a fabric softener or laundry aftertreatment, or if finishing is performed by forced application using capsules loaded with one or more cooling agents, for example on tights.
[0645] Capsules are spherical aggregates containing at least one solid or liquid core enclosed in at least one continuous shell. During the encapsulation process, the one or more cooling agents, cooling agent mixtures or flavoring agent preparations are encapsulated with the aid of a coating material / encapsulating material so that they are in the form of macrocapsules having a diameter of about 0.1 to about 5 mm or microcapsules having a diameter of about 0.0001 to about 0.1 mm.
[0646] Therefore, a further embodiment of the present invention also relates to a physiological cooling agent or a physiological cooling agent mixture or a flavoring preparation in encapsulated form.
[0647] Suitable coating materials are, for example, starches, including their degradation products and chemically or physically produced derivatives (in particular dextrins and maltodextrins), gelatin, gum arabic, agar, gum ghatti, gellan gum, modified and unmodified celluloses, pullulan, curdlan, carrageenan, alginic acid, alginates, pectin, inulin, xanthan gum and mixtures of two or more of these substances.
[0648] Among the above coating materials, gelatin (especially porcine, bovine, poultry and / or fish gelatin) is preferred, which preferably has a swelling coefficient greater than or equal to 20, preferably greater than or equal to 24. Gelatin is also particularly preferred because it is easily available and can be obtained with different swelling coefficients.
[0649] Likewise preferred are maltodextrins (especially based on cereals, especially corn, wheat, cassava or potatoes), which preferably have a DE value in the range of 10 to 20. Also preferred are celluloses (e.g. cellulose ethers), alginates (e.g. sodium alginate), carrageenans (e.g. β-, iota-, λ- and / or κ-carrageenans), gum arabic, curdlan and / or agar.
[0650] Likewise preferred are alginate capsules, such as those described in detail in the following publications: EP 0389700A1, US 4,251,195, US 6,214,376, WO 2003055587 or WO 2004050069A1.
[0651] In a further preferred embodiment, the shell of the capsule consists of melamine-formaldehyde resin or a coacervation product of a cationic monomer or biopolymer (such as chitosan) and an anionic monomer (such as (meth)acrylate or alginate).
[0652] The capsules are usually finely dispersed liquid or solid phases coated with film-forming polymers, during the production of which the polymers are deposited on the material to be coated after emulsification and coagulation or interfacial polymerization. According to another method, molten wax is incorporated into a matrix ("microsponge") which can also be coated as microparticles with film-forming polymers. According to a third method, the particles are coated alternately with polyelectrolytes of different charges ("layer-by-layer" method). The microscopic small capsules can be dried and used like powders.
[0653] In addition to mononuclear microcapsules, multinuclear aggregates are also known, which are also referred to as microspheres, and contain two or more cores distributed in a continuous shell material. Mononuclear or multinuclear microcapsules can also be coated with an additional second, third, etc. shell. The shell can be made up of natural, semi-synthetic or synthetic materials. Natural shell materials include gum arabic, agar, agarose, maltodextrin, alginic acid or its salt, such as sodium alginate or calcium alginate, fat and fatty acid, cetyl alcohol, collagen, chitosan, lecithin, gelatin, albumin, shellac, polysaccharides, such as starch or dextran, polypeptide, protein hydrolyzate, sucrose and wax. Semisynthetic coating materials include chemically modified cellulose, particularly cellulose esters and ethers, such as cellulose acetate, ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose and carboxymethyl cellulose, and starch derivatives, particularly starch ethers and esters. Synthetic coating materials are, for example, polymers such as polyacrylates, polyamides, polyvinyl alcohol or polyvinyl pyrrolidone.
[0654] Examples of coating materials / shell materials used in the prior art for producing microcapsules are the following commercial products (shell materials are shown in brackets): Hallcrest Microcapsules (gelatin, gum arabic), Coletica Thalaspheres (marine collagen), Lipotec Millicapsules (alginic acid, agar), Induchem Unispheres (lactose, microcrystalline cellulose, hydroxypropyl methylcellulose), Unicerin C30 (lactose, microcrystalline cellulose, hydroxypropyl methylcellulose), Kobo Glycospheres (modified starch, fatty acid esters, phospholipids), Softspheres (modified agar) and Kuhs Probiol Nanospheres (phospholipids) as well as Primaspheres and Primasponges (chitosan, alginate) and Primasys (phospholipids).
[0655] Chitosan microcapsules and methods for producing them are well known in the prior art: WO 01 / 01926, WO 01 / 01927, WO01 / 01928, WO 01 / 01929. Microcapsules having an average diameter in the range of 0.0001 mm to 5 mm, preferably 0.001 mm to 0.5 mm, in particular 0.005 mm to 0.1 mm, consisting of a shell membrane and a matrix containing an active ingredient can be obtained, for example, by the following method:
[0656] (1) preparing a matrix from a gel former, a cationic polymer and an active ingredient,
[0657] (2) if necessary, dispersing the matrix in an oil phase,
[0658] (3) Treating the dispersed matrix with an aqueous solution of anionic polymer, and if necessary, removing the oil phase.
[0659] The above steps (1) and (3) are interchangeable, provided that anionic polymers are used in place of cationic polymers in step (1), and vice versa.
[0660] The capsules can also be produced by coating the active ingredient alternately with layers of polyelectrolytes of different charge (layer-by-layer technique). In this context, reference is made to European patent EP 1064088 B1 (Max Planck Society).
[0661] As mentioned above, two essential properties of the novel cooling agents or novel cooling agent mixtures are, on the one hand, the modulation of the TRPM8 receptors as antagonists or agonists and in this way the triggering of a physiological reaction, i.e. a strong and effective cooling effect on the skin or mucous membranes, and, on the other hand, the reduction or masking of unpleasant tastes. However, first of all, the ability to produce a strong and effective cooling effect even in small amounts should be emphasized.
[0662] Therefore, a further aspect of the present invention relates to the use of a physiological cooling agent according to the invention or a physiological cooling agent mixture according to the invention as a modulator of the cold menthol receptor TRPM8, preferably for in vivo and / or in vitro modulation, in particular as a TRPM8 receptor agonist or TRPM8 receptor antagonist.
[0663] In the use according to the invention, the receptor TRPM8 is contacted with at least one cooling agent according to the invention or a physiological cooling agent mixture according to the invention which modulates the sensitivity of these cells to Ca in a cell activity test using cells recombinantly expressing the human TRPM8 receptor. 2+ Ion permeability.
[0664] Suitable modulators can act only as antagonists or agonists, in particular only as agonists, or simultaneously as antagonists and agonists. In particular, depending on the selected concentration of the respective modulator, an agonist or antagonist effect can occur.
[0665] Agonists are substances that mediate the activation of TRPM8 receptors, i.e., induce Ca 2+ Ions flow into cold-sensitive neurons, which convey the sensation of cold.
[0666] On the other hand, "antagonists" are compounds that can counteract this activation of the TRPM8 receptor.
[0667] According to the regulator of the present invention, i.e. the one described physiological cooling agent or the cooling agent mixture, they can be combined with TRPM8 receptor molecules reversibly or irreversibly, specifically or non-specifically to play their effects. Binding is usually non-covalent, via ionic and / or non-ionic, such as hydrophobic, with the interaction of the receptor molecules. The term "specificity" includes exclusive interactions with one or more different TRPM8 receptor molecules (such as TRPM8 molecules from different sources or different subtypes). On the other hand, the term "non-specific" is the interaction of the regulator with several different receptor molecules with different functions and / or sequences, however, it is possible to determine the desired excitement and / or antagonistic regulation (as described above) of TRPM8 receptors.
[0668] In the use according to the invention, preferably, in the above preferred variants, the regulator has an effect on the cell Ca 2+ Ion permeability has either agonistic or antagonistic effects.
[0669] The variant of the use according to the invention in which the modulator is a TRPM8 receptor agonist is particularly preferred.
[0670] Due to their physiological properties of inducing a cooling effect on the skin or mucous membranes, a further aspect of the invention relates to the use of the cooling agents or cooling agent mixtures according to the invention for producing a physiological cooling effect on the skin or mucous membranes of humans or animals.
[0671] Alternatively, the cooling agent according to the invention or the cooling agent mixture according to the invention is used to induce a cooling effect by means of a packaging containing the physiological cooling agent or the physiological cooling agent mixture or a textile containing the physiological cooling agent or the physiological cooling agent mixture.
[0672] A further aspect of the invention relates to the use of the physiological cooling agent or cooling agent mixture according to the invention to improve the taste attributes of condiments due to its additional property of reducing or masking the unpleasant taste (e.g. bitterness or astringency) of condiments. This allows the known taste disadvantages of condiments (especially sweeteners such as stevioside) to be reduced or masked. In particular, even when added in small amounts, pungency, bitterness or metallic aftertastes can be effectively reduced or masked.
[0673] The coolants according to the invention or the physiological coolant mixtures according to the invention or the aroma preparations according to the invention have a wide range of applications, in particular in foods, food supplements, cosmetic or pharmaceutical preparations, animal feed, textiles, packaging or tobacco products.
[0674] In particular, the physiological coolants or physiological coolant mixtures or flavoring preparations according to the invention are used for their cooling and / or flavoring properties in the production of foods, food supplements, cosmetic or pharmaceutical preparations, animal feed, textiles, packaging or tobacco products.
[0675] A further object of the present invention is therefore the use of one or more coolants according to the invention or coolant mixtures according to the invention or flavoring preparations according to the invention for the production of foods, food supplements, cosmetic or pharmaceutical preparations, animal feed, textiles, packaging or tobacco products.
[0676] Due to the advantageous properties described, the cooling agents according to the invention, as represented and defined by the general formula (I) to (VIII), (Va), (VIa), (VIIa) or (VIIIa) or as shown in Table 1, Table 2, Table A or Table B, are suitable for the use according to the invention, i.e. as conditioning agents for producing a physiological cooling effect or for inducing a cooling effect on the skin or mucous membranes of humans or animals, for improving the taste properties of flavoring substances, in particular for reducing or masking unpleasant tastes, for the manufacture of foods, food supplements, cosmetics or pharmaceutical preparations, animal feed, textiles, packaging or tobacco products, or as medicaments, as described in detail herein, and are preferably selected from the compounds shown in Table 5 or Table 6.
[0677] Table 5: Preferred structure according to the present invention
[0678]
[0679]
[0680]
[0681]
[0682]
[0683]
[0684]
[0685]
[0686]
[0687]
[0688]
[0689]
[0690]
[0691] Table 6: Preferred structures for use according to the present invention
[0692]
[0693]
[0694]
[0695]
[0696]
[0697]
[0698]
[0699]
[0700]
[0701]
[0702]
[0703]
[0704]
[0705] Among the above compounds, compounds B-01, B-02, B-03, B-04, B-05, B-06, B-07, B-11, B-14, B-15, B-17, B-18, B-19 and B-21 and compounds A-01, A-02, A-03, A-04, A-05, A-06, A-07, A-08, A-09, A-10, A-11, A-12, A-15, A-16 and A-17 are preferably used because they have significant TRPM8 activation, EC50 values and cooling intensity. However, it is most preferred to use one of compounds B-01, B-02, B-03, B-04, B-05, B-06, B-07 and B-11 and one of compounds A-01, A-02, A-03, A-04, A-05, A-06, A-07, A-08, A-09, A-10, A-11 and A-12 because they have excellent TRPM8 activation, EC50 value and cooling intensity.
[0706] In a further aspect, the present invention therefore also comprises a food, a nutritional supplement, a cosmetic or pharmaceutical preparation, an animal feed, a textile, a packaging or a tobacco product which comprises a physiological cooling agent or a physiological cooling agent mixture according to the invention or a flavoring preparation according to the invention.
[0707] The content of the one or more cooling agents depends on the type and use of the above-mentioned products, and is preferably about 0.1 ppm to 10%, preferably 1% to 10%, by weight based on the total weight of the final product. In oral care applications, such as toothpaste or mouthwash, the content of the one or more cooling agents is 0.1 ppm to 500 ppm.
[0708] A broad concentration range typically used to provide the desired sensitivity adjustment level may be from about 0.001 ppm to 1000 ppm, or from about 0.01 ppm to about 500 ppm, or from about 0.05 ppm to about 300 ppm, or from about 0.1 ppm to about 200 ppm, or from about 0.5 ppm to about 150 ppm, or from about 1 ppm to about 100 ppm.
[0709] Preferably, the food product is a bakery product, such as bread, dry biscuits, cakes, other bakery products, confectionery (such as chocolate, chocolate bar products, other bar products, fruit gum, hard and soft caramels, chewing gum), alcoholic or non-alcoholic beverages (such as coffee, tea, ice tea, wine, wine-based beverages, beer, beer-based beverages, liqueurs, gin, brandy, (carbonated) fruit-based soft drinks, (carbonated) isotonic beverages, (carbonated) soft drinks, nectar, soda, fruit and vegetable juices, fruit or vegetable juice preparations, instant beverages (e.g. instant cocoa drinks, instant tea drinks, instant coffee drinks, instant fruit drinks), meat products (e.g. ham, fresh sausage or raw sausage preparations, seasoned or pickled fresh or cured meat products), eggs or egg products (dried egg products, egg whites, egg yolks), cereal products (e.g. breakfast cereals, granola bars, precooked ready-to-eat rice products), dairy products (e.g. milk drinks, buttermilk drinks, milk ice cream, yogurt, kefir, cream cheese, soft cheese, hard cheese, milk powder, whey, whey drinks, butter, buttermilk , partially or completely hydrolyzed milk protein-containing products), products made from soy protein or other soy isolates (e.g. soy milk and its products, soy protein-containing juice drinks, soy lecithin-containing preparations, fermented products, such as tofu or tempeh or products made therefrom), products made from other plant protein sources, such as oat protein drinks, fruit products (e.g. jam, fruit ice cream, fruit sauce, fruit fillings), products made from soy protein or other soy fractions (e.g. soy milk and its products), fruit preparations (e.g. jam, fruit ice cream, fruit sauce, fruit fillings), vegetable preparations (e.g. ketchup, sauce, dried vegetables, frozen vegetables, precooked vegetables, cooked vegetables), snacks (e.g. baked or fried potato chips or potato dough products, corn or peanut-based extrudates), fat and oil-based products or their emulsions (e.g. mayonnaise, flavored mayonnaise, dressings), other ready-to-eat foods and soups (e.g. dry soups, instant soups, precooked soups), spices, seasoning mixtures, and in particular condiments, which are used for example in snacks: condiments), which are used for example in the snack industry.
[0710] In addition to conventional food ingredients, the abovementioned foods contain at least one effective amount (ie a cooling amount) of at least one cooling agent according to the invention or a cooling agent mixture according to the invention or a flavoring preparation according to the invention.
[0711] The content of cooling agent or cooling agent mixture or flavoring agent in these preparations is preferably about 0.1% to about 10% by weight and in particular about 1% to 2% by weight, based on the total weight of the finished preparation.
[0712] Suitable excipients can be used in the manufacture of products according to the invention, such as foods, food supplements, cosmetics or pharmaceutical preparations, animal feed, textiles, packaging or tobacco products. Suitable excipients include, but are not limited to, emulsifiers, thickeners, food acids, acidity regulators, vitamins, antioxidants, flavor enhancers, active ingredients for masking unpleasant taste impressions, food coloring agents, etc.
[0713] In particular, further customary additives or auxiliary substances, such as flavourings or active ingredients for masking unpleasant taste impressions, may also be added to the above-described products according to the invention.
[0714] Flavoring agents: Preferred flavoring agents are those which produce a sweet taste impression, wherein further flavoring agents producing a sweet taste impression are preferably selected from the group consisting of: vanillin, ethyl vanillin, ethyl vanillyl isobutyrate (= 3-ethoxy-4-isobutyryloxybenzaldehyde), furanones (2,5-dimethyl-4-hydroxy-3(2H)-furanone) and derivatives (e.g. cyclohomofuranone, 2-ethyl-4-hydroxy-5-methyl-3(2H)-furanone), soy sauce ketone (2-ethyl-5- methyl-4-hydroxy-3(2H)-furanone and 5-ethyl-2-methyl-4-hydroxy-3(2H)-furanone), maltol and derivatives (e.g. ethyl maltol), coumarins and derivatives, γ-lactones (e.g. γ-undecanoic acid lactone, γ-nonalactone), δ-lactones (e.g. 4-methyl δ-lactone, masonolactone, δ-decanolactone, Tuberolacton), methyl sorbate, divanillin, 4-hydroxy-2 (or 5)-ethyl-5 ( or 2)-methyl-3(2H)furanone, 2-hydroxy-3-methyl-2-cyclopentenone, 3-hydroxy-4,5-dimethyl-2(5H)-furanone, fruit esters and fruit lactones (e.g., n-butyl acetate, isopentyl acetate, ethyl propionate, ethyl butyrate, n-butyl butyrate, isopentyl butyrate, ethyl 3-methylbutyrate, ethyl n-hexanoate, allyl n-hexanoate, n-butyl n-hexanoate, ethyl n-octanoate, ethyl 3-methyl-3-phenylglycidate, 2-trans-4 -cis-decadienoic acid ethyl ester, 4-(p-hydroxyphenyl)-2-butanone, 1,1-dimethoxy-2,2,5-trimethyl-4-hexane, 2,6-dimethyl-5-heptene-1-al, 4-hydroxycinnamic acid, 4-methoxy-3-hydroxycinnamic acid, 3-methoxy-4-hydroxycinnamic acid, 2-hydroxycinnamic acid, 2,4-dihydroxybenzoic acid, 3-hydroxybenzoic acid, 3,4-dihydroxybenzoic acid, vanillic acid, homovanillic acid, vanillylmandelic acid and phenylacetaldehyde.
[0715] Active ingredients for masking unpleasant taste: In addition, the oral preparations may also contain other substances, which can also be used to mask the taste impression of bitterness and / or astringency. These additional flavoring agents are selected, for example, from the following list: nucleotides (e.g. adenosine 5'-monophosphate, cytidine 5'-monophosphate) or their physiologically acceptable salts, lactisolen, sodium salts (e.g. sodium chloride, sodium laurate), sodium salts (e.g. sodium chloride, sodium lactate, sodium citrate, sodium acetate, sodium gluconate), hydroxyflavanones, preferably eriodictyol, Sterubin (eriodictyol-7-methyl ether), homoeriodictyol, and their sodium, potassium, calcium, magnesium or zinc salts (e.g. sodium chloride, sodium lactate, sodium citrate, sodium acetate, sodium gluconate), their magnesium or zinc salts (especially those described in EP1258200A2), hydroxybenzoic acid amides, preferably 2,4-dihydroxybenzoic acid vanillamide, 2,4-dihydroxybenzoic acid N-(4-hydroxy-3-methoxybenzoyl)benzoic acid amide, 2,4,6-trihydroxybenzoic acid-N-(4-hydroxy-3-methoxybenzyl)amide, 2-hydroxybenzoic acid-N-4-(hydroxy-3-methoxybenzyl)amide, 4-hydroxybenzoic acid-N-(4-hydroxy-3-methoxybenzyl)amide, 2,4-dihydroxybenzoic acid-N-(4-hydroxy-3-methoxybenzyl)amide monosodium salt, 2,4-dihydroxybenzoic acid-N-2-(4-hydroxy-3-methoxyphenyl)acetamide, 2,4-dihydroxybenzoic acid-N-(4-hydroxy-3-ethoxybenzyl)amide, 2,4-dihydroxybenzoic acid-N-(3,4-dihydroxybenzyl)amide and 2-hydroxy-5-methoxy-N-[2-(4-hydroxy-3-methoxyphenyl)ethyl]amide; 4-hydroxybenzoic acid vanillylamide (particularly WO 2006 / 024587); hydroxydeoxybenzoin, preferably 2-(4-hydroxy-3-methoxyphenyl)-1-(2,4,6-trihydroxyphenyl)ethanone, 1-(2,4-dihydroxyphenyl)-2-(4-hydroxy-3-methoxyphenyl)-ethanone and 1-(2-hydroxy-4-methoxyphenyl)-2-(4-hydroxy-3-methoxyphenyl)ethanone) (especially those described in WO 2006 / 106023); hydroxyphenylalkanedione, such as gingerdione-[2], gingerdione-[3], gingerdione-[4], dehydrogingerdione-[2], dehydrogingerdione-[3], dehydrogingerdione-[4]) (especially those described in WO 2007 / 003527); diacetyl trimer (especially those described in WO 2006 / 058893); gamma-aminobutyric acid (especially WO those described in 2005 / 096841);Divanillin (especially those described in WO 2004 / 078302) and 4-hydroxydihydrochalcone (preferably those described in US 2008 / 0227867 A1), especially phloretin and dihydroisoliquiritigenin, amino acids or mixtures formed by whey protein and lecithin, hesperidin disclosed in WO 2007 / 014879, 4-hydroxydihydrochalcone disclosed in WO 2007 / 107596, or chavicolglycosiden described in EP 1955601A1, or extracts from Rubus suavissimus, extracts from Hydrangea macrophylla described in EP 2298084A1, Pellitorin described in EP 2008530A1 and derived aroma compositions, WO Umami compounds described in 2008 / 046895A1 and EP1989944A1, umami compounds described in EP 2064959A1 and EP 2135516A1, vanilla lignans, enterodiol and N-decadienoyl amino acids and mixtures thereof. ;
[0716] A further object of the present invention relates to cosmetic or pharmaceutical preparations which comprise one or more cooling agents according to the invention or cooling agent mixtures according to the invention or flavoring preparations according to the invention.
[0717] The agents according to the invention can be in particular skin cosmetics, hair cosmetics, dermatological, hygiene or pharmaceutical agents. In particular, the active ingredients according to the invention, which have a cooling effect, are used in particular in skin and / or hair cosmetics or as oral care products.
[0718] The hair or skin care composition or preparation according to the present invention is preferably in the form of an emulsion, dispersion, suspension, in the form of an aqueous surfactant preparation, emulsion, lotion, cream, balm, ointment, gel, granule, powder, stick preparation (such as lipstick), foam, aerosol or spray. Such formulations are very suitable for topical preparations. Suitable emulsions are oil-in-water emulsions and water-in-oil emulsions or microemulsions. Typically, hair or skin cosmetic preparations are used for application to the skin (topical) or hair. The term "topical preparation" refers to a preparation suitable for applying the active ingredient to the skin in a finely dispersed form (e.g., in a form that can be absorbed by the skin). For example, aqueous and hydroalcoholic solutions, sprays, foams, foam aerosols, ointments, aqueous gels, O / W or W / O emulsions, microemulsions or cosmetic stick preparations are suitable for this purpose. According to one embodiment of the cosmetic composition of the present invention, it contains a carrier. Preferred carriers are water, gas, water-based liquids, oils, gels, emulsions or microemulsions, dispersions or mixtures thereof. The carrier exhibits good skin compatibility. Aqueous gels, emulsions or microemulsions are particularly advantageous for topical formulations.
[0719] The teachings according to the present invention also include the use of the active ingredient as described herein for medical purposes, in particular for the use of pharmaceutical compositions for the treatment of individuals, preferably mammals, in particular humans, farm animals or livestock. For this purpose, the active ingredient is administered in the form of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and at least one active ingredient according to the present invention and optional additional active ingredients. These compositions can be administered, for example, by oral, rectal, transdermal, subcutaneous, intravenous, intramuscular or intranasal routes.
[0720] Examples of suitable pharmaceutical formulations or compositions include solid dosage forms such as powders, powders, granules, tablets, lozenges, sachets, cachets, coated tablets, capsules (e.g., hard gelatin capsules and soft gelatin capsules), suppositories or vaginal dosage forms, semisolid dosage forms such as ointments, creams, hydrogels, pastes or patches, and liquid dosage forms such as solutions, emulsions (particularly water-in-oil emulsions), suspensions, creams, hydrogels, pastes or patches, creams, hydrogels, pastes or patches, and liquid dosage forms such as solutions, emulsions (particularly oil-in-water emulsions), suspensions (e.g., lotions), injection and infusion preparations, eye drops and ear drops. Implantable delivery devices can also be used to administer the inhibitor according to the present invention. In addition, liposomes, microspheres or polymer matrices can also be used. Possible pharmaceutical agents include cold syrups, wound ointments or wound sprays. These substances can also be incorporated into plasters or tablets, especially if these plasters or tablets contain active ingredients that have an unpleasant taste.
[0721] Therefore, a further object of the present invention comprises a cooling agent or cooling agent mixture according to the invention as a medicament, in particular as a medicament for relieving painful and inflammatory conditions of the skin and mucous membranes. Due to its cooling properties, the cooling agent according to the invention is particularly suitable for preventing, combating or relieving the symptoms of cough, cold, inflammation, sore throat or hoarseness.
[0722] Due to their potent cooling effect, the substances and preparations described herein are also suitable for the treatment of inflammatory conditions of the skin, mucous membranes and joints.
[0723] Because they regulate the properties of receptor TRPM8, wherein the gene expression of the receptor TRPM8, i.e. the expression of the TRPM8 gene, is upregulated in cancer diseases (e.g. in prostate cancer), the pharmaceutical preparations according to the present invention are also preferably used in oncology, preferably for the treatment of prostate cancer or bladder cancer, or for the treatment of bladder weakness. The corresponding protein in the cell is encoded by the corresponding gene in the nucleus. Reading the gene in the nucleus (transcription) leads to the production of messenger RNA (mRNA), which is then "translated" into protein (translation) in the cell on the ribosome. These two processes are generally referred to as gene expression.
[0724] However, astringency, bitterness and / or metallic taste is not only present in the above-mentioned flavorings and sweeteners, but is also associated with many active pharmaceutical ingredients, which makes them difficult to take, especially for children. Typical examples of such active pharmaceutical ingredients are as follows: aspirin, minoxidil, erythromycin, dimethindine, betamethasone, ibuprofen, ketoprofen, dicyclofenac, metronidazole, acyclovir, imiquimod, terbinafine, ciclopirox olamine, paracetamol and other pharmaceutical agents of the nonsteroidal anti-inflammatory drug (NSAID) type and mixtures thereof.
[0725] Therefore, the present invention also comprises a medicament containing one or more cooling agents according to the invention or a cooling agent mixture according to the invention or a flavoring preparation according to the invention in combination with at least one further active pharmaceutical ingredient selected from the group consisting of aspirin, minoxidil, erythromycin, dimethindine, betamethasone, ibuprofen, ketoprofen, dicyclofenac, metronidazole, acyclovir, imiquimod, terbinafine, cyclopiroxolamin, paracetamol and mixtures thereof.
[0726] The subject studies have also shown that the cooling agents according to the invention or the cooling agent mixtures according to the invention, in addition to the cooling effect, also enhance the analgesic properties of nonsteroidal anti-inflammatory substances (NSAIDs), in particular ibuprofen and ketoprofen, which was also not expected by the person skilled in the art. Therefore, the present invention also relates in particular to combinations with pharmaceutical agents of the nonsteroidal anti-inflammatory drug (NSAID) type.
[0727] Such drug combinations are therefore particularly advantageous for use in the treatment of inflammations of the skin and mucous membranes and of the joints.
[0728] The medicament may contain the cooling agent according to the invention or the cooling agent mixture according to the invention and the active pharmaceutical ingredient in a weight ratio of about 1:99 to about 10:90, and in particular 2:98 to about 5:95.
[0729] The physiological cooling effect is also used, for example, in the formulation of ointments for wounds and burns and in preparations for insect bites.
[0730] In the preparation of cosmetics or pharmaceutical compositions according to the present invention, the cooling agent or cooling agent mixture according to the present invention is usually mixed with an excipient or diluted with it. Excipients can be solid, semisolid or liquid materials, which are used as the medium, carrier or medium of the active ingredient. The active ingredient content (of one or more cooling agents according to the present invention simultaneously included) can vary within a wide range, and in each case based on the gross weight of the preparation, is about 0.05ppm to 10% by weight, preferably 0.1ppm to 10% by weight.
[0731] Suitable excipients include, for example, lactose, glucose, sucrose, sorbitol, mannitol, starch, acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup and methylcellulose. In addition, the formulation may contain pharmaceutically acceptable carriers or conventional excipients, such as lubricants, for example tallow, magnesium stearate and mineral oil, wetting agents, emulsifiers and suspending agents, preservatives, such as methyl and propyl hydroxybenzoates; antioxidants; anti-irritants; chelating agents; coating agents; emulsion stabilizers; film formers; gel formers; odor masking agents; flavoring agents; resins; hydrocolloids; solvents; solubilizers; neutralizers; penetration enhancers; pigments; quaternary ammonium compounds; fat excipients and fat enriching agents; ointments, creams or oil bases; silicone derivatives; application aids; stabilizers; sterilants; suppository bases; tablet excipients, such as binders, fillers, lubricants, disintegrants or coating agents; propellants; desiccants; opacifiers; thickeners; waxes; plasticizers; white oils. The relevant embodiments are based on professional knowledge and are fully described in the relevant technical literature.
[0732] The preparations according to the invention may contain cosmetic and / or dermatological and / or pharmacological active agents in addition to conventional additives or auxiliaries. Non-limiting examples of suitable additional active ingredients are: cosmetic and / or dermatological active ingredients; antimicrobial active ingredients; surfactants (anionic surfactants, nonionic surfactants, cationic surfactants, amphoteric or zwitterionic surfactants), oil bodies, emulsifiers, emulsifying agents, antimicrobial agents and other active ingredients zwitterionic surfactants, oil bodies, emulsifiers, fats and waxes, pearlescent waxes, thickeners and thickeners, refatting agents and stabilizers, polymers, silicone compounds, UV protection filters, pigments (especially light protection pigments), moisturizers, biologically active ingredients and antioxidants, deodorants and bacteriostatic agents, enzyme inhibitors, odor absorbers, antiperspirants, film formers, antidandruff agents, swelling agents, insect repellents, solubilizers, preservatives, perfume oils and fragrances, dyes, etc.
[0733] Preferred preparations according to the invention are selected from the group consisting of products for treating, protecting, caring for and cleansing the skin and / or hair or as cosmetic products (as leave-on or rinse-off products).
[0734] Depending on the manufacturing method and ingredients, the formulations include, for example, dispersions, suspensions, creams, lotions or emulsions, gels (including hydrogels, such as hydrodispersible gels, oleogels), sprays (such as pump sprays or sprays with propellants), foams or impregnating solutions for cosmetic wipes, soaps, washing liquids, shower and bath preparations, bath products (capsules, oils, tablets). Foams or impregnating solutions for cosmetic wipes, soaps, washing liquids, shower and bath preparations, bath products (capsules, oils, tablets, salts, bath salts, soaps, etc.), effervescent preparations, skin care products such as lotions, ointments, pastes, gels (as described above), oils, balms, serums, powders (such as face powders, talcum powders), masks, sticks, roll-on sticks, aerosols (foaming, non-foaming or post-foaming), deodorants and / or antiperspirants, mouthwashes and mouthwashes, insect repellents, sunscreens, after-sun products, shaving products, aftershave balms, pre-shave and Aftershave lotion, depilatory, hair care products such as shampoo (including two-in-one shampoo, anti-dandruff shampoo, baby shampoo, dry hair shampoo, concentrated shampoo), conditioner, hair tonic, hair lotion, hair dye, styling cream, pomade, perm and curling agent, hair spray (e.g., styling aid (e.g., gel or wax)), hair straightener (detangler, relaxer), hair dye (e.g., temporary hair dye, semi-permanent hair dye, permanent hair dye), hair conditioner, mousse, eye care products, cosmetics, makeup remover or baby products.
[0735] Particularly preferably, the formulations according to the invention are in the form of an emulsion, in particular a W / O, O / W, W / O / W, O / W / O emulsion, a PIT emulsion (e.g. a Pickering emulsion), a low-oil emulsion, a microemulsion or a nanoemulsion, a gel (including a hydrogel, a hydrodispersible gel, an oleogel) or a solution.
[0736] The total proportion of excipients and additives can be 1% to 50% by weight, preferably 5% to 40% by weight, based on the final formulation. The preparation of the reagent can be carried out by conventional cold or hot processes; preferably, the phase inversion temperature method is used.
[0737] The invention also includes oral care compositions which comprise one or more cooling agents according to the invention or cooling agent mixtures according to the invention or flavoring preparations according to the invention.
[0738] The oral hygiene products according to the invention can be formulated in a manner known per se, for example as toothpaste, toothpaste gel, tooth powder, toothbrush liquid, toothbrush foam, aqueous or hydro-alcoholic oral care product (mouthwash), mouthwash as a two-in-one product, lozenges, mouth spray, dental floss and tooth care chewing gum.
[0739] Toothpaste is generally understood to be a gel-like or pasty preparation of water, thickeners, humectants, abrasives or cleaning agents, surfactants, sweeteners, flavorings, deodorizing active ingredients and active ingredients against oral and dental diseases. All customary cleaning agents, such as chalk, dicalcium phosphate, insoluble sodium metaphosphate, aluminum silicate, calcium pyrophosphate, finely divided synthetic resins, silicon dioxide, aluminum oxide and aluminum oxide trihydrate, can be used in the toothpaste according to the invention.
[0740] Preferably, suitable cleaning agents for the toothpaste according to the invention are firstly finely divided xerogel silica, hydrogel silica, precipitated silica, alumina trihydrate and finely divided α-alumina or mixtures of these cleaning agents, in an amount of 15 to 40% by weight of the toothpaste. Low molecular weight polyethylene glycols, glycerol, sorbitol or mixtures of these products, in an amount of up to 50% by weight, can be used as humectants. Known thickeners include thickening finely divided gel silica and hydrocolloids, such as carboxymethylcellulose, hydroxyethylcellulose, hydroxypropyl guar, hydroxyethyl starch, polyvinyl pyrrolidone, high molecular weight polyethylene glycols, vegetable gums, such as tragacanth, agar, chondrus, gum arabic, xanthan gum and carboxyvinyl polymers (e.g. In addition to the mixture of menthofuran and menthol compounds, the oral and dental care compositions may contain, in particular, surface-active substances, preferably anionic and nonionic high-foaming surfactants, such as those already mentioned above, but in particular alkyl ether sulfates, alkyl polyglycosides and mixtures thereof.
[0741] Other common toothpaste additives are:
[0742] Preservatives and antimicrobial substances, such as methyl, ethyl or propyl paraben, sodium sorbate, sodium benzoate, bromochlorophenol, phenyl salicylate, thymol, etc.;
[0743] antacids, for example organic phosphates, such as 1-hydroxyethane-1,1-diphosphonic acid, 1-phosphonopropane-1,2,3-tricarboxylic acid, etc., as are known, for example, from US Pat. No. 3,488,419, DE 2224430 A1 and DE 2343196 A1;
[0744] Other anti-caries substances, such as sodium fluoride, sodium monofluorophosphate, stannous fluoride;
[0745] Sweeteners, such as sodium saccharin, sodium cyclamate, sucrose, lactose, maltose, fructose or (L-aspartyl-L-phenylalanine methyl ester), stevia extract or its sweetening ingredients, especially rebaudioside;
[0746] Additional flavorings, such as eucalyptus oil, anise oil, cumin oil, caraway oil, methyl acetate, cinnamaldehyde, anethole, vanillin, thymol, and mixtures of these and other natural and synthetic flavorings;
[0747] Pigments, such as titanium dioxide;
[0748] Colorants;
[0749] Buffer substances such as primary, secondary or tertiary alkaline phosphates or citric acid / sodium citrate;
[0750] Wound healing and anti-inflammatory substances such as allantoin, urea, azulene, chamomile active ingredients and acetylsalicylic acid derivatives.
[0751] Hydrotropes, such as ethanol, isopropanol or polyols, can also be used to improve the flow behavior; these substances correspond to the carriers described at the beginning to a large extent. The polyols considered here preferably have 2 to 15 carbon atoms and at least two hydroxyl groups. The polyols may also contain other functional groups, in particular amino groups, or be modified with nitrogen.
[0752] Suitable preservatives include phenoxyethanol, formaldehyde solution, parabens, pentylene glycol or sorbic acid and Silver complexes and other classes of substances known and suitable to those skilled in the art.
[0753] Perfume oils are those already defined above. In particular, peppermint oil, spearmint oil, anise oil, star anise oil, caraway oil, eucalyptus oil, cumin oil, lemon oil, wintergreen oil, clove oil, menthol, etc. may be regarded as fragrances.
[0754] A preferred embodiment of the cosmetic preparation is a toothpaste in the form of an aqueous pasty dispersion containing a polishing agent, a moisturizer, a viscosity regulator and optionally other conventional components, and a mixture of menthofuran and menthol compounds in an amount of 0.5 to 2% by weight.
[0755] In mouthwashes, hydroalcoholic solutions of essential oils of different grades, emulsifiers, astringent and tonic extracts, tartaric acid, antimicrobial additives and flavoring agents can be easily combined. A further preferred embodiment of the invention is a mouthwash in the form of an aqueous or aqueous alcoholic solution containing 0.5% to 2% by weight of a mixture of menthofuran and menthol compounds. In a mouthwash diluted before use, a higher concentration can be used to achieve a sufficient effect, depending on the desired dilution ratio.
[0756] The oral care compositions according to the invention contain preferably 0.1 ppm to 1% by weight, preferably 1 ppm to 0.2% by weight, based on the total weight of the composition, of at least one active ingredient according to the invention, i.e. a cooling agent, or an active ingredient mixture, i.e. a cooling agent mixture or a flavoring preparation.
[0757] The total content of the active ingredient or active ingredients according to the invention or of the freshener mixture or flavoring preparation according to the invention in the ready-to-use mouthwash is preferably 0.01 to 1% by weight, preferably 0.05 to 0.5% by weight, particularly preferably 0.1 to 0.3% by weight (in each case based on the total mouthwash).
[0758] The total content of the active ingredient or active ingredients according to the invention or the cooling agent mixture or flavoring preparation according to the invention in the mouthwash concentrate is 0.1 to 15% by weight, preferably 0.5 to 8% by weight, particularly preferably 1 to 5% by weight (based in each case on the total mouthwash concentrate).
[0759] The total content of the active ingredient or active ingredients according to the invention or of the cooling agent mixture or flavoring preparation according to the invention in toothpaste is 0.1 to 5% by weight, preferably 0.5 to 2% by weight, particularly preferably 0.8 to 1.5% by weight (based in each case on the total toothpaste).
[0760] The invention also includes chewing gums which contain one or more cooling agents according to the invention or cooling agent mixtures according to the invention or flavoring preparations according to the invention.
[0761] Chewing gum compositions contain water-insoluble and water-soluble components usually. The water-insoluble matrix, also referred to as "gum base", usually comprises natural or synthetic elastomers, resins, fats and oils, plasticizers, fillers, colorants and optional waxes. The ratio of the matrix in the total composition is usually 5% to 95% by weight, preferably 10% to 50% by weight, and particularly 20% to 35% by weight. In a typical embodiment of the present invention, the matrix is composed of 20 to 60% by weight of synthetic elastomers, 0 to 30% by weight of natural elastomers, 5 to 55% by weight of plasticizers, 4 to 35% by weight of fillers and a small amount of additives (e.g., colorants, antioxidants, etc.), but the prerequisite is that they can be dissolved in water in small amounts at most.
[0762] Suitable synthetic elastomers include, for example, polyisobutylene having an average molecular weight (according to GPC) of 10,000 to 100,000 and preferably 50,000 to 80,000, isobutylene-isoprene copolymers (butyl elastomers), styrene-butadiene copolymers (styrene:butadiene ratios of, for example, 1:3 to 3:1), polyvinyl acetate having an average molecular weight (according to GPC) of 2,000 to 90,000 and preferably 10,000 to 65,000, polyisoprene, polyethylene, vinyl acetate-vinyl laurate copolymers, and mixtures thereof. Examples of suitable natural elastomers are rubbers, such as smoked or liquid latex or guayule, and natural rubbers, such as Jelutong, Lechi caspi, Perillo, Sorva, Massarandubabalata, Massaranduba chocolate, Nispero, Rosindinba, Chicle, Gutta hang 1kang and mixtures thereof. The choice of synthetic and natural elastomers and the proportions in which they are mixed depend mainly on whether the chewing gum is intended to produce bubbles ("bubble gum"). Preferably, an elastomer mixture containing Jelutong, Lechi caspi, Perillo and Sorva is used.
[0763] Possible fillers or thickeners include magnesium or calcium carbonate, pumice, silicates, especially magnesium or aluminum silicates, clays, aluminum oxide, talc, titanium dioxide, mono-, dicalcium and tri-calcium phosphates and cellulosic polymers.
[0764] Suitable emulsifiers are beef tallow, hardened beef tallow, hardened or partially hardened vegetable oils, cocoa butter, partial glycerides, lecithin, triacetin and saturated or unsaturated fatty acids having 6 to 22 carbon atoms, preferably 12 to 18 carbon atoms, and mixtures thereof.
[0765] Possible colorants and whiteners include types FD and C approved for food coloring, plant and fruit extracts, and titanium dioxide.
[0766] The matrix composition may be wax-containing or wax-free; examples of wax-free compositions may be found, inter alia, in patent specification US Pat. No. 5,286,500.
[0767] In addition to the water-insoluble gum base, chewing gum formulations usually also contain a water-soluble portion, which is formed by, for example, softeners, sweeteners, fillers, flavorings, flavor enhancers, emulsifiers, coloring agents, acidulants, antioxidants, etc., provided that these ingredients have at least sufficient water solubility. Depending on the water solubility of the specific representative, each component can therefore belong to a water-insoluble and water-soluble phase. However, a combination of, for example, a water-soluble and water-insoluble emulsifier can also be used, so that each agent is in a different phase. Typically, the water-insoluble portion accounts for 5% to 95% by weight of the formulation, preferably 20% to 80% by weight.
[0768] Water-soluble softeners or plasticizers are added to chewing gum compositions to improve chewiness and chewing feel, and are generally present in the mixture in an amount of 0.5% to 15% by weight. Typical examples are aqueous solutions of glycerol, lecithin and sorbitol, hardened starch hydrolysates or corn syrup.
[0769] Sugary and sugar-free compounds are suitable for use as sweeteners in amounts of 5% to 95% by weight, preferably 20% to 80% by weight, and particularly 30% to 60% by weight, based on the chewing gum composition. Typical sugar sweeteners are sucrose, glucose, maltose, dextrin, dry invert sugar, fructose, levulose, galactose, corn syrup and mixtures thereof. Sorbitol, mannitol, xylitol, hardened starch hydrolysate, maltitol and mixtures thereof can be used as substitutes for sugar. In addition, so-called HIAS ("high intensity artificial sweeteners"), such as sucralose, aspartame, acesulfame salts, alitame, saccharin and saccharin salts, cyclamic acid and its salts, glycyrrhizin, dihydrochalcone, thaumatin, monellin, etc., alone or in a mixture, can also be considered as additives. Hydrophobic HIAS, the subject of International Patent Application WO 2002091849A1 (Wrigleys), are also particularly effective, as are stevia extracts and their active ingredients, especially rebaudioside A. The amounts of these substances used depend largely on their properties and are generally in the range of 0.02% to 8% by weight.
[0770] Bulking agents, such as polydextrose, oligofructose, inulin (Rafitilin), fructooligosaccharides (NutraFlora), Palatinose oligosaccharides, guar gum hydrolysate (SunFiber), and dextrin, are particularly suitable for the production of low-calorie chewing gum.
[0771] The choice of other flavorings is practically unlimited and is not important to the essence of the invention. Typically, the total amount of all flavorings is from 0.1% to 15% by weight, and preferably from 0.2% to 5% by weight (based on the chewing gum composition). Suitable other flavorings are, for example, essential oils, synthetic flavorings, and the like, such as anise oil, star anise oil, caraway oil, eucalyptus oil, cumin oil, lemon oil, wintergreen oil, clove oil, and the like, which are also used, for example, in oral and dental care compositions.
[0772] The chewing gums may also contain auxiliary substances and additives which are suitable, for example, for dental care, in particular for combating dental plaque and gingivitis, such as chlorhexidine, CPC or triclosan. They may also contain pH regulators (such as buffers or urea), anticaries (such as phosphates or fluorides), biological agents (antibodies, enzymes, caffeine, plant extracts), provided that these substances are approved for use in food and do not interact in an adverse manner.
[0773] The present invention also includes cooling patches.
[0774] The patch according to the invention can be constructed in any desired manner, for example according to a matrix system, a membrane system or a nonwoven system.
[0775] The patch according to the invention is produced in the usual manner.
[0776] The matrix system consists of 3 simple parts: a flexible support film, an adhesive base containing the active ingredient, and a release film. If a non-adhesive base is used, an adhesive must be applied to one edge of the support film to ensure adhesion to the skin.
[0777] In another aspect, the film system has at least five parts: a flexible support film, a reservoir with dissolved or suspended active ingredient, a film for controlling the release of the active ingredient, an adhesive layer applied to the film, and a release film.
[0778] In the nonwoven system, the layer containing the active ingredient consists of an absorbent nonwoven or porous polymer impregnated with a solution or suspension of the active ingredient. This layer is firmly attached to a support film and is coated with a release film. The edge of the support film has an adhesive for application to the skin.
[0779] In principle, all active ingredients according to the invention can be formulated in this way. The excipients used are the customary excipients for producing plasters. In addition to the binder, a polymer with a glass transition temperature between -70 and -10°C, in particular between -55 and -25°C, and a carrier film coated with the binder are usually added, as well as the active ingredient, emulsifiers, thickeners and substances intended to influence the release of the active ingredient and other auxiliaries.
[0780] The above-mentioned viscous polymers with low glass transition temperature are known. Self-adhesive tapes and self-adhesive films are intended to adhere to human skin by only contact, but the cohesive force of the adhesive layer and its adhesion to the carrier film should be greater than the adhesion to the skin, so that they can be removed again without leaving any residue. These are generally based on acrylates and methacrylates of alcohols with 2 to 12 carbon atoms, particularly 4 to 8 carbon atoms, which can contain some other following polymerized comonomers, such as (meth) acrylic acid, (meth) acrylonitrile, (meth) acrylamide, N-tert-butyl (meth) acrylamide, vinyl esters (such as vinyl acetate, vinyl propionate or vinyl butyrate), other vinyl compounds (such as styrene and butadiene). Butyl acrylate and 2-ethylhexyl acrylate are particularly noteworthy. The polymer can be crosslinked by adding small amounts of comonomers with 2 or more copolymerizable double bonds (e.g. diacrylates, such as butanediol diacrylate, or divinyl compounds, such as divinylbenzene) or by adding other crosslinking agents (e.g. melamine-formaldehyde resins). Polyisobutylene and polyvinyl ethers of different molecular weights can also be used as adhesive polymers.
[0781] The particle size of the dispersion should be between 50 and 500 nm, in particular between 50 and 200 nm. The particle size and the degree of crosslinking can be adjusted in a known manner depending on the polymerization conditions and the comonomers. Smaller particle sizes and higher degrees of crosslinking can increase the release of the active ingredient.
[0782] The matrix patch can be produced according to conventional methods, i.e., the active ingredient is dissolved or finely dispersed in a suitable polymer solution, and then the self-adhesive material containing the active ingredient is pulled into a film using a roller or a doctor blade application process. In some cases, it is recommended to dissolve or finely disperse the active ingredient in an organic solvent (e.g., ethanol or acetone) before adding it to the polymer solution. This allows the active ingredient to be better distributed in the polymer.
[0783] The patch can also be produced by incorporating the active ingredient in fine powder form (particle size below 200 μm, in particular below 50 μm) into an aqueous latex dispersion, or dispersing or dissolving it in an aqueous emulsifier solution and mixing the mixture into the aqueous latex dispersion at a temperature of 10 to 80° C., in particular 30 to 70° C. In addition, the salt of the active ingredient in aqueous solution can also be mixed with the polymer dispersion at a pH value at which the active ingredient is mainly present in the form of water-soluble ions. By changing the pH, the active ingredient is subsequently converted into an uncharged, water-insoluble form and simultaneously emulsified into the dispersion.
[0784] The preparation of the active ingredient is very convenient, adding emulsifier and water, and then mixing with polymer dispersion. The dispersion containing active ingredient obtained in this way can be equipped with other additives, and as mentioned above, is pulled out to form a film on a supporting film and dried in a manner known per se. The drying temperature can be between room temperature and 100 ℃, wherein the optimum temperature between the required rapid drying and avoiding the formation of bubbles in the film and the thermal stress on the active ingredient is generally 35 ℃ to 45 ℃. This process has the great advantage of avoiding the use of organic solvents. But, in principle, all other conventional manufacturing processes for matrix patches can also be considered.
[0785] The resulting film has a thickness of 10 to 800 μm, preferably 50 to 300 μm. The film can be produced continuously or discontinuously. The application process can be repeated several times until the film reaches the desired thickness. The adhesive polymer layer contains the active ingredient in a concentration ranging from 1% to 40% by weight, in particular from 5% to 25% by weight. The same concentration also applies to the storage liquid in the membrane system and the active ingredient solution or dispersion of the nonwoven or porous polymer impregnated in the nonwoven system.
[0786] As emulsifiers for the active ingredient according to the invention (i.e. the coolant according to the invention or the coolant mixture according to the invention or the flavoring preparation according to the invention) and the polymer, surfactants customary for this purpose are used, for example sodium salts of long-chain fatty acids and sulfuric acid half esters of (optionally oxyethylated) fatty alcohols as examples of anionic surfactants, and polyoxyethylated alkylphenols and long-chain fatty alcohols (e.g. hexadecane-(l)-ol and glycerol fatty acid partial esters as examples of nonionic surfactants and auxiliary emulsifiers).
[0787] For example, polyacrylic acid or cellulose derivatives can be used to adjust the desired viscosity of the substance to be extracted. For example, melamine-formaldehyde resin can be used as an additional crosslinking agent to increase the cohesion and thus the adhesive properties of the membrane.
[0788] Swelling agents, such as polyvinylpyrrolidone, cellulose derivatives or polyacrylates, have the effect of improving the release of the active ingredient, since the film can absorb more water, thereby reducing the diffusion resistance. The release of the active ingredient can also be improved by adding hydrophilic plasticizers (such as glycerol, 1,2-propylene glycol of polyethylene glycol) and lipophilic plasticizers (such as triacetin, dibutyl phthalate or isopropyl myristate).
[0789] Matrix patches generally result in 1st order release of the active ingredient. The use of fillers that adsorb the active ingredient (e.g., fumed silica, microcrystalline cellulose, or lactose) results in approximately 0th order release.
[0790] The support film on which the adhesive composition containing the active ingredient is dried is practically impermeable to both the active ingredient and water vapor. For example, it can be composed of an aluminum-plastic composite film, a metallized plastic film, a plastic film having a barrier layer (e.g., polyvinylidene chloride) on the active ingredient side, or a simple plastic film (e.g., polyester film).
[0791] The patch according to the invention is constructed according to a membrane system and is also produced in the usual manner. The patch constructed according to the nonwoven system is made by dipping a nonwoven or porous polymer attached to a support membrane into a solution or dispersion of the active ingredient in a hydrophilic or lipophilic solvent or solvent mixture. A water-impermeable peeling membrane is then applied.
[0792] In principle, the active ingredient content in the preparations according to the invention can vary within wide ranges, for example from 0.1 ppm to 10% by weight, preferably from 1 ppm to 10% by weight.
[0793] The invention also relates to a textile product provided with the cooling agent according to the invention or the cooling agent mixture according to the invention.
[0794] Finishing textiles with cooling agents having a cooling effect is particularly used where the garment can come into direct contact with the skin so that the active ingredients can exert their effects by transdermal transfer, for example locally or systemically. Recently, there have been reports of textiles being equipped with so-called health additives, i.e. substances that promote health.
[0795] On the other hand, insecticidal finishes are attractive for material protection purposes, such as finishing textiles to prevent insect damage, and are particularly suitable for repelling parasites such as mosquitoes.
[0796] A fundamental problem when finishing textiles with active ingredients is the binding of the active ingredient to a textile carrier, which on the one hand must ensure the durability of the finish and on the other hand must be selected in such a way that the active ingredient does not lose its effect. Various methods have been proposed in the prior art.
[0797] For example, cyclodextrins have been proposed for binding active ingredients to textiles. Cyclodextrins are cyclic oligosaccharides formed by enzymatic degradation of starch. The most common cyclodextrins are α-, β- and γ-cyclodextrin, which consist of six, seven or eight α-1,4-linked glucose units. Cyclodextrin molecules are characterized by their ring structure of essentially constant size. The inner diameter of the ring is about 570 pm for α-cyclodextrin, about 780 pm for β-cyclodextrin and about 950 pm for γ-cyclodextrin. Due to their structure, cyclodextrins are able to capture guest molecules, especially hydrophobic guest molecules, in varying amounts until saturation.
[0798] The prior art describes the finishing of textiles with perfumes and other low-molecular organic active ingredients, which are bound to the textiles via an amylose-containing substance having an amylose content of at least 30%. Due to the amylose content of the amylose-containing substance, the active ingredient is bound to the textile and released in a controlled manner, so that the effect is maintained over a long period of time. It is assumed that the active ingredient is reversibly bound in the form of an inclusion complex in the cavity formed by the helical conformation of amylose, similar to cyclodextrins, so that on the one hand the active ingredient is fixed on the surface of the textile carrier and on the other hand a controlled release is possible.
[0799] In addition to amylose, all substances, in particular amylose-containing starches, i.e. native starches, modified starches and starch derivatives, whose amylose content is at least 30% by weight, in particular at least 40% by weight, are suitable for finishing textiles according to the invention. The starch can be natural, for example corn starch, wheat starch, potato starch, sorghum starch, rice starch or arrowroot starch, obtained by partial digestion of native starch or chemical modification. Pure amylose itself is also suitable, for example enzymatically obtained amylose, for example amylose obtained from sucrose. Mixtures of amylose and starch are also suitable, provided that the total amylose content is at least 30% by weight (based on the total weight of the mixture). It should be understood that all amylose or amylose-containing substances expressed in % by weight here and below, in the case of mixtures of amylose and starch, always refer to the total weight of amylose + starch, unless expressly stated otherwise. Particularly suitable according to the invention are amylose-containing substances, in particular amylose and amylose-containing starches and amylose / starch mixtures, whose amylose content is at least 40% by weight, in particular at least 45% by weight (based on the total weight of the substance). Usually, the amylose content does not exceed 90% by weight, in particular 80% by weight. Such substances are known and commercially available. For example, amylose-containing starches are available from the company Cerestar under the trade name Sold by National Starch under the trade name V and VII sales.
[0800] In order to bind the active ingredient to the textile, the textile can be finished with an amylose-containing substance, generally in an amount of at least 0.5% by weight, preferably at least 1% by weight, in particular at least 2% by weight, in each case based on the weight of the textile. Generally, the amount of amylose-containing substance used is not more than 25% by weight, generally not more than 20% by weight, in particular not more than 15% by weight, based on the weight of the textile, in order not to affect the tactile properties of the textile. First, the textile material is finished with the amylose-containing substance itself and the finished textile is then treated with a suitable active substance preparation. In this way, the amylose-containing substance on the textile material is loaded with the active ingredient. However, the amylose-containing substance can also be used together with the active ingredient for finishing the textile. In this case, the active ingredient and the amylose-containing substance can be used both as a mixture of the individual components and in the ready-made form of an amylose-active ingredient complex. Generally, the active ingredient is used in an amount sufficient to achieve the desired effect. The upper limit is determined by the maximum absorption capacity of the amylose units of the amylose-containing substance used, and is usually not more than 20% by weight, usually not more than 10% by weight (based on the amylose content of the substance). If necessary, the active ingredient is usually used in the following amounts: 0.00001% to 15% by weight, 0.0001% to 10% by weight, 0.001% to 5% by weight, 0.005% to 1% by weight or 0.1% to 10% or 0.5 to 5% by weight (based on the amylose content of the amylose-containing substance).
[0801] Combinations of the active substances according to the invention with other active substances which are known per se and suitable for the finishing of textiles can also be used for the finishing of textiles.
[0802] In principle, all organic compounds and mixtures of organic compounds known as active substances and which cause physiological effects in organisms (such as humans and animals, including microorganisms) are suitable as additional active substances. These include active substances known to form inclusion complexes with cyclodextrins. Particularly suitable are active substances with hydrocarbon groups and in particular aliphatic, cycloaliphatic and / or aromatic structures. The molecular weight of the active ingredient is generally less than 1000 Daltons and is generally in the range of 100 to 600 Daltons. Inorganic compounds known to be able to be incorporated in cyclodextrins (such as hydrogen peroxide) are also suitable.
[0803] Other active ingredients include pharmaceutical active ingredients and active ingredients that promote the health of organisms (especially humans), and are also commonly referred to as "health additives". Unlike pharmaceutical active ingredients, health additives do not necessarily have a therapeutic effect. On the contrary, the effect of promoting health can be based on a variety of factors, such as care, stimulation, beauty or other effects. Also suitable are organic active ingredients that resist parasites. These include, for example, active ingredients against fungi and / or microorganisms, such as fungicides and bactericides, or active ingredients against animal pests such as snails, worms, mites, insects and / or rodents, such as nematicides, molluscicides, insecticides, miticides, rodenticides and anthelmintic active ingredients, as well as active ingredients against weeds, i.e. herbicides or spices.
[0804] Preferred active pharmaceutical ingredients are those known to be absorbed through the skin. These include, for example, ibuprofen, flurbiprofen, acetylsalicylic acid, acetaminophen, apomorphine, butylated hydroxytoluene, matricaria, guaiac, chlorthalidone, cholecalciferol, dicoumarol, digoxin, phenytoin, furosemide, hydroflumethiazide, indomethacin, iproniazid phosphate, nitroglycerin, nicotine, nicotinamide, ouabain, oxprenolol, papaverine alkaloids (e.g., papaverine, laurodamine, ixaverine and narcotine) and berberine, retinol, trans-retinoic acid, purotin, spironolactone, sulpiride, theophylline, theobromine, corticosteroids and derivatives (e.g., testosterone, 17-methyltestosterone, cortisone, corticosterone, dexamethasone, triamcinolone, methylprednisolone, phenytoin, oxaprenolol, nicotine, nicotinamide, oxaprenolol, papaverine alkaloids (e.g., papaverine, laurodamine, ixaverine and narcotine) and berberine, retinol, trans-retinoic acid, purotin, spironolactone, sulpiride, theophylline, theobromine, corticosteroids and derivatives (e.g., testosterone, 17-methyltestosterone, cortisone, corticosterone, dexamethasone, triamcinolone, methylprednisolone, The invention also includes the following: estrogens and progestogens (e.g. estradiol, estriol, ethinylestradiol-3-methyl ether, norethindrone and ethinyl progesterone, as well as phenylethylamines and derivatives (e.g. tyramine, adrenaline, noradrenaline and dopamine). According to the invention, examples of suitable active substances according to the invention which have an antiparasitic action are, for example, nematicides, bactericides, fungicides, insecticides, anthelmintics, acaricides and molluscicides. Examples of bactericidal and fungicidal substances include: antibiotics, for example cycloheximide, griseofulvin, kasugamycin, natamycin, polyoxin, streptomycin, penicillin or gentamicin;
[0805] Organic compounds and complexes of biocidal metals, for example complexes of silver, copper, tin and / or zinc, such as bis(tri-n-butyltin) oxide, copper, zinc and tin naphthenates, quinoline-copper, for example Cu-8, tri-N-(cyclohexyldiazodioxo)-aluminum, N-(cyclohexyldiazodioxo)-tributyltin, bis-N-(cyclohexyldiazodioxo)-copper;
[0806] Quaternary ammonium salts, for example benzyl-Cs- to cis-alkyldimethylammonium halides, in particular the chlorides (benzalkonium chloride);
[0807] Aliphatic nitrogen fungicides and bactericides, such as cymoxanil, dodicin, guazidine, cymoxanil, dodecamorph, fenpropimorph, fenpropimorph, tridecamorph;
[0808] Substances with a peroxide group, such as hydrogen peroxide, and organic peroxides, such as dibenzoyl peroxide;
[0809] Organochlorine compounds, such as chlorhexidine;
[0810] triazole fungicides such as azaconazole, cyproconazole, benzyltriazole, difenoconazole, diniconazole, epoxiconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, metconazole, propiconazole, fluconazole, tebuconazole and trichlorfon; strobilurins such as orysastrobin, fluoxastrobin, kresoxim-methyl, fenoxystrobin, orysastrobin, picoxystrobin, pyraclostrobin and trifloxystrobin;
[0811] sulfonamides, such as tolylfluanid and diflunisal;
[0812] Iodine compounds, for example diiodomethyl-p-tolylsulfone, napcocide, 3-iodo-2-propargyl alcohol, 4-chlorophenyl-3-iodopropyl formal, 3-bromo-2,3-diiodo-3-propenyl ethyl carbonate, 2,3,3-triiodoallyl alcohol, 3-iodo-2-propynyl-n-hexylcarbamate, 3-bromo-2,3-diiodo-2-propenyl alcohol, 3-iodo-2-propynyl phenylcarbamate, 3-iodo-2-propynyl n-butylcarbamate, 0-1-(6-iodo-3-oxohex-5-ynyl)phenylcarbamate, 0-1-(6-iodo-3-oxohex-5-ynyl)butylcarbamate;
[0813] Isothiazolinones, for example N-methylisothiazolin-3-one, 5-chloro-N-methylisothiazolin-3-one, 4,5-dichloro-N-octylisothiazolin-3-one, 1,2-benzisothiazol-3(2H)-one, 4,5-trimethylisothiazolin-3-one and N-octylisothiazolin-3-one.
[0814] Examples of insecticides and acaricides are: organophosphates, for example, acephate, methyl pyrithion, azinphos-methyl, chlorpyrifos, methyl chlorpyrifos, chlorfenvinphos, diazinon, dichlorvos, dicrotophos, dimethoate, ethion, ethion, fenitrothion, fenthion, isoxathion, malathion, methamidophos, methidathion, methyl parathion, mefenphos, monocrotophos, sulfoxide, paraoxon, parathion, phenthion, phosphamidon, phosphamidon, phosphamidon, methyl pyrithion, phosphamidon ... abiprophos, profenofos, prothiophos, thioprophos, triazophos, trichlorfon; in particular pyrethroids, for example acralthrin, allethrin, bioallethrin, barthrin, bifenthrin, bioethanomethrin, cyclopyrimidine, cypermethrin, cyfluthrin, beta-cyfluthrin, cyhalothrin, gamma-cyhalothrin, lambda-cyhalothrin, cypermethrin, alpha-cypermethrin, beta-cypermeth ... Cypermethrin, λ-Cypermethrin, ζ-Cypermethrin, Cypermethrin, Deltamethrin, Dimethrin, Permethrin, Fenprithrin, Cypermethrin, Cypermethrin, Cypermethrin, Cypermethrin, Cypermethrin, Cypermethrin, Cypermethrin, Cypermethrin, Fluvinate, Tau-fluvinate, Furfural Permethrin, Permethrin, Bio-Permethrin esters, trans-permethrin, phenothrin, pralothrin, profluthrin, permethrin, resmethrin, bioresmethrin, d-resmethrin, tefluthrin, cyclopentethrin, tetrathrin, tralomethrin, transfluthrin, ethomethrin, trifluthrin, benzylthrin, Protrifenbute and flutomethrin; pyrrole and pyrazole insecticides, such as acetothrin, ethiprole, fipronil, tebufenpyrad, tolfenpyrad, chlorfenapyr and flutomethrin.
[0815] Examples of mosquito repellent active ingredients are, in particular, anthraquinones, acridinium bases, copper cyclohexane, dimethicone, dibutyl phthalate, dimethyl phthalate, dimethyl carbonate, ethyl hexanediol, caproic acid amide, methoxyquin-butyl, N-methyl neodecanoamide, camphor, bergamot oil, pyrethrum oil, clove oil, geranium oil, thyme oil, and in particular diethyl-m-toluenethiamine and 2-(2-hydroxyethyl)-1-methylpropyl 1-piperidinecarboxylate (picaridin). Examples of health additives include in particular the substances and substance mixtures listed below, such as fats, preferably fats of vegetable origin, such as lecithin, vegetable oils such as jojoba oil, tea tree oil, clove oil, evening primrose oil, almond oil, coconut oil, avocado oil, soybean oil, etc., fatty acids, such as ω-6 fatty acids, linolenic acid, linoleic acid, waxes of animal or vegetable origin such as beeswax, candelilla wax, shea butter, sago oil, mango kernel oil, Japan wax, etc., vitamins, in particular fat-soluble vitamins, such as tocopherols, vitamins of animal or vegetable origin such as beeswax, candelilla wax, shea butter, sago resin, mango kernel butter, Japan wax, etc., such as tocopherol, vitamin E, vitamin A, etc., corticosteroids such as cortisone, corticosterone, dexamethasone, triamcinolone, methylprednisolone, fludrocortisone, fluocortolone, prednisone, prednisolone, progesterone, amino acids such as arginine, methionine; plant extracts such as algae extract, horse chestnut extract, mango extract, etc.
[0816] In order to improve the washing fastness of the finishing agent according to the invention, it has proven useful to fix the amylose-containing substance to the textile with a binder. Suitable binders include film-forming, water-insoluble polymers and low-molecular reactive substances that polymerize when heated. Generally, the amount of binder used is such that the weight ratio of amylose-containing substance to water-insoluble polymer is in the range of 1:1 to 100:1, preferably in the range of 1.5:1 to 50:1, in particular in the range of 2:1 to 20:1.
[0817] Typically, the film-forming polymer is used in the form of an aqueous dispersion of finely divided polymer particles. The particle size is secondary to the success of the present invention. However, it is typically below 5 μm (weight average) and is typically between 50 nm and 2 μm.
[0818] Specifically, the film-forming polymer can have a glass transition temperature TG in the range of -40°C to 100°C, preferably -30°C to +60°C, in particular -20°C to +40°C. If the polymer binder comprises several polymer components, at least the main component should have a glass transition temperature in this range. Specifically, the glass transition temperature of the main component is in the range of -30°C to +60°C, and particularly preferably in the range of -20°C to +40°C. Preferably, all polymer components have glass transition temperatures in these ranges. The specified glass transition temperature refers to the "midpoint temperature" determined using DSC according to ASTM-D3418-82. For crosslinkable binders, the glass transition temperature refers to the non-crosslinked state.
[0819] Examples of suitable film-forming polymers are based on the following polymer classes:
[0820] (1) Polyurethane resin;
[0821] (2) Acrylate resin (pure acrylate: copolymer of alkyl acrylate and alkyl methacrylate);
[0822] (3) Styrene acrylate (copolymer of styrene and alkyl acrylate);
[0823] (4) styrene / butadiene copolymer;
[0824] (5) Polyvinyl esters, in particular polyvinyl acetate and copolymers of vinyl acetate and vinyl propionate;
[0825] (6) Vinyl ester olefin copolymers, such as vinyl acetate / ethylene copolymers;
[0826] (7) Vinyl ester acrylate copolymers, such as vinyl acetate / alkyl acrylate copolymers and vinyl acetate / alkyl acrylate ethylene terpolymers
[0827] Such polymers are known and commercially available, for example, polymers of classes (2) to (7) in the form of aqueous dispersions under the names ACRONAL, STYROFAN, BUTOFAN (BASF-AG), MOWILITH, MOWIPLUS, APPRETAN (Clariant), VINNAPAS, VINNOL (WACKER). Suitable aqueous polyurethane dispersions (1) for the process according to the invention are in particular those for coating textiles. Suitable substances are known to the person skilled in the art. Aqueous dispersions are commercially available, for example, under the trade name VINNOL from Alberdingk. BAYERAG Stahl, Waalwijk, Netherlands or BASFSE The film-forming polymer can be purchased under the trade name of, or can be produced according to known processes (such as those described in the relevant technical literature). The film-forming polymer can be self-crosslinking, that is, the polymer has functional groups (crosslinkable groups), and when the composition is dried or heated, these functional groups can react with each other, with the functional groups of amylose or with low molecular weight crosslinking agents to form bonds. Examples of crosslinkable functional groups include aliphatic bonded OH groups, NH-CH2-OH groups, carboxylic acid groups, anhydride groups, blocked isocyanate groups and amino groups. Polymers that still have free OH groups as reactive groups are usually used. Typically, the ratio of reactive functional groups is 0.1 to 3 mol / kg polymer. Crosslinking can be achieved in the polymer by the reaction of complementary reactive functional groups. Preferably, the crosslinking of the polymer is achieved by adding a crosslinking agent, which has reactive groups that are complementary to the functional groups of the crosslinking agent in terms of reactivity. Suitable functional group pairs with complementary reactivity are known to those skilled in the art. Examples of such pairs are: OH / COOH, OH / NCO, NH2 / COOH, NH2 / NCO and M 2+ / COOH, where M 2+ Represents divalent metal ions, such as Zn 2+ , Ca 2+ or Mg 2+ Examples of suitable crosslinkers are the diols or polyols mentioned below for the polyurethanes; primary or secondary diamines, preferably primary diamines, for example alkylenediamines such as hexamethylenediamine, diethylenetriamine, triethylenetetramine, tetraethylenepentamine, N,N-bis[(aminopropyl)amino]-ethane, 3,6-dioxaoctanediamine, 3,7-dioxanononanediamine, 3,6,9-trioxaundecanediamine or Jeffamine, (4,4-diaminobicyclopentanediamine) The crosslinking agent is preferably selected from the group consisting of (4,4'-diamino-3,3-dimethyldicyclohexyl)methane, ...
[0828] As an alternative to fixing the amylose-containing substance with a water-insoluble polymer, the amylose or the amylose-containing substance can also be fixed to the textile material with a reactive compound having at least one group reactive toward the OH group of the amylose and at least one further functional group reactive toward functional groups on the fibers of the textile material, such as an OH group, an NH2 group or a COOH group. The reactive compounds include the above-mentioned crosslinking agents and the substances proposed in DE 4035378 A for fixing cyclodextrins, such as N-hydroxymethyl and N-alkoxymethyl derivatives of urea or urea compounds, such as dimethylol urea (bis(hydroxymethyl)urea), di(methoxymethyl)urea, dimethylol alkanediol diurethanes, such as N,N-dimethylolethylene urea (N,N-bis(hydroxymethyl)imidazolin-2-one), N,N-dimethylol-dihydroxyethylene urea (N,N-bis(hydroxymethyl)-4,5-dihydroxyimidazolin-2-one), dimethylolpropylene urea, etc. Such materials are commercially available in the form of aqueous formulations for finishing textiles, for example under the trade name BASF SE and Active substances which can be used for fixing amylose-containing substances to textile materials include, in particular, compounds having 2, 3, 4 or more (possibly reversibly blocked) isocyanate groups, in particular polyisocyanate prepolymers based on polyether and polyester polyurethanes which are reversibly blocked with hydrogen sulfites or CH-acid compounds or oximes (e.g. butanone oxime), as described in DE 2837851, DE 19919816 and in the earlier patent application EP 03015121. Such products are also commercially available, for example from Rotta GmbH, Mannheim under the trade name 367 and 357 was purchased commercially.
[0829] For the fixation of the amylose-containing substance, the known processes for the fixation of cyclodextrins can also be used in an analogous manner, wherein the cyclodextrin or, in the present case, the amylose-containing substance is provided with a reactive anchor, for example by mixing it with dicarboxylic acids or dicarboxylic anhydrides such as maleic acid, fumaric acid, maleic anhydride, succinic acid, succinic anhydride or adipic acid, with diisocyanates such as toluene diisocyanate, isophorone diisocyanate, tetramethylene diisocyanate or hexamethylene diisocyanate, or with aminocarboxylic acids such as toluene diisocyanate, isophorone diisocyanate, tetramethylene diisocyanate or hexamethylene diisocyanate, for example toluene diisocyanate, isophorone diisocyanate, tetramethylene diisocyanate or hexamethylene diisocyanate, or reacting it in a manner known per se with aminocarboxylic acids, so that one of the functional groups present in these compounds reacts with the OH groups of the amylose-containing substance, while the other remains for bonding to the reactive groups of the fiber material. Reactive anchors can also be produced on amylose-containing materials by reaction with 1,3,5-trichlorotriazine, 2,3-dichloroquinoxaline-5,6-carboxylic acid chloride and chlorodifluoropyrimidine. In addition, alkoxysilanes such as diethoxydimethylsilane, dimethoxydimethylsilane, phenyltriethoxysilane, tetraethoxysilane and dimers, trimers and higher condensation products of these compounds can also be used to fix amylose.
[0830] In principle, all textile materials can be finished in this way, i.e. unfinished as well as finished. Textile materials here and hereinafter include woven, knitted, knitted and nonwoven fabrics. Textile materials can consist of natural fiber yarns, synthetic fiber yarns and / or blended yarns. In principle, all fiber materials that are usually used for the production of textiles can be regarded as fiber materials. These include cotton, wool, hemp, sisal, linen, ramie, polyacrylonitrile, polyester, polyamide, viscose, silk, acetate, triacetate, aramid, etc., as well as mixtures of these fiber materials.
[0831] The textile material can be finished or treated with the amylose-containing substance in a manner known per se, for example by the described process for finishing textiles with cyclodextrins.
[0832] Examples include processes where the amylose-containing material, possibly as a complex with an active ingredient, has been spun into fibers, filaments and / or yarns for the production of textiles.
[0833] However, the textile material is usually treated with the amylose-containing substance or the complex of the amylose-containing substance and the active ingredient before or after finishing. Usually, the textile is treated with an aqueous liquid containing a sufficient amount of the amylose-containing substance and, if desired, the active ingredient. Depending on the type of application and the desired amount of amylose-containing substance to be applied, the concentration of the amylose-containing substance in the liquid is in the range of 1% to 40% by weight, in particular in the range of 2% to 20% by weight, and especially in the range of 4% to 15% by weight.
[0834] The type of treatment is secondary and can be applied, for example, as a minimal application (e.g. by spraying), as a normal application in a padding mill or as a high humidity application. In this case, the textile material is immersed in an aqueous liquid. If necessary, excess liquid can be removed, for example by squeezing to a liquid absorption rate of about 30% to 120%. Another possibility for treating textiles with amylose-containing substances or complexes of amylose-containing substances and active ingredients is to prepare a liquid with water, which contains the desired amount of amylose-containing substances and (if necessary) active ingredients, for example 0.5% to 20% by weight (based on the mass of the textile to be finished). The textile material is soaked with the treatment liquid in a suitable finishing device (e.g. reel carriage; drum carriage; paddle, etc.) for a period of time, for example 10 to 60 minutes, and then squeezed and / or rotated as described above. The liquid ratio is generally in the range of 1:2 to 1:50, in particular in the range of 1:3 to 1:20.
[0835] Such processes are known to those skilled in the art from relevant technical literature.
[0836] Typically, the treatment with the liquid is followed by a drying process. The temperature is typically in the range of 100° C. to 200° C., preferably in the range of 120° C. to 180° C. Drying can be carried out in the apparatus typically used for this purpose, in the case of finished products, for example, by drying at the above-mentioned temperatures. For non-finished products, the textile material is typically passed through one or more stenters after application.
[0837] If the amylose-containing substance is used together with a film-forming polymer, drying results in the amylose-containing substance being fixed on the textile fibers. Typically, the drying temperature will not be less than 100° C., preferably in the range of 120° C. to 200° C., in particular in the range of 140° C. to 180° C. Drying typically requires 1 to 10 minutes, in particular 1 to 2 minutes, but longer drying times are also suitable. For treatment with an aqueous liquid, it has been found that it is advantageous if the aqueous liquid contains, in addition to the amylose-containing substance and possible active substances, at least one surfactant (or surface-active substances) which is suitable for dispersing the amylose-containing substance and the active substance in the aqueous liquid. Preferably, the surfactant is an oligomeric or polymeric dispersant. In contrast to low molecular weight surfactants, the term oligomeric or polymeric dispersant encompasses such dispersants, whose number average molecular weight is typically at least 2000 Daltons, for example 2000 to about 100000 Daltons, in particular in the range of about 3000 to 70000 Daltons. Typically, the aqueous solution contains the polymeric or oligomeric dispersant in an amount of 0.5 to 20% by weight, preferably 1 to 18% by weight, in particular 5 to 15% by weight, (based on the amylose-containing substance).
[0838] Suitable oligomeric or polymeric dispersants are soluble in water and include neutral and amphoteric water-soluble polymers and cationic and anionic polymers, the latter being preferred. Examples of neutral polymeric dispersants are polyethylene oxide, ethylene oxide / propylene oxide copolymers (preferably block copolymers), polyvinyl pyrrolidone and copolymers of vinyl acetate and vinyl pyrrolidone.
[0839] Preferred anionic oligomeric or polymeric dispersants are characterized in that they have carboxyl groups and / or sulfonic acid groups and are usually used as salts, for example alkali metal salts or ammonium salts. Preferred anionic dispersants are, for example, carboxylated derivatives of cellulose, such as carboxymethylcellulose, homopolymers of ethylenically unsaturated C3 to C8 monocarboxylic acids and C4 to C8 dicarboxylic acids (e.g. acrylic acid, methacrylic acid, maleic acid, itaconic acid), copolymers of at least two different ethylenically unsaturated C3 to C8 monocarboxylic acids and C4 to C8 dicarboxylic acids as described above, and copolymers of at least one of the above ethylenically unsaturated C3 to C8 monocarboxylic acids or C4 to C8 dicarboxylic acids with at least one neutral comonomer. Examples of neutral comonomers are: N-vinyllactams such as N-vinylpyrrolidone, vinyl esters of aliphatic C2- to C16-carboxylic acids such as vinyl acetate, vinyl propionate, amides of the abovementioned ethylenically unsaturated carboxylic acids such as acrylamide, methacrylamide, etc., hydroxy-C1 to C4 alkyl (meth)acrylates such as hydroxyethyl acrylate and hydroxyethyl methacrylate, esters of ethylenically unsaturated C3 to C8 monocarboxylic acids or C4 to C8 dicarboxylic acids with polyethers, for example esters of acrylic acid with polyethers, for example esters of acrylic acid or methacrylic acid with polyethylene oxide or ethylene oxide / propylene oxide block copolymers, vinyl aromatic compounds such as styrene and C2 to C16 olefins such as ethylene, propylene, 1-hexene, 1-octene, 1-decene, 1-dodecene, etc. Homopolymers of ethylenically unsaturated sulfonic acids such as styrenesulfonic acid and acrylamidepropanesulfonic acid and copolymers thereof with the abovementioned comonomers are also preferred. The proportion of ethylenically unsaturated acids in the copolymers is generally at least 20% by weight and not more than 90% by weight, in particular 80% by weight (based in each case on the total weight of all monomers constituting the polymer). Copolymers of at least one of the abovementioned acids and at least one comonomer are known for this purpose and are commercially available, for example copolymers of acrylic acid and maleic acid under the Sokalan brand from BASF SE.
[0840] Other preferred anionic dispersants are phenolsulfonic acid-formaldehyde condensates and naphthalenesulfonic acid-formaldehyde condensates (eg the Tamol and Setamol brands from BASF) and ligninsulfonates.
[0841] Suitable dispersants are also: low molecular anionic, nonionic, cationic, amphoteric and zwitterionic surfactants. Suitable surfactants are: for example, alkali metal salts, ammonium or amine salts of C8 to C18 alkyl sulfates, such as sodium lauryl sulfate; C8 to C18 alkyl sulfonates, such as lauryl sulfonate; C8 to C18 alkyl ether sulfates; and C8 to C18 alkyl ethoxylates; polyoxyethylene sorbitol esters; C8 to C18 alkyl glycinates; C8 to C18 alkyl dimethylamine oxides; betaine, etc. Preferred are alkyl sulfates and alkyl sulfonates.
[0842] If the amylose-containing substance is not used together with a film-forming, water-insoluble polymer, the textile can be treated with the polymer in a separate step. In particular, the treatment is carried out together with the amylose-containing substance. Therefore, a specific embodiment relates to a process, in which the aqueous solution additionally comprises a dispersed, film-forming, water-insoluble polymer of the above-mentioned type. The amount of film-forming polymer is selected so that the weight ratio of amylose-containing substance to water-insoluble polymer is in the range of 1:1 to 100:1, preferably in the range of 1.5:1 to 50:1, in particular in the range of 2:1 to 20:1.
[0843] The finishing of textiles with the cooling agent according to the invention or the cooling agent mixture according to the invention can be carried out in a separate operation or simultaneously in one operation with the finishing with the amylose-containing substance.
[0844] If the textile is treated with the active ingredient in a separate working step, the textile is also treated with an aqueous liquid of the active ingredient. For this purpose, the usually water-insoluble active ingredient is usually emulsified or dispersed in water, if necessary using suitable surface-active substances. Suitable surface-active substances are in particular the above-mentioned low molecular weight surfactants, preferably nonionic surfactants, in particular polyoxyethylene sorbitan esters, esters of mono- or oligosaccharides with C6 to C18 fatty acids, particularly preferably C8 to C18 alkyl polyoxyethylene ethers, especially those with a degree of ethoxylation in the range of 6 to 50.
[0845] Typically, the aqueous solution contains an amount of active substance of 0.1 to 10% by weight, in particular 0.2 to 5% by weight. The amount of surfactant is typically in the range of 0.5 to 50% by weight, based on the active substance, in particular in the range of 3 to 30% by weight. The active ingredient can be applied from the aqueous liquid using the usual methods, for example via a muslin. However, it is also possible to apply the active ingredient and the amylose-containing substance in a single operation. In this case, the amylose-containing substance can be treated according to the method so that the aqueous liquid of the amylose-containing substance now also contains at least one active ingredient. The active ingredient can be added to the liquid alone or in the form of an inclusion compound, i.e. in the form of a host-guest complex with the amylose-containing substance.
[0846] The cooling agent or cooling agent mixture according to the present invention can be used for finishing any textile, i.e., non-finished product and finished product. Herein and hereinafter, textile materials include woven fabrics, knitted fabrics, knitted fabrics and nonwoven fabrics. Textile materials can be composed of natural fiber yarns, synthetic fiber yarns and / or blended yarns. In principle, all fiber materials commonly used in the production of textiles can be regarded as fiber materials. These include cotton, wool, hemp, sisal fiber, flax, ramie, polyacrylonitrile fiber, polyester fiber, polyamide fiber, viscose fiber, silk, acetate fiber, triacetate fiber, aramid fiber, etc., and the mixture of these fiber materials. Glass fiber and the mixture of the above-mentioned fiber material and glass fiber, such as glass fiber / Kevlar mixture, are also suitable. The type of textile material depends mainly on the required application. The textile to be finished can be a finished product, such as clothing, including underwear and outerwear, such as shirts, trousers, jackets, outdoor, hiking and military equipment, roofs, tents, nets, such as insect nets and curtains, hand towels and bath towels, sheets, etc. Likewise, finishing can be done on raw materials in bales or rolls.
[0847] Finishing with amylose-based active ingredients means that the active ingredients remain in the finished textile even after multiple washings. In addition, textiles finished in this way have a pleasant feel, which is particularly beneficial for the wearing comfort of garments made from these textiles.
[0848] In addition to protecting humans, textiles containing active substances against parasites such as insects and mites are also particularly suitable for protecting animals from ticks, mites, fleas and the like.
[0849] The present invention also relates to cooling tobacco products.
[0850] The active ingredients according to the invention, i.e. the coolants according to the invention or the coolant mixtures according to the invention or the flavoring preparations according to the invention, can also advantageously be used to manufacture tobacco products. Examples of such tobacco products include cigars, cigarettes, pipe tobacco, chewing tobacco and snuff. The manufacture of tobacco products to which coolant additives are added is known per se.
[0851] In principle, the active ingredient content, ie the content of the coolant or coolant mixture according to the invention, can vary within wide ranges, for example from 0.05 ppm to 10% by weight, preferably from 0.1 ppm to 10% by weight.
[0852] The active ingredients according to the invention are also advantageously suitable for producing packaging materials.
[0853] Production is also carried out in a manner known per se. The active ingredient can be incorporated into the packaging material in free or, for example, encapsulated form, or applied to the packaging material in free or encapsulated form. In this way, suitably equipped plastic packaging materials can be produced based on information in the literature on the production of polymer films. The production of suitable coated papers is also known to those skilled in the art.
[0854] Finally, the present invention relates to a method for regulating the cold menthol receptor TRPM8, in particular for regulating the cold menthol receptor TRPM8 in vitro and / or in vivo, comprising the following steps:
[0855] (i) providing at least one physiological cooling agent according to the invention or a physiological cooling agent mixture according to the invention or providing a cosmetic or pharmaceutical preparation according to the invention; and
[0856] (ii) contacting the cooling agent or cooling agent mixture or the cosmetic or pharmaceutical preparation of step (i) with a receptor; or
[0857] A method for producing a physiological cooling effect on the skin or mucous membranes comprising the steps of:
[0858] (iii) providing at least one physiological cooling agent according to the invention or a physiological cooling agent mixture according to the invention or providing a cosmetic or pharmaceutical preparation according to the invention; and
[0859] (iv) contacting the cooling agent or cooling agent mixture or cosmetic or pharmaceutical preparation of step (iii) with human skin or mucous membrane; or
[0860] A method for improving the taste properties of a flavoring substance comprising the following steps:
[0861] (v) providing at least one physiological cooling agent according to the invention or a physiological cooling agent mixture according to the invention or providing a cosmetic or pharmaceutical preparation according to the invention and at least one flavoring agent;
[0862] (vi) mixing the two components; and, where appropriate
[0863] (vii) incorporating the mixture into an oral dosage form.
[0864] Further aspects of the invention are apparent from the following examples and the appended patent claims. Example
[0865] The following examples are intended to illustrate the invention without limiting it. Unless otherwise indicated, all data refer to weight.
[0866] Preparation of the Active Ingredients: The active ingredients / cooling agents used according to the present invention can be prepared by those skilled in the art of organic synthesis using known synthetic methods, as described in more detail below.
[0867] Cloning of human TRPM8
[0868] The starting point for cloning the human TRPM8 receptor is the LnCaP cDNA library. This library is commercially available (e.g. BioChain, Hayward, USA), or can be generated from the androgen-sensitive human prostate adenocarcinoma cell line LnCaP (e.g. ATCC, CRL1740 or ECACC, 89110211) using standard kits.
[0869] The TRPM8 coding sequence (see, for example, http: / / www.ncbi.nlm.nih.gov / entrez / viewer.fcgi?db=nuccore&id=109689694) can be PCR amplified and cloned using standard methods. The human TRPM8 gene isolated in this way was used to generate plasmid plnd_M8. Alternatively, the TRPM8 gene can also be produced synthetically.
[0870] Generation of HEK293 test cells
[0871] A stably transfected HEK293 cell line was generated using human TRPM8 DNA as a test cell system. HEK293 was preferred as it offers the possibility to induce TRPM8 expression using tetracycline via the introduced plasmid.
[0872] Methods for generating suitable test cell systems are known to the expert and can be found in the relevant specialist literature.
[0873] Determination of TRPM8 modulators
[0874] A test similar to that already described by Behrendt HJ et al. in the document Br. J. Pharmacol. 141, 2004, 737-745 was performed. Ca 2+ Sensitive dyes (e.g., FURA, Fluo-4, etc.) quantify receptor agonism or antagonism. Agonists alone result in Ca 2+ signal increases; antagonists, such as menthol, cause Ca 2+ Signal reduction (in each case detected using Fluo-4 dye, which is Ca 2+ ions have different fluorescence characteristics).
[0875] First, fresh cultures of transformed HEK cells were prepared in cell culture flasks in the usual manner. HEK293-TRPM8 test cells were separated from the cell culture flasks using trypsin and 40,000 cells / well were seeded in 96-well plates (Greiner #655948 poly-D-lysine coated) with 100 μl of culture medium. To induce TRPM8 receptors, tetracycline was added to the growth medium (DMEM / HG, 10% FCS without tetracycline, 4 mM L-glutamine, 15 μg / ml blasticidin, 100 μg / ml hygromycin B, 1 μg / ml tetracycline).
[0876] The next day, cells were loaded with Fluo-4AM dye and tested as follows: 100 μl / well staining solution Ca-4 kit (RB 141, Molecular Devices) was added to each 100 μl culture medium (DMEM / HG, 10% FCS without tetracycline, 4 mM L-glutamine, 15 μg / ml blasticidin, 100 μg / ml hygromycin B, 1 μg / ml tetracycline).
[0877] Incubate in incubator, 30 min / 37°C / 5% CO2, 30 min / room temperature (RT).
[0878] Prepare test substances (different concentrations in 200 μl HBSS buffer), as well as positive controls (different concentrations of menthol, eserin or ronomycin in 200 μl HBSS buffer) and negative controls (200 μl HBSS buffer alone). Add test substances in an amount of 50 μl / well and measure fluorescence changes at 485 nm excitation, 520 nm emission (e.g. in FLIPR detection device, molecular instrument or NovoStar, BMG), and evaluate the efficacy of different substances / concentrations and measure ECG at 485 nm excitation, 520 nm emission (e.g. in FLIPR detection device, molecular instrument or NovoStar, BMG), and evaluate the efficacy of various substances / concentrations and determine EC50 values.
[0879] The test substances were used in triplicate in the assay at concentrations of 0.1-200 μM. Typically, the compounds were stored in DMSO solution and diluted to a maximum DMSO concentration of 2% for the assay. Surprisingly, our evaluations when performing the assay showed that the compounds to be used according to the invention (as described herein) are particularly suitable as agonists of TRPM8.
[0880] The activity related to the activation of the active substance and TRPM8 channel is determined using the assay. This is done in a concentration-dependent manner. For each active substance, 6 to 10 concentrations are measured as a standard. The EC50 value can be determined from the determined activity value using mathematical methods (4-parameter or 5-parameter Logistic curve fitting) as the inflection point of the Sigmoidal curve. These are standard biochemical methods familiar to experts.
[0881] EC50 values determined according to the present invention for exemplary selected modulators are shown below in Tables 7 and 8. The EC50 value of substance WS-3 was determined to be 1.72 μM, which served as a reference.
[0882] Table 7: EC50 values of modulators according to the invention
[0883]
[0884]
[0885]
[0886]
[0887]
[0888]
[0889]
[0890]
[0891]
[0892]
[0893]
[0894]
[0895] Table 8: EC50 values of modulators according to the invention
[0896]
[0897]
[0898]
[0899]
[0900]
[0901]
[0902]
[0903]
[0904]
[0905]
[0906]
[0907]
[0908]
[0909] The EC50 value describes the concentration of cooling substance required to achieve half-peak effect and is therefore a measure of the potency of an agonist drug (drug potency depends on dose or concentration), wherein the potency corresponds to the reciprocal value of the EC50. Thus, a low EC50 value corresponds to a high drug potency.
[0910] Therefore, it can be seen from Tables 7 and 8 above that the compounds according to the present invention described herein have excellent cooling properties and can produce a strong cooling effect even at low concentrations, and are generally well below the EC50 reference value of 1.72 μM for substance WS-3.
[0911] As shown in Table 7 above, those structures of general formula (I), (II), (V) and (VI) have proven to be particularly advantageous, wherein R1 and R2 each represent a phenyl group, X represents an S atom, Y represents a methylene group or a methylene group substituted with a methyl or ethyl group, and Z represents -NH-cyclopropyl, -NH-CH3, -N(CH3)2 or azetidine. In addition, it can be observed that in the structures, m and n each represent 1.
[0912] As shown in Table 8 above, those structures of general formula (III), (IV), (VII) and (VIII) have proven to be particularly advantageous, wherein R1 and R2 each represent a phenyl group, X represents an S atom or a cyclopropyl group or a CH2 group or piperidine, Y represents a methylene group or a methylene group substituted by a methyl group, and Z represents -NH-CH3, -NH-CH2-CH3, -NH-cyclopropyl or -CS-CH3. In addition, it is observed that in the structures, m represents 0 or 1, or n represents 1.
[0913] Therefore, regarding EC50 values, compounds B-01, B-02, B-03, B-04, B-05, B-06 and B-07 having EC50 values ≤ 1.0 μM and compounds A-01, A-02, A-03, A-04, A-06, A-07 and A-08 having EC50 values ≤ 1.0 μM are particularly preferred.
[0914] For compounds B-01, B-02, B-03, B-04, B-05, B-06 and B-07 and compounds A-01, A-02, A-03, A-04, A-06, A-07 and A-08 (TRPM8 activity ≥ 100% and EC value ≤ 1.0 μM), particularly effective cooling effects were observed with respect to TRPM8 activity and EC50 values.
[0915] In addition to the above-mentioned TRPM8 activity and active ingredient potency (EC50 value), the compounds according to the invention also exhibit a strong cooling effect.
[0916] In order to quantify the cooling effect, comparative tests were performed using menthane-3-carboxylic acid-N-ethylamide as a reference. For these comparative tests, the technicians substituted menthane-3-carboxylic acid-N-ethylamide (also known as WS-3) for one or more of the compounds to be used according to the invention. Trained panelists (n=10 to 11) then performed a sensory evaluation of the intensity of the cooling effect of the individual compounds or active ingredients as described below and compared them with one another.
[0917] The cooling intensity was tested as follows: a test solution containing 5 ppm of the compound according to the invention and a corresponding solution containing 30 ppm of the reference substance WS-3 were tasted in a 5% sugar solution. This concentration of WS-3 was chosen because it has been shown that WS-3 exhibits a good cooling effect at such concentrations. The panelists tasted the corresponding test solution for exactly 40 seconds, rinsed the entire oral cavity with the corresponding test solution, and then spit out the sample or reference solution. After tasting, the test subjects scored the corresponding cooling intensity one minute later on a scale from 1 (very weak) to 9 (very strong).
[0918] Tables 9 and 10 below show the results of sensory tasting of exemplary selected compounds according to the present invention.
[0919] Table 9: Results of sensory tasting of exemplary cooling agents
[0920]
[0921]
[0922] Table 10: Results of sensory tasting of exemplary cooling agents
[0923]
[0924]
[0925]
[0926] Surprisingly, it has been shown that the compounds described herein produce a significantly stronger or comparable cooling effect compared to the WS-3 reference sample. In particular, it has been shown that the reference sample containing WS-3 showed a cooling intensity of about 5.4 in the sensory evaluation, while the cooling intensity of the substances according to the invention, for example, compound B-01 was 4.2, compound B-02 was 4.1, compound B-11 was 5.3, compound A-02 was 5.4, compound A-09 was 4.66, and compound A-10 was 5.38.
[0927] It should also be noted that despite the six-fold higher concentration of WS-3, it is able to produce a significantly lower cooling intensity. In contrast, in order to produce a significantly stronger cooling effect than conventional cooling substances (such as WS-3), the concentration of the compounds according to the invention must be significantly lower. This shows that even when used at low concentrations, the compounds according to the invention produce a strong and therefore efficient cooling effect and only very small amounts need to be used in the corresponding final formulations (e.g. product formulations containing these cooling substances) to produce a cooling effect that is considered to be strong.
[0928] In this case, it is preferred that, in a corresponding comparison, the cooling effect of the samples with the compound to be used according to the invention is preferably prolonged by at least 10 minutes, preferably by at least 15 minutes, more preferably by at least 20 minutes, even more preferably by at least 30 minutes, particularly preferably by at least 60 minutes, most preferably by at least 90 minutes, compared to a reference sample containing WS-3.
[0929] Synthesis Example:
[0930] Preparation of the compounds according to the invention
[0931] Method A:
[0932]
[0933] 2-Oxazolethiol derivative (1 equivalent) and bromocarboxylic acid or chlorocarboxylic acid (1.2 equivalents) are dissolved in anhydrous DMF, and N, N-diisopropylethylamine (1.5 equivalents) is added at room temperature. The reaction solution is stirred at room temperature until uHPLC control indicates complete conversion. The reaction mixture is then diluted with water and acidified to about pH 3 with 1M hydrochloric acid. It is extracted with DCM, and the combined organic phase is washed with water and filtered through a phase separator. After the organic phase is concentrated, a 2-oxazolecarboxylic acid derivative of satisfactory purity is obtained for the next reaction step.
[0934] The 2-oxazolecarboxylic acid derivative obtained in method A (1 equivalent) and the desired amine (as a THF solution if necessary) (3 equivalents) are dissolved in ethyl acetate and HATU (1.5 equivalents), and then N,N-diisopropylethylamine (5 equivalents) is added at room temperature; more DIPEA is added dropwise until the pH is adjusted to about 9. The reaction solution is stirred at room temperature until the uHPLC control indicates complete conversion. It is then diluted with saturated NaHCO3 solution and extracted with DCM. The combined organic phases are filtered through a phase separator. After the organic phase is concentrated, the crude product is purified by column chromatography to obtain the desired oily or solid product.
[0935] Method B:
[0936]
[0937] 2-Oxazolethiol derivative (1 equivalent) and bromoamide or chloramide (1.2 equivalents) are dissolved in anhydrous acetone and K2CO3 (2 equivalents) are added at room temperature or dissolved in anhydrous DMF and diisopropylethylamine (1.5 equivalents) is added at room temperature. The reaction solution is heated to 40 ° C and stirred until uHPLC control indicates complete conversion. Then it is diluted with water and extracted with EtOAc or DCM. The combined organic phase is washed with water and saturated NaCl solution and dried with MgSO4. After the organic phase is concentrated, the crude product is purified by column chromatography to obtain the desired oily or solid product.
[0938] Method C:
[0939]
[0940] The carboxylic acid derivative (1 equivalent) is dissolved in anhydrous DCE and cooled to 0-5 ℃. Add 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (1.1 equivalents) and stir for 30 minutes. Then add benzoin (1 equivalent), then add DMAP (1.2 equivalents). The reaction mixture is heated to room temperature and stirred for 24 hours. Then use DCM to dilute the mixture, and first filter three times with 10 % by weight citric acid solution, then filter with saturated NaHCO3 solution and filter through a phase separator. After the organic phase is concentrated, an ester of satisfactory purity is obtained, for the next reaction step. If it is a cooling agent, the product is purified by column chromatography to obtain the required oily or solid product.
[0941] Ester (1 equivalent) and ammonium acetate (5 equivalents) are dissolved in acetic acid and refluxed for 90 minutes, and after being cooled to room temperature, reaction mixture is added in water and extracted with dichloromethane. The organic phase merged is filtered and concentrated by phase separator. Product can be used for next step reaction without further purification. If it is a cooling agent, product is purified by column chromatography to obtain required oily or solid product.
[0942] The oxazole derivative (1 equivalent) is dissolved in a mixture of THF and water (1:1) and cooled to 0°C. LiOH monohydrate (2 equivalents) is then added. LiOH monohydrate (2 equivalents) is then added, slowly warmed to room temperature, and stirred until complete conversion is detected. The reaction solution is then diluted with water and acidified to pH 3 with 10 wt % citric acid. The aqueous solution is extracted with DCM. The combined organic phases are dried over MgSO4 and concentrated. The carboxylic acid derivative can be used in the next reaction step without further purification. If it is a cooling agent, the product is purified by column chromatography to obtain the desired oily or solid product.
[0943] The carboxylic acid derivative (1 equivalent) and the desired amine (if necessary, as a THF solution) (1 equivalent) are dissolved in DMF and cooled to 0°C. HATU (1 equivalent) is then added, followed by N,N-diisopropylethylamine (3 equivalents). HATU (1 equivalent) is then added, followed by N,N-diisopropylethylamine (3 equivalents). The reaction solution is stirred at room temperature until uHPLC control indicates complete conversion. It is then diluted with water and extracted with DCM. The combined organic phases are washed with water, washed three times with 10% by weight citric acid, and finally washed with saturated NaHCO3 and filtered through a phase separator. The solvent is removed under vacuum. The crude product is purified by column chromatography to obtain the desired oily or solid product.
[0944] Method D:
[0945]
[0946] Diphenylphosphoryl azide (1.1 eq.) and triethylamine (1.1 eq.) were added to a solution of the oxaprozine derivative (1 eq.) in anhydrous toluene and stirred at room temperature. The reaction process was monitored by HPLC. After complete conversion, the reaction was diluted with toluene and washed with water. The organic phase was dried over MgSO4 and concentrated in vacuo. The crude product was dissolved in MeOH and stirred at 75 °C for 24 hours and then concentrated in vacuo. The crude product was purified by column chromatography (reverse phase) to obtain the desired product as an oil or solid. The carbamate (1 eq.) was dissolved in THF / MeOH (2:1) and a 2M NaOH solution (16 eq.) was added. The reaction mixture was heated to 70 °C and stirred until HPLC control showed complete conversion. The reaction mixture was then cooled to room temperature and diluted with water. It was extracted three times with a mixture of chloroform and isopropanol (7:3) and the combined organic phase was filtered through a phase separator and concentrated. The product was used for the next step without further purification. If it is a cooling agent, the product is purified by column chromatography to obtain the desired product as an oil or solid.
[0947] The amine derivative (1 equivalent) is dissolved in anhydrous DCM, then triethylamine (2 equivalents) is added, followed by acetyl chloride (1.2 equivalents). The reaction mixture is stirred at room temperature until HPLC control shows complete conversion. The reaction mixture is diluted with DCM, and washed with saturated NaHCO solution. The organic phase is filtered and concentrated in vacuo by a phase separator. The crude product is purified by column chromatography to obtain the required oily or solid product.
[0948] Method E:
[0949]
[0950] Oxazole carboxylic acid (1 equivalent) and N, O-dimethylhydroxylamine hydrochloride (1 equivalent) are dissolved in DMF. HATU (1.5 equivalents) and diisopropylethylamine (5 equivalents) are added, and the reaction mixture is then stirred at room temperature until HPLC control shows complete conversion. The reaction mixture is diluted with half-saturated NaHCO3 solution and extracted three times with DCM. The combined organic phases are washed with water and saturated NaCl solution, filtered through a phase separator and concentrated in vacuo. The crude product is purified by column chromatography to obtain the desired oily or solid product.
[0951] Weinreb amide (1 equivalent) was dissolved in anhydrous THF and cooled to 0°C. Grignard solution in THF was slowly added at 0°C, and after addition, the reaction mixture was stirred at room temperature until HPLC control showed complete conversion. The reaction was quenched by adding saturated NH4Cl solution and the aqueous phase was extracted three times with EtOAc. The combined organic phases were dried over MgSO4 and concentrated in vacuo. The crude product was purified by column chromatography to obtain the desired oily or solid product.
[0952] Method F:
[0953]
[0954] 2-imidazolethiol derivative (1 equivalent) is dissolved in anhydrous dimethylformamide and corresponding organic halogen compound (1.2 equivalents), then diisopropylethylamine (1.5 equivalents) is added. The reaction mixture is stirred at room temperature until HPLC control shows complete conversion. The reaction mixture is then diluted with water and extracted with DCM. The organic phase merged is dried and concentrated in vacuo through MgSO4. The crude product is purified by column chromatography to obtain the desired oily or solid product.
[0955] Method G:
[0956]
[0957] Benzil derivative (1 equivalent), dimethoxy ester (1.3 equivalents) and ammonium acetate (7 equivalents) are dissolved in acetic acid, and refluxed and stirred in a nitrogen atmosphere until HPLC control shows complete conversion. The reaction mixture is then cooled to room temperature and water is added. It is then adjusted to alkalinity and extracted with DCM with 25 % by weight ammonia. The organic phase merged is dried and concentrated in vacuo through MgSO. The product can be used for the next step reaction without further purification. The final product is purified by column chromatography to obtain the required oily or solid product. The corresponding carboxylic acid and the corresponding amides are prepared as described in method D.
[0958] Method H:
[0959]
[0960] For pyrazine: The benzil derivative (1 equivalent) was dissolved in methanol and glycinamide hydrochloride (1.1 equivalents), then NaOH (2 equivalents) was added and stirred at 70°C for 4 hours. The reaction mixture was then cooled to room temperature, 2M hydrochloric acid was added and stirred for 30 minutes. Saturated NaHCO3 solution was then added, the solid was filtered off and washed with methanol. The crude product was purified by column chromatography to obtain the desired oily or solid product.
[0961] For 1,2,4-triazine: The benzil derivative (1 eq.) was dissolved in acetic acid and heated to 100°C. Thiosemicarbazide (2 eq.) or the corresponding semicarbazide hydrochloride (1 eq.) was added. Thiosemicarbazide (2 eq.) or the corresponding semicarbazide hydrochloride (1 eq.) was added and stirred at reflux for 6 hours. The reaction mixture was then cooled to 5°C, the resulting solid was filtered off and washed with water. After vacuum drying, it was used in the next reaction step without further purification.
[0962] Method I:
[0963]
[0964] A suspension of Lawessons reagent (2 equivalents) and pyrazinol (1 equivalent) in THF was stirred at reflux overnight. The reaction mixture was then cooled to room temperature and diluted with water. The combined organic phases were extracted with ether and dried over Na2SO4, filtered and concentrated in vacuo. The crude product was purified by column chromatography to obtain the desired oily or solid product.
[0965] Method J:
[0966]
[0967] The thiol or alcohol or amine derivative (1 equivalent) is dissolved in acetone and Na2CO3 (1.5 to 6 equivalents) is added. The bromine compound (1.1 to 1.5 equivalents) is added to the suspension and stirred under reflux until the reaction control by DC shows complete conversion. The solid is filtered and washed with acetone. The filtrate is co-evaporated with silica. Purification by column chromatography gives the desired oily or solid product.
[0968] Method K:
[0969]
[0970] The thiol or alcohol or amine derivative (1 equivalent) is dissolved in acetone and Na2CO3 (1.5 to 6 equivalents) is added. 2-bromomethyl ester (1 equivalent) is added to the suspension and stirred at 60°C until complete conversion is shown by reaction control by DC. The reaction mixture is then cooled to room temperature, filtered and washed with acetone. The filtrate is concentrated and the resulting crude product is purified by column chromatography to obtain the desired methyl ester in an oily or solid state. The methyl ester (1 equivalent) is stirred overnight at 80°C in a 2M amine (10 equivalents) in THF. The reaction solution is then concentrated in vacuo. The crude product is purified by column chromatography to obtain the desired amide in an oily or solid state.
[0971] Methods L and L':
[0972]
[0973] The thiol (1 equivalent) was dissolved in acetone, Na2CO3 (1.5 equivalents) was added, and then iodomethane (1 equivalent) was added. The reaction mixture was stirred at 60°C until DC control showed complete conversion. The reaction mixture was then filtered and washed with acetone. The filtrate was concentrated. The product can be used for the next step without further purification. The final product was purified by column chromatography to obtain the desired oily or solid product. Methyl sulfide (1 equivalent) and the desired amine (10 equivalents) were stirred at high temperature (up to 120°C) until DC control showed complete conversion. The reaction mixture was then concentrated in vacuo, and the resulting crude product was purified by column chromatography. Methyl sulfide (1 equivalent) and the desired alcohol (1 equivalent) were dissolved in anhydrous DMF, and Cs2CO3 (1 equivalent) was added. The reaction mixture was stirred at 100°C until DC control showed complete conversion. The reaction mixture was then filtered off and concentrated in vacuo. The resulting crude product was purified by column chromatography.
[0974] Method M:
[0975]
[0976] The thioether (1 eq.) was dissolved in anhydrous DCM and cooled to 0°C. 3-Chlorobenzene (3 eq.) was added and the reaction solution was warmed to room temperature and stirred overnight. The reaction was then quenched with 5 wt.% aqueous sodium metabisulfite solution and stirred for one hour. The phases were separated and the organic phase was washed with water, filtered through a phase separator and concentrated in vacuo. The crude product was purified by column chromatography to give the desired product as an oil or solid.
[0977] The following Table 11 lists analytical data used to identify the synthesized compounds according to the present invention. In numerical values, decimal points are indicated by dots.
[0978] Table 11: 1H-NMR and 13C-NMR data of the cooling agent according to the present invention (decimal points)
[0979]
[0980]
[0981]
[0982]
[0983]
[0984]
[0985]
[0986]
[0987]
[0988]
[0989]
[0990]
[0991]
[0992]
[0993]
[0994]
[0995]
[0996]
[0997]
[0998]
[0999]
[1000]
[1001]
[1002]
[1003]
[1004]
[1005]
[1006]
[1007]
[1008]
[1009]
[1010]
[1011]
[1012]
[1013]
[1014]
[1015]
[1016]
[1017]
[1018]
[1019]
[1020]
[1021]
[1022] Formulation Examples
[1023] Formulation Examples of Cosmetic Preparations
[1024] The following formulation examples F1 to F54 show various formulations for cosmetic and pharmaceutical preparations. Here, coolant 1 represents compound B-11 according to the present invention, coolant 2 represents compound A-02, coolant 3 represents compound A-09, and coolant 4 represents compound A-10. The coolants are used in pure form.
[1025] In the following tables, decimal points are shown as dots.
[1026] Table F1 Transparent liquid soap (quantity expressed in weight percentage)
[1027]
[1028] Table F2 Liquid detergent soap (quantity expressed in weight percentage)
[1029]
[1030] Table F3 Body care lotion (quantity expressed in weight percentage)
[1031]
[1032]
[1033] Table F4 Body care lotion containing triclosan (amount expressed as weight percentage)
[1034]
[1035] Table F5 Care Cleansing Dew (quantity expressed in weight percentage)
[1036]
[1037]
[1038] Table F6 Liquid soap (quantity expressed in weight percentage)
[1039]
[1040] Table F7 Shampoo (quantity expressed in weight percentage)
[1041]
[1042]
[1043] Table F8 Two-in-one shampoo (quantity expressed in weight percentage)
[1044]
[1045] Table F9 Anti-dandruff shampoo (quantity expressed in weight percentage)
[1046]
[1047]
[1048] Table F10 Rinse-off Conditioner Containing Crinipan (Amount by Weight Percentage)
[1049]
[1050]
[1051] Table F11 Spray-type hair conditioner containing zinc pyrithione - leave-in type (amount in weight percentage)
[1052]
[1053] Table F12 Conditioner with UV protection function (quantity by weight percentage)
[1054]
[1055]
[1056] Table F13 Shower gel (quantity expressed in weight percentage)
[1057]
[1058] Table F14 Shaving foam (quantity expressed in weight percentage)
[1059]
[1060]
[1061] Table F15 Depilatory Cream (quantity expressed as weight percentage)
[1062]
[1063] Table F16 Aftershave (quantity expressed in weight percentage)
[1064]
[1065] Table F17 Roll-on gel deodorant formulation (amount expressed in weight percentage)
[1066]
[1067]
[1068] Table F18 Fresh deodorant roll-on (quantity expressed in weight percentage)
[1069]
[1070] Table F19 Deodorant sticks (quantity expressed as weight percentage)
[1071]
[1072]
[1073] Table F20 Antiperspirant sticks (quantity expressed in weight percentage)
[1074]
[1075] Table F21 Spray (quantity expressed in weight percentage)
[1076]
[1077]
[1078] Table F22 Antiperspirant (quantity expressed in weight percentage)
[1079]
[1080] Table F23 Spray deodorant containing triclosan (amount by weight percentage)
[1081]
[1082]
[1083] Table F24 O / W emulsion (quantity expressed in weight percentage)
[1084]
[1085] Table F25 Body lotion (quantity expressed in weight percentage)
[1086]
[1087]
[1088] Table F26 Cream (quantity expressed in weight percentage)
[1089]
[1090] Table F27 Cream (quantity expressed in weight percentage)
[1091]
[1092]
[1093] Table F28 Hand and body creams (amounts in weight percentage)
[1094]
[1095]
[1096] Table F29 Facial cream (amount expressed as weight percentage)
[1097]
[1098]
[1099] Table F30 Moisturizing Cream (quantity expressed in weight percentage)
[1100]
[1101]
[1102] Table F31 Anti-wrinkle cream (quantity expressed in weight percentage)
[1103]
[1104] Table F32 Disinfectant Skin Care Oil (quantity expressed in weight percentage)
[1105]
[1106]
[1107] Table F33 Antibacterial wound ointment (quantity expressed as weight percentage)
[1108]
[1109] Table F34 Moisturizing facial mask (quantity expressed in weight percentage)
[1110]
[1111]
[1112] Table F35 Spray disinfectant gel (quantity expressed in weight percentage)
[1113]
[1114]
[1115] Table F36 Mineral Cleansing Gel (quantity by weight percentage)
[1116]
[1117] Table F37 Anti-acne facial cleanser (quantity expressed as weight percentage)
[1118]
[1119] Table F38 Sunscreen formulations (quantities expressed as weight percentage)
[1120]
[1121]
[1122] Table F39 Sunscreen spray (quantity expressed in weight percentage)
[1123]
[1124]
[1125] Table F40 Sunscreen spray O / W, SPE15-20 (quantity in weight percentage)
[1126]
[1127]
[1128] Table F41 Sunscreen (W / O), SPF40 (quantity in weight percentage)
[1129]
[1130] Table F42 Sunscreen lotion (W / O) (quantity expressed as weight percentage)
[1131]
[1132]
[1133] Table F43 After-sun gel (quantity expressed in weight percentage)
[1134]
[1135]
[1136] Table F44 After-sun lotion (quantity expressed in weight percentage)
[1137]
[1138] Table F45 Hair gel (quantity expressed in weight percentage)
[1139]
[1140]
[1141] Table F46 Silicone emulsion (quantity expressed in weight percentage)
[1142]
[1143] Table F47 Microemulsion gel (quantity expressed as weight percentage)
[1144]
[1145]
[1146] Table F48 Air fresheners in gel form (quantities expressed in weight percentage)
[1147]
[1148] Table F49 Textile cleaning agents (quantity expressed in weight percentage)
[1149]
[1150]
[1151] Table F50 Toothpaste (quantity expressed in weight percentage)
[1152]
[1153] Table F51 Mouthwash (quantity expressed in weight percentage)
[1154]
[1155]
[1156] Table F52 Toothpaste with anti-plaque and anti-halitosis effects (amount by weight percentage)
[1157] Ingredients (INCI) quantity Sodium Carboxymethyl Cellulose 1.00 glycerin 12.50 70% Sorbitol aqueous solution 29.00 Saccharin Sodium 0.20 Sodium fluoride 0.22 Azepan-2,2-diphosphate disodium salt 1.00 Bromochlorophenol 0.10 Mint flavor 0.90 Coolant 1 0.10 Parsley Seed Oil 0.15 Abrasive Silica 15.00 Thickening Silica 5.00 Sodium dodecyl sulfate (SDS) 1.50 Distilled water Add to 100.00
[1158] Table F53 Toothpaste and mouthwash two-in-one products (quantity by weight percentage)
[1159]
[1160]
[1161] Table F54 Other toothpaste formulations (amount expressed in weight percentage)
[1162]
[1163] Formulation Examples of Food Preparations
[1164] The following formulation examples F55 to F63 show various formulations for food preparations. Here, coolant 1 represents compound B-11 according to the present invention, coolant 2 represents compound A-02, coolant 3 represents compound A-09, and coolant 4 represents compound A-10. The coolants are used in pure form.
[1165] Table F55 Chewing gum (quantity expressed in weight percentage)
[1166] Ingredients (INCI) quantity Chewing gum base ("gum base") 15-25 Glucose syrup 20-30 Powdered sugar 50-60 Coolant 1 0.001-10 Plasticizers (such as glycerol) 1-2 water 3-6
[1167] Table F56 Other chewing gum formulations (amounts expressed in weight percentage)
[1168]
[1169] Table F55 Sugar-free chewing gum (quantity expressed in weight percentage)
[1170]
[1171] Table F58 Pudding, formulation (100 ml) (quantity in grams)
[1172]
[1173]
[1174] Table 59 Gummy candy (quantity expressed in weight percentage)
[1175] Ingredients (INCI) quantity water Add to 100 Sugar (Refined Sugar C4) 42.10 Glucose syrup (dextrose 40) 37.30 Hardened vegetable fat, melting point 32℃-36℃ 6.60 Lecithin (emulsifier, soy lecithin) 0.30 Gelatin (Pork Gelatin) 0.80 Gummy Type-S30 4.80 Raspberry flavoring 0.22 Coolant 4 0.08
[1176] Table 60 Fruit flavor chewing gum (quantity expressed as weight percentage)
[1177] Ingredients (INCI) quantity water Add to 100 sucrose 34.50 Glucose syrup, DE40 31.89 IsoSyrupC*TruSweet01750(CerestarGmbH) 1.50 Gelatine240Bloom 8.20 Yellow and red dye 0.01 Citric Acid 0.20 Coolant 1 0.10
[1178] Table 61 Directly edible gelatin capsules (quantity expressed in weight percentage)
[1179]
[1180]
[1181] Table F62 Non-stick chewing gum (quantity expressed in weight percentage)
[1182]
[1183]
[1184] Table F63 Filled Hard Candies (Quantity in Weight Percentage)
[1185]
[1186]
Claims
1. Physiological cooling agents of the following general formula: General formula (Va) Or general formula (VIa) wherein in each case, in formulae (Va) and (VIa), and their salts, in particular acid addition salts with inorganic or organic acids, wherein the cooling agent may be present in stereoisomerically pure form or as a mixture of different stereoisomers; Or general formula (VIIa) Or general formula (VIIIa) wherein in each of formulae (VIIa) and (VIIIa), or R 1 and R 2 Together with the C atoms to which they are bonded, they form conjugated or non-conjugated ring systems; and their salts, in particular acid addition salts with inorganic or organic acids, wherein the cooling agent may be present in stereoisomerically pure form or as a mixture of different stereoisomers.
2. The physiological cooling agent according to claim 1, wherein in the general formulae (Va) to (VIIIa), Y represents a substituted methylene group, preferably a methylene group substituted by a methyl group, an ethyl group, a straight-chain or branched butyl group or a straight-chain or branched propyl group.
3. The physiological cooling agent according to claim 1 or claim 2, wherein the physiological cooling agent of general formula (Va) or (VIa) is selected from the compounds according to the following Table A: Table A: and their salts, in particular acid addition salts formed with inorganic or organic acids, wherein the cooling agent may be present in stereoisomerically pure form or as a mixture of different stereoisomers, preferably in, The physiological cooling agent is selected from compounds B-01, B-02, B-03, B-05, B-07, B-11 and B-18; or Wherein the physiological cooling agent of general formula (VIIa) or (VIIIa) is selected from the compounds according to the following Table B: Table B: and their salts, in particular acid addition salts with inorganic or organic acids, wherein the cooling agent may be present in stereoisomerically pure form or as a mixture of different stereoisomers, preferably wherein the physiological cooling agent is selected from compounds A-02, A-05, A-09, A-10 and A-12.
4. Physiological cooling agents of the following general formula: General formula (I) Or general formula (II) Or general formula (III) Or general formula (IV) wherein in each of formulae (I) to (IV), and their salts, in particular acid addition salts with inorganic or organic acids, wherein the cooling agent may be present in stereoisomerically pure form or as a mixture of different stereoisomers.
5. The physiological cooling agent according to claim 4, wherein in the general formula (I) and (II) X stands for S; and / or Y represents an optionally substituted straight or branched chain alkyl group; and / or m represents 0 or 1; and / or or Wherein in the general formula (III) and (IV) X is S or SO 2 or an optionally substituted linear or branched alkyl group or an optionally substituted cycloalkyl group or a piperidinyl group; and / or Y represents an optionally substituted straight-chain or branched alkyl group; and / or m represents 0 or 1.
6. The physiological cooling agent according to claim 4 or claim 5, which is represented by the following general formula: General formula (V) Or general formula (VI) wherein in each case, in formulae (V) and (VI), and their salts, in particular acid addition salts with inorganic or organic acids, wherein the cooling agent may be present in stereoisomerically pure form or as a mixture of different stereoisomers. or It is given by the following general formula: General formula (VII) Or general formula (VIII) Wherein in each of formula (VII) and (VIII), 7. The physiological cooling agent according to any one of claims 1 to 6, wherein in addition, the above-mentioned optionally substituted groups have one or more substituents such that:
8. A physiological cooling agent according to any one of claims 1 to 7, wherein in the general formulae (I) to (VIII) and (Va) to (VIIIa), the residue R 1 and R 2 may be the same or different and independently have the following meanings: R 1 is H or an optionally substituted C1 to C3 alkyl group or an optionally substituted phenyl group, preferably an optionally substituted phenyl group; and / or R 2 represents H or an optionally substituted C1 to C3 alkyl group or an optionally substituted phenyl group, preferably an optionally substituted phenyl group.
9. The physiological cooling agent according to any one of claims 4 to 8, wherein in the general formulae (I) to (VIII), Y represents a methyl group or a methyl group substituted by a methyl group, an ethyl group, a butyl group or a propyl group.
10. The physiological cooling agent according to any one of claims 1 to 9, wherein in the general formulae (I) to (VIII) and (Va), (VIIa) and (VIIIa), Z is selected from: -NH 2 、-NH-CH 3 、-NH-CH 2 -CH 3 、-NH-CH 2 -CH 2 -CH 3 、-NH-CH 2 -CH 2 -CH 2 -CH 3 、-NH-CH(CH 3 )-CH(CH 3 ) 2 、NH-CH(CH 3 )-CH 2 -CH 2 -CH 3 、-NH-CH 2 -CH(CH 3 ) 2 、-NH-CH 2 -CH 2 -O-CH 3 、-NH-CH(CH 3 )-CH 2 -O-CH 3 、-NH-C(=O)-CH 3 、-NH-C(=O)-O-CH 3 、-NH-CH(CH 3 )-CH 2 -OH, -NH-CH 2 -furanyl, -NH-CH 2 -tetrahydrofuranyl, -NH-CH 2 -phenylthio, -NH-tolyl, -NH-CH-(CH 3 ) 2 、-NH-C(CH 3 ) 3 , -NH-cyclopropyl, -NH-cyclobutyl, -NH-cyclopentyl, -N(CH 3 ) 2 、-N(CH 3 )-cyclohexyl, -N(CH 2 -CH 3 ) 2 , azetidinyl, pyrrolidinyl, piperidinyl, azetidinyl, pyrrolyl, pyridinyl, -O, -OH, -O-CH 3 、-OC(=O)-CH 3 , oxetane, -CH 3 、-CH 2 -CH 3 、-CH(CH 3 ) 2 、-C(OH)-CH 2 -OH, cyclopropyl, phenyl and -CH 2 -S-CH 3 ; and wherein in the general formula (VIa), Z is selected from: -NH 2 、-NH-CH 3 、-NH-CH 2 -CH 3 、-NH-CH 2 -CH 2 -CH 3 、-NH-CH 2 -CH 2 -CH 2 -CH 3 、-NH-CH(CH 3 )-CH(CH 3 ) 2 、-NH-CH(CH 3 )-CH 2 -CH 2 -CH 3 、-NH-CH 2 -CH(CH 3 ) 2 、-NH-CH 2 -CH 2 -O-CH 3 、-NH-CH(CH 3 )-CH 2 -O-CH 3 、-NH-C(=O)-CH 3 、-NH-C(=O)-O-CH 3 、-NH-CH(CH 3 )-CH 2 -OH, -NH-CH 2 -furanyl, -NH-CH 2 -tetrahydrofuranyl, -NH-CH 2 -phenylthio, -NH-tolyl, -NH-CH-(CH 3 ) 2 、-NH-C(CH 3 ) 3 , -NH-cyclopropyl, -NH-cyclobutyl, -NH-cyclopentyl, -N(CH 3 ) 2 、-N(CH 3 )-cyclohexyl, -N(CH 2 -CH 3 ) 2 , azetidinyl, pyrrolidinyl, piperidinyl, azetidinyl, pyrrolyl, pyridinyl, -O, -O-CH 3 、-OC(=O)-CH 3 , oxetane, -CH 3 、-CH 2 -CH 3 、-CH(CH 3 ) 2 、-C(OH)-CH 2 -OH, cyclopropyl, phenyl and -CH 2 -S-CH 3 .
11. The physiological cooling agent according to any one of claims 4 to 10, wherein the physiological cooling agent of general formula (I), (II), (V) or (VI) is selected from the compounds according to the following Table 1: Table 1: and their salts, in particular acid addition salts with inorganic or organic acids, wherein the cooling agent may be present in stereoisomerically pure form or as a mixture of different stereoisomers, preferably in, The physiological cooling agent is selected from compounds B-01, B-02, B-03, B-04, B-05, B-06, B-07, B-11, B-18 and B-19; or Wherein the physiological cooling agent of general formula (III), (IV), (VII) or (VIII) is selected from the compounds according to the following Table 2: Table 2: and their salts, in particular acid addition salts with inorganic or organic acids, wherein the cooling agent may be present in stereoisomerically pure form or as a mixture of different stereoisomers, preferably wherein the physiological cooling agent is selected from the group consisting of compounds A-02, A-04, A-05, A-06, A-07, A-08, A-09, A-10, A-12, A-16, A-17 and A-18.
12. The physiological cooling agent according to any one of claims 1 to 11, wherein the salt of the cooling agent is selected from: (1) an acid addition salt formed with an inorganic acid or an acid addition salt formed with an organic acid, wherein the organic acid is preferably a monovalent or polyvalent carboxylic acid; or (2) Salts formed when the acidic protons present in the starting compound are replaced by metal ions, or coordinated with organic bases, the metal ions being particularly alkali metal ions, alkaline earth ions or aluminum ions.
13. Physiological cooling agent mixtures comprising or consisting of composition: (a) one, two, three or more cooling agents according to any one of claims 1 to 12; and optionally (b) at least one other physiological cooling agent; and / or optionally (c) at least one solvent.
14. The physiological coolant mixture according to claim 13, wherein the physiological coolant forming component (b) is selected from the group consisting of: menthol, menthol methyl ether (FEMA GRAS 4054), monomenthyl glutamate (FEMA GRAS 4006), menthyl-1,2-propanediol (FEMA GRAS 3784), dimenthyl glutarate (FEMA GRAS 4604), hydroxymethylcyclohexyl ethyl ketone (FEMA GRAS 4742), 2-(4-ethylphenoxy)-N-(1H-pyrazol-3-yl)-N-(thiophen-2-ylmethyl)acetamide (FEMA GRAS 4880), WS-23 (2-isopropyl-N,2,3-trimethylbutanamide, FEMA GRAS 3804), N-(4-(cyanomethyl)phenyl)-2-isopropyl-5,5-dimethylcyclohexanecarboxamide (FEMA GRAS 4882), N-(3-hydroxy-4-methoxyphenyl)-2-isopropyl-5,5-dimethylcyclohexanecarboxamide (FEMA GRAS 4881), N-(2-hydroxy-2-phenylethyl)-2-isopropyl-5,5-dimethylcyclohexane-1-carboxamide (FEMA GRAS 4896), 3,4-methylenedioxycinnamic acid, (E)-3-benzo[1,3]dioxol-5-yl-N,N-diphenyl-2-acrylamide (FEMA GRAS 4788), menthol propylene glycol carbonate (FEMA GRAS 3806), N-ethyl oxalate, monomethyl succinate (FEMA GRAS 3810), WS-3 (N-ethyl-p-menthane-3-carboxamide, FEMA GRAS3455), menthol glycol carbonate (FEMA GRAS 3805), WS-5 (3-(p-menthane-3-carboxamido) ethyl acetate, FEMA GRAS 4309), WS-12 (1R, 2S, 5R)-N-(4-methoxyphenyl)-p-menthane carboxamide (FEMAGRAS 4681), WS-27 (N-ethyl-2,2-diisopropylbutanamide, FEMAGRAS 4557), N-cyclopropyl-5-methyl-2-isopropylcyclohexanecarboxamide (FEMAGRAS 4693), WS-116 (N-(1,1-dimethyl-2-hydroxyethyl)-2,2-diethylbutanamide, FEMAGRAS 4603), menthoxyethanol (FEMAGRAS 4154), N-(4-cyanomethylphenyl)-p-menthane carboxamide (FEMAGRAS 4496), N-(2-(pyridin-2-yl)ethyl)-3-p-menthanecarboxamide (FEMAGRAS 4549), N-(2-hydroxyethyl)-2-isopropyl-1-2,3-dimethylbutanamide (FEMAGRAS 4602), (2S,5R)-N-[4-(2-amino-2-oxoethyl)phenyl]-p-menthanecarboxamide (FEMAGRAS 4684), N-cyclopropyl-5-methyl-2-isopropylcyclohexanecarboxamide (FEMAGRAS 4693), 2-[(2-p-menthoxy)ethoxy]-ethanol (FEMAGRAS 4718), (2,6-diethyl-5-isopropyl-2-methyltetrahydropyran (FEMAGRAS 4680), trans-4-tert-butylcyclohexanol (FEMAGRAS 4724), 2-(p-tolyloxy)-N-(1H-pyrazol-5-yl)-N-((thien-2-yl)methyl)acetamide (FEMAGRAS 4809), menthone glycerol ketal (FEMAGRAS 3807 and 3808), (-)-menthoxypropane-1,2-diol, 3-(1-menthoxy)-2-methylpropane-1,2-diol (FEMA GRAS 3849), isopulegol, (+)-cis- and (-)-trans-p-menthane-3,8-diol (62:38, FEMA GRAS 4053), 2,3-dihydroxy-p-menthane, 3,3,5-trimethylcyclohexanone glycerol acetal, pyrrolidone carboxylic acid menthyl ester, 3,6-dioxaheptanoic acid (1R,3R,4S)-3-menthyl ester, methoxyacetic acid (1R,2S,5R)-3-menthyl ester, 3,6,9-trioxadecanoic acid (1R,2S,5R)-3-menthyl ester, 3,6,9-trioxadecanoic acid (1R,2S,5R)-3-menthyl ester, (2-hydroxyethoxy)acetic acid (1R,2S,5R)-3-menthyl ester, 11-hydroxy-3,6,9-trioxaundecanoic acid (1R,2S,5R)-menthyl ester, cubebol (FEMA GRAS4497), 4-(dimethylamino)-4-oxobutyric acid 2-isopropyl-5-methylcyclohexyl ester (FEMA GRAS 4230), menthyl lactate (FEMA GRAS 3748), 6-isopropyl-3,9-dimethyl-1,4-dioxaspiro[4.5]decan-2-one (FEMA GRAS4285), N-benzo[1,3]-dioxol-5-yl-3-p-menthanecarboxamide, N-(1-isopropyl-1,2-dimethylpropyl)-1,3-benzodioxol-5-carboxamide, N-(R)-2-oxotetrahydrofuran-3-yl-(1R,2S,5R)-p-menthane-3-carboxamide, a mixture of 2,2,5,6,6-pentamethyl-2,3,6,6a-tetrahydropentalene-3a(1H)-ol and 5-(2-hydroxy-2-methylpropyl)-3,4,4-trimethylcyclopent-2-en-1-one; (2S,5R)-2-isopropyl-5-methyl-N-(2-(pyridin-4-yl)ethyl)cyclohexanecarboxamide; (1S,2S,5R)-N-(4-(cyanomethyl)phenyl)-2-isopropyl-5-methylcyclohexanecarboxamide, 1,7-isopropyl-4,5-methyl-bicyclo[2.2.2]oct-5-ene derivatives, 4-methoxy-N-phenyl-N-[2-(pyridin-2-yl)ethyl]benzamide, 4-methoxy-N-phenyl-N-[2-(pyridin-2-yl)ethyl]benzenesulfonamide, 4-chloro-N-phenyl-N-[2-(pyridin-2-yl)ethyl]benzenesulfonamide, 4-cyano-N-phenyl-N-[2-(pyridin-2-yl)ethyl]-benzenesulfonamide, 4-((diphenylmethyl)phenyl)- 4-((Bis(4-methoxyphenyl)methylamino)methyl)-2-methoxyphenol, 4-((1,2-diphenylethylamino)methyl)-2-methoxyphenol, 4-((diphenylmethyloxy)methyl)-2-methoxyphenol, 4-((9H-fluoren-9-ylamino)methyl)-2-methoxyphenol, 4-((diphenylmethylamino)methyl)-2-ethoxyphenol, 1-(4-methoxyphenyl)-2-(1-methyl-1H-benzo[d]imidazol-2-yl)vinyl-4-methoxybenzoate, 2-(1-isobutylamino)-2-methoxyphenol Propyl-6-methyl-1H-benzo[d]imidazol-2-yl)-1-(4-methoxyphenyl)vinyl-4-methoxybenzoate, (Z)-2-(1-isopropyl-5-methyl-1H-benzo[d]imidazol-2-yl)-1-(4-methoxyphenyl)vinyl-4-methoxybenzoate, 3-alkyl-p-methan-3-ol derivatives, derivatives of the following groups: fenchyl, D-bornyl, L-bornyl, exonorbornyl, 2-methylisobornyl, 2-ethylfenchyl, 2-methylbornyl, cis-pinan-2-yl, whipping and isobornyl, menthyl oxamate ester derivatives, menthyl 3-oxocarboxylate, N-α-(menthanecarbonyl)amino acid amides, p-menthanecarboxamide and WS-23 analogs, (-)-(1R,2R,4S)-dihydrocymene, p-menthane alkoxyamides, cyclohexane derivatives, butanone derivatives, a mixture of 3-menthoxy-1-propanol and 1-menthoxy-2-propanol, 1-[2-hydroxyphenyl]-4-[2-nitrophenyl]-1,2,3,6-tetrahydropyrimidin-2-one, 4-methyl-3-(1-pyrrolidinyl)-2-[5H]-furanone, and cooling agents according to the following table:, and cooling agents according to the table below and their salts, especially acid addition salts with inorganic or organic acids, and mixtures of the above cooling agents / compounds.
15. A physiological cooling agent mixture according to claim 13 or claim 14 wherein component (a) and component (b) are present in a weight ratio of from about 0.1:99 to about 99:0.
1.
16. A physiological cooling agent mixture according to any one of claims 13 to 15, wherein the solvent forming component (c) is selected from the group consisting of benzyl alcohol, 2-phenylethanol, benzyl benzoate, diethyl succinate, triethyl citrate, triacetin, ethanol, peppermint oil, anethole, Optamint, propylene glycol, phenoxyethanol and mixtures thereof.
17. Flavoring preparations containing or consisting of the following substances composition: (d) one, two, three or more cooling agents according to any one of claims 1 to 12 or a mixture of physiological cooling agents according to any one of claims 13 to 16; and (e) at least one flavoring substance.
18. The flavoring formulation according to claim 17, wherein the flavoring agent forming component (e) is selected from the group consisting of acetophenone, allyl hexanoate, α-ionone, β-ionone, anisaldehyde, anisyl acetate, anisyl formate, anethole, benzaldehyde, benzothiazole, benzyl acetate, benzyl alcohol, benzyl benzoate, β-ionone, butyl butyrate, butyl hexanoate, butenylphthalide, carvone, camphene, caryophyllene, eucalyptol, cinnamyl acetate, citral, citronellol, citronellal, citronellyl acetate, cyclohexyl acetate, cymene, damascenone , decalactone, dihydrocoumarin, methyl o-aminobenzoate, methyl o-aminobenzoate, dodecalactone, ethoxyethyl acetate, ethyl butyric acid, ethyl butyrate, ethyl decanoate, ethyl caproate, ethyl crotonate, ethyl furanone, ethyl guaiacol, ethyl isobutyrate, ethyl isovalerate, ethyl lactate, ethyl methylbutyrate, ethyl propionate, eucalyptol, eugenol, ethyl heptanoate, 4-(p-hydroxyphenyl)-2-butanone, γ-decalactone, geraniol, geranyl acetate, geranyl acetate, grapefruit aldehyde, methyl dihydrojasmonate (e.g., ), piperonal, 2-heptanone, 3-heptanone, 4-heptanone, trans-2-heptenal, cis-4-heptenal, trans-2-hexenal, cis-3-hexenol, trans-2-hexenoic acid, trans-3-hexenoic acid, cis-2-hexenyl acetate, cis-3-hexenyl acetate, cis-3-hexenyl hexanoate, trans-2-hexenyl hexanoate, cis-3-hexenyl formate, cis-2-hexyl acetate, cis-3-hexyl acetate, trans-2-hexyl acetate, cis-3-hexyl formate, p-hydroxybenzyl acetone, isopentanol, isopentanyl isovalerate, isobutyl butyrate, isobutylaldehyde, isoeugenol methyl ether, isopropyl methylthiazole, lauric acid, levulinic acid, linalool, linalool oxide, linalyl acetate, Menthol, menthofuran, methyl anthranilate, methyl butanol, methyl butyric acid, 2-methylbutyl acetate, methyl caproate, methyl cinnamate, 5-methylfurfural, 3,2,2-methylcyclopentenolone, 6,5,2-methylheptenone, methyl dihydrojasmonate, methyl jasmonate, methyl 2-methylbutyrate, 2-methyl-2-pentenoic acid, methyl thiobutyrate, 3,1-methylthiohexanol, 3-methylthiohexyl acetate, nerol, neryl acetate, trans, trans-2,4-nonadienal, 2,4-nonadienol, 2,6-nonadienol, 2,4-nonadienol, nootkatone, δ-octalactone, γ-octalactone, 2-octanol, 3-octanol, 1,3-octenol, 1-octyl acetate, ethyl 3-octyl ester of iodine, palmitic acid, paraldehyde, phellandrene, pentanedione, phenylethyl acetate, phenylethyl alcohol, phenylethyl isovalerate, piperonal, propionaldehyde, propyl butyrate, menthol, menthol, sweet orange aldehyde, thiothiazole, terpinene, terpineol, terpinolene, 8,3-thiomenthanone, 4,4,2-thiomethylpentanone, thymol, δ-undecanoic acid lactone, γ-undecanoic acid lactone, valencia orangene, valeric acid, vanillic acid, vanillin, acetoin, ethyl vanillin, ethyl vanillyl isobutyrate (= 3-ethoxy-4-isobutyryloxybenzaldehyde), 2,5-dimethyl-4-hydroxy-3(2H)-furanone and its derivatives (preferably cyclohomofuranone (= 2-ethyl-4-hydroxy-5- methyl-3(2H)-furanone), soy sauce ketone (=2-ethyl-5-methyl-4-hydroxy-3(2H)-furanone and 5-ethyl-2-methyl-4-hydroxy-3(2H)-furanone), maltol and maltol derivatives (preferably ethyl maltol), coumarin and coumarin derivatives, γ-lactone (preferably γ-undecanoic acid lactone, γ-nonalactone, γ-decanoic acid lactone), δ-lactone (preferably 4-methyl-δ-decanoic acid lactone, masonolactone, δ-decanoic acid lactone, Tuberolacton), methyl sorbate, divanillin, 4-hydroxy-2(or 5)-ethyl-5(or 2)-methyl-3(2H)-furanone, 2-hydroxy-3-methyl-2-cyclopentenone, 3-hydroxy-4,5-dimethyl-2(5H)-furanone, isopentyl acetate, ethyl butyrate, n-butyl butyrate, isopentyl butyrate, ethyl 3-methylbutyrate, ethyl hexanoate, allyl hexanoate, n-butyl hexanoate, ethyl octanoate, ethyl 3-methyl-3-phenylglycidate, ethyl 2-trans-4-cis-decadienoate, 4-(p-hydroxyphenyl)-2-butanone, 1,1-dimethoxy-2,2,5-trimethyl-4-hexane, 2,6-dimethyl-5-heptene-1-al and phenylacetaldehyde, 2-methyl-3-(methylthio)furan, 2-methyl-3-furanthiol, bis(2-methyl-3-furanyl) disulfide, furfurylthiol, methylthiopropionaldehyde, 2-acetyl-2-thiazoline, 3-mercapto-2-pentanone, 2,5-dimethyl-3-furanthiol, 2,4,5-trimethylthiazole, 2-acetylthiazole, 2,4-dimethyl-5-ethylthiazole, 2-acetyl-1-pyrroline, 2-methyl-3-ethylpyrazine, 2-ethyl-3, 5-dimethylpyrazine, 2-ethyl-3,6-dimethylpyrazine, 2,3-diethyl-5-methylpyrazine, 3-isopropyl-2-methoxypyrazine, 3-isobutyl-2-methoxypyrazine, 2-acetylpyrazine, 2-pentylpyridine, (E,E)-2,4-decadienal, (E,E)-2,4-nonadienal, (E)-2-octenal, (E)-2-nonenal, 2-undecenal, 12-methyltridecanal, 1-penten-3-one, 4-hydroxy-2 ,5-dimethyl-3(2H)-furanone, guaiacol, 3-hydroxy-4,5-dimethyl-2(5H)-furanone, 3-hydroxy-4-methyl-5-ethyl-2(5H)-furanone, cinnamaldehyde, cinnamyl alcohol, methyl salicylate, isopulegol and stereoisomers, enantiomers, positional isomers, diastereomers, cis / trans isomers or epimers of these substances (not explicitly mentioned herein); and / or epimers of these substances; and / or, wherein the flavoring agent forming component (e) is selected from: erythritol, threitol, arabitol, ribitol, xylitol, sorbitol, mannitol, galactitol, lactitol, miracle fruit protein, monellin, thaumatin, curculigo sweet protein, bunazhen sweet protein, Magap, sodium cyclamate, acesulfame, neohesperidin dihydrochalcone, saccharin sodium salt, aspartame, super aspartame, neotame, alitame, sucralose, stevioside, rebaudioside, lugduname, carrelame, sucrononate, sucrooctate, monatine, phenylodulcin, glycine, D-leucine, D-threonine, D-asparagine, D-phenylalanine, D-tryptophan, L-proline, hernandulcin, dihydrochalcone glycosides, glycyrrhizin, glycyrrhizic acid Its derivatives and salts, extracts of Glycyrrhizza glabra ssp., extracts of Lippia dulcis, extracts of Momordica ssp., mogroside, sweet hydrangea and stevioside and mixtures thereof.
19. A flavouring formulation according to claim 17 or claim 18, wherein component (d) and component (e) are present in a weight ratio of 1:99 to 99:
1.
20. The physiological cooling agent according to any one of claims 1 to 12 or the physiological cooling agent mixture according to any one of claims 13 to 16 or the flavoring preparation according to any one of claims 17 to 19 in encapsulated form.
21. Use of a physiological cooling agent according to any one of claims 1 to 12 and 20 or a physiological cooling agent mixture according to any one of claims 13 to 16 and 20 as a modulator, in particular for the in vivo and / or in vitro modulation of the cold menthol receptor TRPM8, in particular as a TRPM8 receptor agonist or as a TRPM8 receptor antagonist.
22. Use of a physiological cooling agent according to any one of claims 1 to 12 and 20 or a physiological cooling agent mixture according to any one of claims 13 to 16 and 20 for producing a physiological cooling effect on the skin or mucous membranes in humans or animals, or for inducing a cooling effect by means of a packaging containing the physiological cooling agent or the physiological cooling agent mixture or a textile containing the physiological cooling agent or the physiological cooling agent mixture.
23. Use of a physiological cooling agent according to any one of claims 1 to 12 and 20 or a physiological cooling agent mixture according to any one of claims 13 to 16 and 20 for improving the taste properties of a seasoning, in particular for reducing or masking an unpleasant taste.
24. Use of a physiological cooling agent according to any one of claims 1 to 12 and 20 or a physiological cooling agent mixture according to any one of claims 13 to 16 and 20 or a flavoring preparation according to any one of claims 17 to 19 and 20 for the manufacture of food, food supplements, cosmetic or pharmaceutical preparations, animal feed, textiles, packaging or tobacco products.
25. Food, food supplement, cosmetic or pharmaceutical preparation, animal feed, textile, packaging or tobacco product comprising a physiological cooling agent according to any one of claims 1 to 12 and 20 or a physiological cooling agent mixture according to any one of claims 13 to 16 and 20 or a flavoring preparation according to any one of claims 17 to 19 and 20, in particular in an amount of 0.1 ppm to 10% by weight, in particular 1 to 10% by weight, based on the total weight of the finished product.
26. The pharmaceutical composition according to claim 25, comprising an additional pharmaceutically active ingredient selected from the group consisting of aspirin, minoxidil, erythromycin, dimethindine, betamethasone, ibuprofen, ketoprofen, dicyclofenac, metronidazole, acyclovir, imiquimod, terbinafine, ciclopirox olamine, paracetamol and other pharmaceutical agents of the nonsteroidal anti-inflammatory drug (NSAID) type and mixtures thereof.
27. A pharmaceutical preparation according to claim 25 or claim 26 for use as a medicament, in particular for the prevention or treatment of pain and inflammation of the skin and mucous membranes, in particular for the prevention or treatment of symptoms of cough, cold, inflammation, sore throat or hoarseness, or for the treatment of inflammation of the skin and mucous membranes and joints, or for the treatment of prostate cancer or bladder cancer, or for the treatment of bladder weakness.
28. A method for regulating, in particular for regulating the cold menthol receptor TRPM8 in vitro and / or in vivo, the method The following steps are involved: (ia) providing at least one physiological cooling agent according to any one of claims 1 to 12 and 20 or a mixture of physiological cooling agents according to any one of claims 13 to 16 and 20 or providing a cosmetic or pharmaceutical preparation according to any one of claims 25 to 27; and (iia) contacting the cooling agent or the cooling agent mixture or the preparation of step (ia) with the receptor; or A method for producing a physiological cooling effect on the skin or mucous membranes, the method comprising the following steps: (ib) providing at least one physiological cooling agent according to any one of claims 1 to 12 and 20 or a mixture of physiological cooling agents according to any one of claims 13 to 16 and 20 or providing a cosmetic or pharmaceutical preparation according to any one of claims 25 to 27; and (iib) contacting the cooling agent, the cooling agent mixture or the preparation of step (ib) with human skin or mucous membrane; or A method for improving the taste properties of a flavoring substance, the method comprising the steps of: (ic) providing at least one physiological cooling agent according to any one of claims 1 to 12 and 20 or a mixture of physiological cooling agents according to any one of claims 13 to 16 and 20 and at least one flavoring agent; (iic) mixing the two components; and, if necessary, (iiic) incorporating the mixture into an oral formulation.
